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ABSTRACT 
 
NEUROPATHY DETECTION, QUALITY OF LIFE TOOLS & TREATMENT 
 FOR TYPE 2 DIABETES 
 
Jennifer J. Brown 
Old Dominion University, 2016 
Director: Dr. Sheri Colberg-Ochs 
 
Type 2 diabetes (T2D) mellitus has become the epidemic of the new millennium, with an 
estimated 382 million people affected worldwide as of 2013, and statistics projected towards 592 
million by the year 2035.  With the development of diabetes, complications have risen, with 
diabetic neuropathy becoming one of the most prevalent, affecting between 10–90% of those 
with the disease.  Diabetic peripheral neuropathy (DPN) is difficult to detect in early stages of 
pathology, yet devastating once significant damage has taken place.  Cardiac autonomic 
neuropathy (CAN), which is often silent, is associated with autonomic nervous system (ANS) 
dysfunction and increased risk for sudden death.  Therefore, the purposes of this dissertation 
were early detection, assessment of quality of life (QOL) and disease intervention.  Study I 
explored the effectiveness of the 128-Hz tuning fork, the 1-g and 10-g monofilaments, and the 
QOL-DN as tools for the early detection of DPN in overweight, obese and inactive (OOI), 
prediabetes (PD), and type 2 diabetes (T2D) individuals.  Study II compared three QOL 
assessments: the QOL-DN, the PN-QOL-97 and the NeuroQOL-28, in OOI, PD and T2D 
individuals.  Study III involved the execution of a double blinded, placebo controlled exploration 
of melatonin as a potential intervention for the improvement of ANS and sleep dysfunction in 
T2D. 
The results of Study I suggest that the 1-g monofilament and QOL-DN measures 
correlate to NC-Stat DPN Check portable nerve conduction study (NCS) findings, that these 
iii 
 
measures function well for early detection purposes, and that the 128-Hz tuning fork is a useful 
screening tool in OOI, PD and T2D populations, despite lack of correlation to NCS measures.  
The results of Study II suggest that the QOL-DN and the NeuroQOl-28 QOL instruments 
significantly predict NCS results, indicating that these measures are useful for screening and 
accurately assessing neuropathy within our populations of interest.  Study III results indicate that 
a 10 mg dose of melatonin taken 30 minutes prior to bedtime for four weeks has a positive effect 
on PSQI Subjective Sleep Quality, systolic blood pressure (SBP) in deep breathing and Valsalva 























This dissertation is dedicated to the academic heroes of the  
Human Movement Sciences Department of Old Dominion University. 
Thank you for investing in me through all my years of training. 
 
 
Dr. Sheri Colberg, Dr. Kim Baskette, Dr. Shana Pribesh and Dr. Aaron Vinik: thanks for your 
help through the challenges life has brought.  I’ll be sure to pay it forward. 
 
 
To my father, Dr. A. Andrew Robertson (1939-2009); 
you were with me every late night of writing on this project. 




First, I must acknowledge that these projects have been accomplished with the financial 
support of Old Dominion University’s Darden College of Education (DCOE) and the Human 
Movement Sciences (HMS) Department.  Working to achieve a doctorate is a lofty goal, and to 
have the support of one’s university is both an honor and a necessity to achieve success.  The 
DCOE and HMS Department provided support through GTA teaching positions, stipends, tuition 
scholarships, and a Doctoral Dissertation Fellowship.  These valuable gifts allowed me to 
complete my training and doctoral projects with greater focus. 
My committee has gone above and beyond to assist me in my studies, offering insight 
throughout my doctoral career and guidance through the projects on the following pages.  My 
mentor, Dr. Sheri Colberg-Ochs, has invested countless hours into my training, and willingly 
made herself available to assist me in any way possible to help me achieve success, and I am 
forever indebted to her for her investment.  Dr. Colberg, I am grateful beyond words for the 
example you have set for me as a professor, investigator, mentor, collaborator, role model and 
approachable human being.  Thank you, from the bottom of my heart, for your patience and 
encouragement through all of the moments leading to this success.  I wish you well in all of your 
new endeavors, and know that Old Dominion University will miss your motivating influence.  
You’ve made an incredible impact in my life and in the lives of many others while you have 
been here.  Dr. Baskette, thank you for the investment of your time, ideas, and support, all of 
which have been provided at key moments during this journey.  I would also like to thank Dr. 
Aaron I. Vinik, who has both challenged and supported me in countless ways during my training.  
Dr. Vinik, your keen insight into the world of diabetes and neuropathy has provided inspiration 
as I’ve spent countless hours reading articles and preparing this manuscript.  Thank you for 
vi 
 
investing your facility resources and staff to support the Melatonin project.  Lastly, I thank Dr. 
Pribesh for her support, for pushing me at key moments and challenging me on many levels 
during my training as a doctoral student. 
At this level, it takes more than a committee to accomplish this many projects in such a 
short time period.  Many thanks to Dr. Carolina Casellini, and in her absence, Dr. Aaron Vinik, 
for performing the physicals on the melatonin subjects, and to Dr. Henri Parson for negotiating 
the joint venture project between ODU and EVMS.  Special thanks to the EVMS Strelitz 
Diabetes Center research and clinic staff, for all of their support.  Much appreciation to Benjamin 
Liu, Morgan Huskey and Anthony Ponce for their commitment to show up and help throughout 
data collection at Old Dominion University.  
To my husband, Gil and two children, Natalie and Keagan: your support as I have walked 
through this degree has meant the world.  Thank you for the countless loving ways you have 
arrived to help make this happen during the moments that I have needed it the most.  In your 
efforts to show care for me as your wife, mother and friend, you have given me a great gift by 
supporting me as I have pursued this training.  I, in turn, hope that the use of this degree will 
become a great gift to others.  To my mother, Doris Robertson, thank you for your unwavering 
support for me in all that I set out to do.  Your love of education, and encouragement as I have 
pursued it, has been a blessing for all three of my degrees.  To my father, Dr. A. Andrew 
Robertson, who was not here to see this degree started or completed; you were and still are, an 
incredible example of tenacity, love and faith.  Thank you for instilling in me the values of faith, 
family, hard work and persistence.  Without these qualities, I would have surely not have reached 




TABLE OF CONTENTS 
LIST OF TABLES .......................................................................................................... III 
LIST OF FIGURES ......................................................................................................... V 
 
INTRODUCTION ............................................................................................................ 6 
PART A: NEUROPATHY SCREENING TOOLS ....................................................... 9 
The Problem .......................................................................................................... 9 
Purpose and Significance of the Study ................................................................. 9 
Research Design.................................................................................................. 10 
Study Design Approach. ........................................................................... 10 
Variables. ................................................................................................... 10 
Research Questions ............................................................................................. 11 
Research Hypotheses .......................................................................................... 11 
Assumptions. ............................................................................................. 11 
Limitations. ............................................................................................... 12 
Delimitations. ............................................................................................ 13 
Operational Definitions ....................................................................................... 13 
Expected Outcomes ............................................................................................ 17 
PART B: NEUROPATHY QUALITY OF LIFE TOOLS .......................................... 19 
The Problem ........................................................................................................ 19 
Purpose & Significance of the Study .................................................................. 19 
Research Design.................................................................................................. 20 
Research Questions ............................................................................................. 20 
Research Hypotheses .......................................................................................... 21 
Assumptions. ............................................................................................. 21 
Limitations. ............................................................................................... 21 
Delimitations. ............................................................................................ 22 
Operational Definitions ....................................................................................... 22 
Expected Outcomes ............................................................................................ 26 
PART C: MELATONIN AND AUTONOMIC NERVOUS SYSTEM FUNCTION . 28 
The Problem ........................................................................................................ 28 
The Purpose & Significance of the Study ........................................................... 28 
Research Design.................................................................................................. 29 
Research Questions ............................................................................................. 29 
Research Hypotheses .......................................................................................... 29 
Assumptions. ............................................................................................. 30 
Limitations. ............................................................................................... 30 
Delimitations. ............................................................................................ 30 
Operational Definitions ....................................................................................... 30 




CHAPTER II ................................................................................................................... 35 
REVIEW OF THE LITERATURE ................................................................................ 35 
PART A: NEUROPATHY SCREENING TOOLS ..................................................... 36 
Diabetic Peripheral Neuropathy .......................................................................... 36 
Neuropathy Screening & Assessment ................................................................. 38 
The Tuning Fork. ....................................................................................... 41 
The 1-g and 10-g Monofilaments. ............................................................. 42 
The Norfolk Quality of Life Diabetic Neuropathy Tool. .......................... 44 
NC-Stat DPN Check. ................................................................................. 46 
Glycohemoglobin Testing. ........................................................................ 47 
Summary ............................................................................................................. 49 
TABLES ............................................................................................................. 51 
FIGURES ............................................................................................................ 55 
PART B: NEUROPATHY QUALITY OF LIFE TOOLS .......................................... 56 
Health Related Quality of Life (HRQOL) .......................................................... 56 
Norfolk Quality of Life Diabetic Neuropathy Instrument (QOL–DN). .... 59 
The Peripheral Neuropathy Quality of Life Instrument (PN-QOL-97). ... 61 
Neuropathy-and Foot Ulcer-Specific Quality of Life Instrument             
(NeuroQOL-28). ........................................................................................ 63 
NC-Stat DPN Check. ................................................................................. 65 
Glycohemoglobin Testing. ........................................................................ 67 
Summary ............................................................................................................. 68 
PART C: MELATONIN & AUTONOMIC NERVOUS SYSTEM FUNCTION ....... 70 
Melatonin ............................................................................................................ 70 
Cardiovascular Autonomic Neuropathy & Diabetes .......................................... 72 
Symptoms. ................................................................................................. 74 
Measuring Cardiac Autonomic Dysfunction. ............................................ 75 
Glycohemoglobin Testing. ........................................................................ 77 
Summary ............................................................................................................. 78 
TABLES ............................................................................................................. 80 
CHAPTER III ................................................................................................................. 81 
PROJECT I: NEUROPATHY SCREENING TOOLS ................................................ 81 
INTRODUCTION .............................................................................................. 81 
METHODS ......................................................................................................... 84 
RESULTS ........................................................................................................... 89 
DISCUSSION ..................................................................................................... 91 
CONCLUSION ................................................................................................... 97 
TABLES ............................................................................................................. 98 
FIGURES .......................................................................................................... 103 
CHAPTER IV ............................................................................................................... 105 
PROJECT II: NEUROPATHY QUALITY OF LIFE TOOLS .................................. 105 
INTRODUCTION ............................................................................................ 105 
ix 
 
METHODS ....................................................................................................... 107 
RESULTS ......................................................................................................... 112 
DISCUSSION ................................................................................................... 115 
CONCLUSION ................................................................................................. 121 
TABLES ........................................................................................................... 122 
CHAPTER V ................................................................................................................ 131 
PROJECT III: MELATONIN AND THE AUTONOMIC NERVOUS SYSTEM .... 131 
INTRODUCTION ............................................................................................ 131 
METHODS ....................................................................................................... 133 
RESULTS ......................................................................................................... 138 
DISCUSSION ................................................................................................... 142 
CONCLUSION ................................................................................................. 147 
TABLES ........................................................................................................... 148 
CHAPTER VI ............................................................................................................... 155 
CONCLUSIONS............................................................................................... 155 
REFERENCES ................................................................................................. 158 
APPENDICES .................................................................................................. 189 
A.  SCREENING QUESTIONNAIRE ................................................... 190 
B.  QOL-DN ............................................................................................ 191 
C.  PN-QOL-97 ....................................................................................... 196 
D.  NEUROQOL-28 ................................................................................ 222 
E.  NEUROLOGICAL FORM ................................................................ 230 
F.  INCLUSION/EXCLUSION SCREENING FORM ........................... 231 
G.  PSQI .................................................................................................. 233 
H.  ELSEVIER LICENSE ....................................................................... 236 




LIST OF TABLES 
Table          Page 
 
IIB.1 Descriptors of different kinds of neuropathic pain  ................................ 51 
 
IIB.2 Diagnostic Assessment of DPN Using Bedside Tests ............................ 52 
 
IIB.3 Advanced Objective Testing for DN  ..................................................... 53 
 
IIB.4. Stages as Defined by the Criteria Given by Mayo ................................. 53 
 
IIC.1 CAN Testing  .......................................................................................... 80 
 
III.1. Participant Characteristics ...................................................................... 98 
 
III.2.    Gender and Group Characteristics .......................................................... 99 
 
III.3. NCS Results ............................................................................................ 100 
 
III.4. Sural NCS, Signs, and Symptoms .......................................................... 101 
 
III.5. Spearman’s Correlations (Log Transformed) ......................................... 102 
 
IV.1. Participant Characteristics ...................................................................... 122 
 
IV.2. Gender and Group Characteristics .......................................................... 123 
 
IV.3. NCS Results ............................................................................................ 124 
 
IV.4. Sural NCS, Signs, and Symptoms .......................................................... 125 
 
IV.5. Spearman’s Correlations (Log Transformed) ......................................... 126 
 
IV.6. Instrument Completion Times ................................................................ 127 
 
IV.7. QOL-DN Regression Results ................................................................. 128 
 
IV.8. PN-QOL-97 Regression Results ............................................................. 129 
 
IV.9. NeuroQOL-28 Regression Results ......................................................... 130 
 




Table  ................................................................................................................ Page 
 
V.2. Correlations ............................................................................................ 149 
 
V.3. Log Transformed HRV Friedman’s ANOVA Results ........................... 150 
 
V.4. Log Transformed Pairwise Comparisons ............................................... 151 
 
V.5. Sleep Questionnaire Results: Friedman’s ANOVA ............................... 152 
 
V.6. Sleep Questionnaire: Pairwise Comparisons .......................................... 153 
 
V.7. Sudoscan Results .................................................................................... 154 
v 
 
LIST OF FIGURES 
 
Figure          Page 
 
IIA.1.  Clinical manifestation of small-fiber and large-fiber  
neuropathies ........................................................................................................ 55 
 
III.1.  The 128-Hz Tuning Fork .......................................................................... 103 
 
III.2.  Monofilament Application Clinical manifestation of small-fiber 








 Diabetes is a metabolic disorder, and when present, indicates that an individual has high 
blood glucose (BG) levels relating to insulin production or usage, or potentially both of these 
metabolic processes (Center for Disease Control and Prevention, 2014).  This elevated BG status, 
or hyperglycemia, affects various cells throughout the body that perform both vital and 
secondary functions, including key brain, organ and muscle tissue processes.  Debilitating by 
nature, diabetes often goes undetected, with one out of four unaware that they have developed 
the disease until symptoms elevate to the point where significant damage may be present or a 
major event may occur (Center for Disease Control and Prevention, 2014). 
The debilitating effects of diabetes stretches worldwide, affecting 382-387 million 
people, creating an impact on 29.1 million, or 9.3% of the United States population (Center for 
Disease Control and Prevention, 2014; Guariguata et al., 2013; International Diabetes 
Federation, 2014).  With an estimated 21 million who have been diagnosed and another 8.1 
million who remain undiagnosed, the International Diabetes Federation and research estimates 
the impact of diabetes to climb into the staggering 590-592 million range across the globe by the 
year 2035 (Guariguata et al., 2013; International Diabetes Federation, 2014).  The largest number 
of new diabetes cases are in the 45 to 64 age range, and interventions aiming to stop diabetes 
processes at earlier stages in younger populations seem prudent, as the disease is gaining a 






Great emphasis has been placed on developing management strategies for commonly 
associated complications such as neuropathy (Shah & Mueller, 2012) and weight gain 
(Courcoulas, 2015; Golomb, Ben David, Glass, Kolitz, & Keidar, 2015); yet long term resolution 
remains elusive once disease pathways have set their course.  Extensive research has been 
performed determining the linkage between diabetes and other diseases, including the effects of 
insulin on the brain, metabolic syndrome, depression, and various forms of neuropathy (Alberti 
et al., 2009; Chen, Wang, Zhu, Li, & Teng, 2014; Mezuk, Eaton, Albrecht, & Golden, 2008; 
Smith, Gerardi, Lessard, Reyna, & Singleton, 2013; Vinik, Nevoret, Casellini, & Parson, 2013).  
Existing research provides foundational opportunities for positive impact on the health of 
millions who currently suffer with diabetes, as a major focus is on the modification of 
management of the disease, in hopes to halt its progression.  Yet, there is still much to learn 
regarding how to prevent the initial onset in the earliest stages, and how to ignite changes before 
long standing hyperglycemia sets in, negatively affecting quality of life (QOL) (Alexander, 
Landsman, & Grundy, 2006; Nichols, Alexander, Girman, Kamal-Bahl, & Brown, 2006; 
Phillips, Ratner, Buse, & Kahn, 2014). 
 Hyperglycemia at any stage is an unhealthy process that lays the groundwork for 
significant pathophysiological processes (Mustafa, Alemam, & Hamid, 2012; Papanas & Ziegler, 
2012).  The development of earlier intervention practices is logical for numerous reasons.  The 
cutoff points dictating glycemic levels that define diabetes relate to the associations found 
between particular glucose levels and significant increases in microvascular complications such 
as retinopathy and nephropathy (Buysschaert & Bergman, 2011).  It is vital to encourage 
individuals whose glucose levels reside within cautionary ranges, such as prediabetes (PD), to 





diabetes (T2D).  Research indicates that individuals with PD in the HbA1C range of 6.1–6.4% 
are at significant risk for the development of T2D and typically progress to T2D within three to 
five years (ADA, 2016).  Developing new tools and programs that assess risk prior to this time of 
pathophysiological dysfunction is a practical course of action.  
Early detection and intervention is key if society desires to attenuate the impending 
impact that T2D and prediabetes is expected to have on the modern world in the upcoming years 
of 2030 to 2035.  Diabetes in its latter forms has already launched its assault on the body, often 
in irreparable ways and, thus, early detection of complications and treatment of them is key to 
achieve the best scenarios for health and positive outcomes.  It is with these concepts in mind 







PART A: NEUROPATHY SCREENING TOOLS 
The Problem 
 T2D and PD are worldwide health problems, with rapidly increasing numbers 
(International Diabetes Federation, 2014; Ruterbusch, 2014).  DPN is a significant complication 
associated with acute and chronic hyperglycemic conditions such as T2D and PD, yet little 
research exists evaluating the ability of low-cost screening tools to effectively detect the earliest 
stages of the disease.  Given that DPN is frequently debilitating (Vinik et al., 2013), early 
detection of the disease would best allow for treatment and management, hopefully deterring 
long-term deficits in ambulation (Eikenberg & Davy, 2013; Papanas & Ziegler, 2012).  Research 
scientists agree that catching the pathology in the earliest stages is important to prevent major 
complications and loss of quality of life, thus targeted efforts must be made to detect DPN during 
the earliest stages of hyperglycemia (Ferrannini, Gastaldelli, & Iozzo, 2011; Papanas & Ziegler, 
2012; Prevention of Type 2 Diabetes: From Science to Therapy, 2012).  This involves evaluating 
PD and individuals with elevated, but not clinically diagnosable hyperglycemia.  Multiple tools 
exist to screen T2D populations, yet these tools have not been used extensively in PD or 
subclinical populations. 
 
Purpose and Significance of the Study  
 Evaluating simple screening tools and their ability to effectively detect earlier stages of 





alongside PD and T2D subjects allowed a fresh look at how these particular tools could be used.  
The hope of this research was that we might uncover simple ways to disclose early DPN or 
subclinical neuropathy.  PD and T2D populations served as control subjects, allowing us to 
compare our data to previous research, while seeking new answers for early DPN and subclinical 
neuropathy detection.  We aimed to evaluate the effectiveness of three neuropathy screening 
tools: the 128-Hz tuning fork, the 1-g and 10-g monofilaments, and the QOL–DN for the 
purposes of early DPN detection, utilizing predefined definitions from literature (Tesfaye, 2010).  
We also hoped to determine which screening tool was the most effective, while comparing our 
results back to a standardized criterion measure of portable nerve conduction in the form of the 
NC-Stat DPN Check (Neurometrix Inc., Waltham, MA). 
 
Research Design 
 Study Design  Approach.  The proposed study took an observational and correlational 
approach paired with a quantitative data collection.  Individuals were screened and categorized 
by HbA1C values and prior diagnoses, creating specific groups to study (see Appendix A) (OOI, 
PD, T2D). 
Variables.  A criterion variable approach was implemented, with the NC-Stat DPN 
Check device providing a nerve conduction testing evaluation of the sural nerve, bilaterally.  Our 
other variables, the 128-Hz tuning fork, 1-g and 10-g monofilaments, and the QOL–DN (see 
Appendix B), were compared to this standard of testing.  HbA1C test data combined with 
previous PD or T2D diagnosis identified OOI, PD and T2D populations with continuous 





Dependent variables (DV) included the tuning fork data, monofilament testing, and QOL–DN 
results, which consisted of continuous, interval level data.  
 
Research Questions  
RQ1: To what extent will:  
1a: the 128-Hz tuning fork detect early DPN in an OOI, PD and T2D population? 
1b: the 1-g and 10-g monofilaments detect early DPN in an OOI, PD and T2D 
population? 
1c: the QOL–DN detect early DPN in an OOI, PD and T2D population? 
RQ2: Which tool will be the most sensitive for detecting early DPN?  
 
Research Hypotheses 
H1: The 128-Hz tuning fork and QOL–DN tools will provide excellent mechanisms for 
detecting early DPN in OOI, PD and T2D populations. 
H2: The QOL-DN will be the most sensitive measure to detect early or undisclosed DPN in an 
OOI, PD and T2D population. 
 
Assumptions.  Assumptions included accurate reporting on the part of our participants.  
This includes believing that they would be invested in accurately participating in tests that 
involved their voluntary response, such as tuning fork, and monofilament testing and that 
participating individuals would answer questions honestly on the provided patient reported 





our research were likely to report truthfully and be invested in the task at hand, as they were not 
paid for their time, and willingly participated of their own free will in the study.  The 
psychometric properties of the QOL-DN have been previously evaluated for populations with 
diabetes and also, for the purposes of revealing undisclosed DPN in varied populations; 
therefore, in this research study we assumed that the psychometric properties of this instrument 
would be effective in our OOI individuals.  
Limitations.  Old Dominion University has limited clinical equipment for related to 
diabetes testing.  The HbA1C testing machine that was used within the study is a validated 
machine (Lenters-Westra & Slingerland, 2010), yet oral glucose tolerance testing is preferred by 
some research scientists, particularly for individuals with cardiac autonomic neuropathy (CAN) 
(Farhan et al., 2012).  DPN and CAN often coexist, yet we did not test for CAN and, therefore, 
cannot account for unknown discrepancies.  Temperature and humidity have been found to affect 
monofilament results, by affecting the potential validity of the instrument in extremely high 
temperatures as well as high testing volumes in short periods of time (Booth & Young, 2000; 
Haloua, Sierevelt, & Theuvenet, 2011).  Temperature was accounted for by limiting 
monofilament storage and use to normal climate controlled room temperatures and monitored 
these values.  Humidity was monitored, but not controlled beyond what the Old Dominion 
University air-conditioning and heating systems accounted for.  Preparation for monofilament 
usage followed previously stated guidelines and recommendations, with testing amounting to far 
less than 100 compressions per day per instrument (Booth & Young, 2000).  The NC-Stat DPN 
Check device was used solely to test the sural nerve; therefore, deficits in nerve function relating 
to other nerves of the lower leg were not confirmed through this device.  Previous research has 





inactive population and, therefore, we should take this into account in the interpretation of our 
findings. 
Delimitations.  Individuals were screened through the provided screening questionnaire 
located in the appendix (see appendix A).  None of the research staff were trained physicians.  
We did not ask for medical records to confirm individual reporting.  We did not evaluate medical 
conditions or attempt to diagnose neuropathy, but instead referred individuals to appropriate 
medical staff if research findings indicated potential deficits related to DPN. 
 
Operational Definitions 
Confirmed DSPN: “The presence of an abnormality of nerve conduction and symptom or 
symptoms or a sign or signs of neuropathy confirms DSPN.  If nerve conduction is 
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence) 
may be used.  To assess for the severity of DSPN, several approaches can be 
recommended: the graded approach; various continuous measures of sum scores of 
neurologic signs, symptoms, or nerve test scores; scores of function of activities of daily 
living (ADLS); or scores of predetermined tasks or of disability” (Prevention of Type 2 
Diabetes: From Science to Therapy, 2012, p. 120).  Additional resources to support this 
definition include Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, 
Spallone, and Vinik (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, 
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).  
Diabetes: The American Diabetes Association clearly classifies diabetes into four categories 
(ADA, 2014, 2016; Zhou & Zhou, 2014): 





complete insulin deficiency. 
2.  Type 2 diabetes (T2D): caused by a progressive insulin secretory defect combined 
with insulin resistance). 
3.  Gestational diabetes mellitus (GDM): diabetes which is diagnosed during pregnancy, 
usually in the second or third trimester, yet is not considered overt diabetes. 
4.  Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes, 
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment, 
organ transplants). 
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C) 
value of > 6.5% or a fasting glucose of > 126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; 
Zhou & Zhou, 2014) with clear diagnostic criteria.  Without clear diagnostic criteria, an 
immediate retest should be done to confirm the results, or two diagnostic tests with clear 
confirmation confirms diagnosis. 
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of 
the nervous system, singly or combined.  It may be silent and go undetected while 
exercising its ravages; or it may present with clinical symptoms and signs that, although 
nonspecific and insidious, with slow progression, also mimic those seen in many other 
diseases” (Vinik et al., 2013, pg. 747). 
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have 
been diagnosed with diabetes.  It is frequently reported as a late complication resulting in 
multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al., 
1995; Vinik et al., 2013).  Generally, DPN is viewed in subdivisions, such as: 





sensorimotor polyneuropathy (DSPN), which is a common type of neuropathy 
experienced by diabetes patients (Sadosky, 2008; Vinik, Ullal, Parson, & Casellini, 2006; 
Vinik et al., 2013). 
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten 
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016).  This test is used to diagnose 
prediabetes and diabetes.  It is also used to monitor people with diabetes.” 
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average 
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016).  The hemoglobin 
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and 
sometimes joins with the glucose in the bloodstream.  This test is called hemoglobin A1C 
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red 
blood cells with glucose attached to the A1c component, which is proportional to the 
amount of glucose in the blood.  
Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes. The oral 
glucose tolerance test is given by a health care professional after an overnight fast.  A 
blood sample is taken, then the patient drinks a high-glucose beverage provided by the 
health care professional.  Blood samples are taken at intervals for 2 to 3 hours and the 
results are compared with a standard and show how the body uses glucose over time 
(ADA, 2014, 2016). 
Possible DSPN: The presence of symptoms or signs of DSPN including any of the following: 
symptoms—decreased sensation; positive neuropathic sensory symptoms (e.g. “asleep 
numbness,” prickling or stabbing, burning or aching pain) predominantly in the toes, feet 





absent ankle reflexes (Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 
120).  Additional resources to support this definition include Tesfaye et al. (2010) and 
Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, 
Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).  
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically 
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016).  
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou & 
Zhou, 2014).  These individuals should be considered to be in a place of increased risk 
for both cardiovascular disease (CVD) and diabetes development.  HbA1C values > 6.0 
should be considered very high risk for the development of diabetes and aggressive 
interventions are advised. 
Probable DSPN: “The presence of a combination of symptoms and signs of neuropathy including 
two or more of any of the following: neuropathic symptoms, decreased distal sensation, 
or unequivocally decreased or absent ankle reflexes” (Prevention of Type 2 Diabetes: 
From Science to Therapy, 2012, p. 120).  Additional resources to support this definition 
include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, 
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013). 
Small fiber neuropathy (SFN): “SFN should be graded as follows: (1) possible: the presence of 
length-dependent symptoms and/or clinical signs of small fiber damage; (2) probable: the 
presence of length dependent symptoms, clinical signs of small fiber damage, and normal 
sural nerve conduction; and (3) definite: the presence of length dependent symptoms, 





at the ankle and/or abnormal thermal thresholds at the foot (Prevention of Type 2 
Diabetes: From Science to Therapy, 2012, p. 120).  Additional resources to support this 
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, 
Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 
2013). 
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically 
diagnostic, symptomology; may apply to blood glucose, HbA1C levels, DPN, or other 
diabetes symptomology (Mustafa et al., 2012).  
Subclinical DSPN: “The presence of no signs or symptoms of neuropathy is confirmed with 
abnormal nerve conduction or a validated measure of SFN (with class 1 evidence)” 
(Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 120).  Definitions 
relating to possible, probable and confirmed DSPN can be used for clinical practice and 
confirmed DSPN and subclinical definitions can be used for research studies.  Additional 
resources to support this definition include Tesfaye et al. (2010) and Vinik et al. (2013) 
(Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, 
et al., 2010; Vinik et al., 2013). 
 
Expected Outcomes 
 This study examined the diagnostic utility of the 128-Hz tuning fork, 1-g and 10-g 
monofilaments, and QOL-DN for the purposes of subclinical neuropathy screening and to 
determine which was the most effective.  Previous studies indicated that all three of these 
measures have been both sensitive and reliable in T2D populations; therefore, we expected the 





had limited usage with PD populations, and their utility needs further validation, yet we expected 
high reliability and specificity from all three measures in detecting DPN in a PD population.  The 
unique outcome of the study was determined to be ascertaining which measure is the most 
sensitive and specific for determining subclinical DPN detection, and we predicted that the QOL-
DN would provide a mechanism for detecting sensation loss that is able to be noticed by the 
participant.  We also expected that the 128-Hz tuning fork would be a useful mechanism for 







PART B: NEUROPATHY QUALITY OF LIFE TOOLS 
The Problem 
 DN is often experienced in T2D, and research has also confirmed DN in PD populations, 
raising questions as to when DN develops (Marrero et al., 2014; Papanas & Ziegler, 2012) and 
how soon it affects QOL.  QOL is a significant issue in diabetes management, and quick 
assessment seems prudent for medical screenings in research, yet little attention has been given 
to the completion burden related to QOL instruments, as the time to complete certain measures 
are reported as unknown or somewhat lengthy (Smith, Lamping, & Maclaine, 2012).  Accurate 
and effective assessment of QOL measures can be a benefit for healthcare providers and patients 
alike in a multitude of settings, yet some debate exists regarding which instruments are the most 
effective for determining QOL.  
 
Purpose & Significance of the Study 
 The purpose of the study was to compare the measures of the QOL–DN, the PN-QOL-97, 
and the NeuroQOL-28 in a mixed population that included OOI, PD and T2D individuals to 
determine which instrument was the most effective at detecting DPN at various stages while 
comparing the findings back to a criterion standard of NC–Stat DPN Check (NeuroMetrix, 
Waltham, MA).  Completion times were tracked for each instrument, allowing a comparison of 
the time investment needed to utilize each chosen method. 





population, it may open up new opportunities to evaluate the effectiveness of these instruments 
in early DPN and subclinical populations.  Further examination of these instruments could 
provide opportunity to strengthen the measures and reveal unknown caveats. 
 
Research Design 
 Study Design Approach.  The proposed study took an observational and correlational 
approach paired with a quantitative data collection.  Individuals were screened and categorized 
by HbA1C values and prior diagnoses, creating specific groups to study (see Appendix A) (OOI, 
PD, T2D).  A criterion variable was implemented, with NC-Stat DPN Check nerve conduction 
testing being presented as the criterion that determining normal or abnormal values for the sural 
nerve.  The effectiveness of the content of the other variables, the QOL-DN, the NeuroQOL-28 
and PN-QOL-97, was compared to this standard of testing (see Appendices B, C and D). 
 
Research Questions 
RQ 1: To what extent will the three instruments differ in their ability to detect DN in OOI, PD 
and T2D populations? 
RQ 2: To what extent will the results of the three instruments correlate with the NC-Stat DPN 
Check? 








H 1: We hypothesized that the QOL–DN and PN-QOL-97 would more clearly identify signs 
of early DN when compared to the NC-Stat DPN Check results. 
H 2: We hypothesized that all three instruments would correlate with the NC-Stat DPN Check 
results at 60 or higher, with the QOL-DN yielding the strongest relationship. 
H 3: We hypothesized that the NeuroQOL-28 would be quickest to complete, followed by the 
QOL-DN and the PN-QOL-97. 
 
Assumptions.  Assumptions included accurate reporting on the part of our participants, 
that they would answer questions honestly on the provided questionnaires, and be invested in 
accurate participation.  We justified that individuals choosing to engage in our research were 
likely to report truthfully and be invested in the task at hand, as they were not paid for their time 
and were involved in the study by their own choice.  The psychometric properties of the QOL-
DN have been previously evaluated for populations with diabetes and also, for the purposes of 
revealing undisclosed DPN in varied populations; therefore, in this research study we assumed 
that the psychometric properties of this instrument would be effective in our OOI individuals. 
Limitations.  Old Dominion University has limited clinical equipment for related to 
diabetes testing.  The HbA1C testing machine that was used within the study is a validated 
machine (Lenters-Westra & Slingerland, 2010), yet oral glucose tolerance testing is preferred by 
some research scientists, particularly for individuals with cardiac autonomic neuropathy (CAN) 
(Farhan et al., 2012).  We did not test for CAN and, therefore, cannot account for unknown 
discrepancies.  Lack of random assignment and use of volunteers for subjects created potential 





influencing this method.  The NC-Stat DPN Check device was used solely to test the sural nerve; 
therefore, deficits in nerve function relating to other nerves of the lower leg were not confirmed 
through this device.  Previous research has not investigated the validity of the QOL-DN, the PN-
QOL-97 and the NeuroQOL-28 specifically within an overweight, obese and inactive population 
and, therefore, we should take this into account in the interpretation of our findings. 
Delimitations.  Individuals were screened to help determine eligibility for participation 
(see appendix A).  The researchers were not trained physicians.  We did not ask for medical 
records to confirm individual reporting.  We did not evaluate medical conditions or attempt to 
diagnose neuropathy, but instead referred individuals to medical staff if research findings 
indicated potential deficits related to PN or other medical conditions that presented themselves. 
 
Operational Definitions 
Confirmed DSPN: “The presence of an abnormality of nerve conduction and symptom or 
symptoms or a sign or signs of neuropathy confirms DSPN.  If nerve conduction is 
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence) 
may be used.  To assess for the severity of DSPN, several approaches can be 
recommended: the graded approach; various continuous measures of sum scores of 
neurologic signs, symptoms, or nerve test scores; scores of function of activities of daily 
living (ADLS); or scores of predetermined tasks or of disability” (Prevention of Type 2 
Diabetes: From Science to Therapy, 2012, p. 120).  Additional resources to support this 
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, 






Diabetes: The American Diabetes Association clearly classifies diabetes into four categories 
(ADA, 2014, 2016; Zhou & Zhou, 2014): 
1.  Type 1 diabetes (T1D): caused by beta cell destruction, and most often leads to 
complete insulin deficiency. 
2.  Type 2 diabetes (T2D): caused by a progressive insulin secretory defect combined 
with insulin resistance. 
3.  Gestational diabetes mellitus (GDM):  diabetes that is diagnosed during pregnancy, 
usually in the second or third trimester, yet is not considered overt diabetes. 
4.  Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes, 
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment, 
organ transplants). 
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C) 
value of > 6.5% or a fasting glucose of > 126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; 
Zhou & Zhou, 2014) with clear diagnostic criteria.  Without clear diagnostic criteria, an 
immediate retest should be done to confirm the results, or two diagnostic tests with clear 
confirmation confirms diagnosis. 
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of 
the nervous system, singly or combined.  It may be silent and go undetected while 
exercising its ravages; or it may present with clinical symptoms and signs that, although 
nonspecific and insidious with slow progression, also mimic those seen in many other 
diseases” (Vinik et al., 2013, pg. 747). 
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have 





multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al., 
1995; Vinik et al., 2013).  Generally, DPN is viewed in subdivisions, such as: 
focal/multifocal neuropathies, diabetic amyotrophy, symmetric polyneuropathies and 
sensorimotor polyneuropathy (DSPN), which is a common type of neuropathy 
experienced by diabetes patients (Sadosky, 2008; Vinik et al., 2006; Vinik et al., 2013). 
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten 
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016).  This test is used to diagnose 
prediabetes and diabetes.  It is also used to monitor people with diabetes”. 
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average 
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016).  The hemoglobin 
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and 
sometimes joins with the glucose in the bloodstream.  This test is called hemoglobin A1C 
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red 
blood cells with glucose attached to the A1c component, which is proportional to the 
amount of glucose in the blood.  
Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes. The oral 
glucose tolerance test is given by a health care professional after an overnight fast.  A 
blood sample is taken, then the patient drinks a high-glucose beverage provided by the 
health care professional.  Blood samples are taken at intervals for 2 to 3 hours and the 
results are compared with a standard and show how the body uses glucose over time 
(ADA, 2014, 2016). 
Possible DSPN: The presence of symptoms or signs of DSPN including any of the following: 





numbness,” prickling or stabbing, burning or aching pain) predominantly in the toes, feet 
or legs; or signs—symmetric decrease of distal sensation, or unequivocally decreased or 
absent ankle reflexes (Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 
120).  Additional resources to support this definition include Tesfaye et al. (2010) and 
Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, 
Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013).  
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically 
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016). 
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou & 
Zhou, 2014).  These individuals should be considered to be in a place of increased risk  
for both cardiovascular disease (CVD) and diabetes development.  HbA1C values > 6.0 
should be considered very high risk for the development of diabetes and aggressive 
interventions are advised. 
Probable DSPN: “The presence of a combination of symptoms and signs of neuropathy including 
two or more of any of the following: neuropathic symptoms, decreased distal sensation, 
or unequivocally decreased or absent ankle reflexes” (Prevention of Type 2 Diabetes: 
From Science to Therapy, 2012, p. 120).  Additional resources to support this definition 
include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, Freeman, 
Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 2013). 
Small fiber neuropathy (SFN): “SFN should be graded as follows: (1) possible: the presence of 
length-dependent symptoms and/or clinical signs of small fiber damage; (2) probable: the 





sural nerve conduction; and (3) definite: the presence of length dependent symptoms, 
clinical signs of small fiber damage, normal sural nerve conduction, and altered IENFD 
at the ankle and/or abnormal thermal thresholds at the foot (Prevention of Type 2 
Diabetes: From Science to Therapy, 2012, p. 120).  Additional resources to support this 
definition include Tesfaye et al. (2010) and Vinik et al. (2013) (Tesfaye, Boulton, Dyck, 
Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, et al., 2010; Vinik et al., 
2013). 
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically 
diagnostic, symptomology; may apply to blood glucose, HbA1C levels, DPN, or other 
diabetes symptomology (Mustafa et al., 2012). 
Subclinical DSPN: “The presence of no signs or symptoms of neuropathy is confirmed with 
abnormal nerve conduction or a validated measure of SFN (with class 1 evidence)” 
(Prevention of Type 2 Diabetes: From Science to Therapy, 2012, p. 120).  Definitions 
relating to possible, probable and confirmed DSPN can be used for clinical practice and 
confirmed DSPN and subclinical definitions can be used for research studies.  Additional 
resources to support this definition include Tesfaye et al. (2010) and Vinik et al. (2013) 
(Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, Vinik, 
et al., 2010; Vinik et al., 2013). 
 
Expected Outcomes 
 This research attempted to evaluate  the QOL-DN, the PN-QOL-97 and the NeuroQOL-
28 in a mixed population in order to determine which instrument was the most effect at detecting 





the sural nerve provided by the NC-Stat DPN Check (NeuroMetrix, Waltham, MA).  Average 






PART C: MELATONIN AND AUTONOMIC NERVOUS SYSTEM FUNCTION 
The Problem 
 CAN is a serious complication of diabetes, presenting with various degrees of severity 
throughout research.  While the concept of neuropathy research is well represented for the 
diabetic foot, CAN dysfunction and appropriate treatment for this disorder has not been well 
investigated.  Circadian patterns are often disrupted in T2D and associated dysfunction and 
pathology aligns with this disruption. 
 Autonomic nervous system function (ANS) is frequently affected in T2D, leaving an 
altered state of dysfunction that negatively affects circadian rhythms.  This altered state affects 
sleep quality, ANS function, and creates a state of CAN, which ultimately places individuals at 
significant risk for early mortality. 
 
The Purpose & Significance of the Study 
 Melatonin supplementation provides an opportunity for rebalancing the ANS in T2D.  
Melatonin has been found to be effective in resetting the circadian clock of the ANS, and we 
postulated that it may help improve ANS function in T2D patients, providing relief from sleep 
dysfunction, ANS pathology, and ultimately attenuate the pathophysiology of CAN. 
 The overall purpose of this research was to investigate whether the underlying central, 
cardiac, and peripheral defects that were observed in T2D could be improved or reversed by a 





was evaluated through the effects of a high dose supplemental melatonin on autonomic balance 
in baroreflex sensitivity (BRS). 
 
Research Design 
 This study investigated the potential positive effects of a single, high dose of nightly 
melatonin supplements on autonomic balance and baroreflex sensitivity in adults with T2D.  
Autonomic balance in T2D subjects was studied at baseline and following 4 weeks of 10 mg 
dose of melatonin or placebo in a double-blinded, randomized design, with no washout period 




RQ1: To what extent is the ANS altered in individuals with T2D at baseline testing? 
RQ2: To what extent will melatonin improve baseline study measures of ANS function? 
 
Research Hypotheses 
H1: We hypothesized that the ANS misconducts, causing a neuroinflammatory response, 
leading to impairment and that the proposed study measures would evaluate this 
phenomenon. 






Assumptions.  Assumptions included accurate reporting on the part of our participants.  
This includes the basic assumption that individuals would answer questions honestly on the 
provided questionnaires, be invested in accurately participating in tests that involve their 
voluntary response, and accurately report consumption of the provided pills for each leg of the 
study.  The Eastern Virginia Medical School Strelitz Diabetes Center provided the ANSAR and 
Sudoscan testing for patient evaluation on location at their outpatient facility.  We assumed that 
all equipment beyond our control was well maintained and in proper working order for the use of 
this study. 
Limitations.  Old Dominion University has excellent movement exercise laboratory 
testing equipment, still, limited clinical testing equipment for clinical diabetes testing.  The 
hemoglobin A1C (HbA1C) testing machine that was transported to Eastern Virginia Medical 
School is valid and reliable, yet oral glucose tolerance testing is preferred for working with CAN 
patients with diabetes (Farhan et al., 2012).  Our sample was quite small for this pilot study, and 
all inferences within the written literature should take this into account. 
Delimitations.  We did not ask for medical records to confirm individual reporting. Oral 
glucose tolerance testing was not performed with the CAN patients due to financial limitations.  
Bloodwork was not drawn to confirm fasted states of participants due to financial limitations. 
 
Operational Definitions 
Diabetes: The American Diabetes Association clearly classifies diabetes into four categories 
(ADA, 2014, 2016; Zhou & Zhou, 2014): 
1.  Type 1 diabetes (T1D):  caused by beta cell destruction, and most often leads to 





2.  Type 2 diabetes (T2D):  caused by a progressive insulin secretory defect combined 
with insulin resistance). 
3.  Gestational diabetes mellitus (GDM):  diabetes which is diagnosed during pregnancy, 
usually in the second or third trimester, yet is not considered overt diabetes. 
4.  Diabetes due to other causes, such as neonatal diabetes, maturity-onset diabetes, 
pancreatic disease causes (cystic fibrosis), drug or chemical causes (HIV/AIDS treatment, 
organ transplants).  
Diabetes Diagnostic Criteria: Diabetes may be diagnosed with a hemoglobin A1C (HbA1C) 
value of > 6.5% or a fasting glucose of >126 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; 
Zhou & Zhou, 2014) with clear diagnostic criteria.  Without clear diagnostic criteria, an 
immediate retest should be done to confirm the results, or two diagnostic tests with clear 
confirmation confirms diagnosis. 
Diabetic neuropathy (DN): “DN is represented by clinical syndromes affecting distinct regions of 
the nervous system, singly or combined.  It may be silent and go undetected while 
exercising its ravages; or it may present with clinical symptoms and signs that, although 
nonspecific and insidious with slow progression, also mimic those seen in many other 
diseases” (Vinik et al., 2013, pg. 747). 
Diabetic peripheral neuropathy (DPN): DPN is commonly experienced by individuals who have 
been diagnosed with diabetes.  It is frequently reported as a late complication resulting in 
multiple syndromes, with no universal viewpoint for classification (Vinik, Mitchell, et al., 
1995; Vinik et al., 2013).  Generally, DPN is viewed in subdivisions, such as:  
focal/multifocal neuropathies, diabetic amyotrophy, symmetric polyneuropathies and 





experienced by diabetes patients (Sadosky, 2008; Vinik et al., 2006; Vinik et al., 2013). 
E/I Ratio: Represents a ratio of expiration to inspiration; standardized cardiac reflex test based on 
deep breathing recommended by American Diabetes Association for the evaluation of 
CAN; primarily tests cardiac parasympathetic functions (Gulichsen, Fleischer, Ejskjaer, 
Eldrup, & Tarnow, 2012; Vinik et al., 2013). 
Fasting plasma glucose: “a check of a person's blood glucose level after the person has not eaten 
for 8 to 12 hours (usually overnight) (ADA, 2014, 2016).  This test is used to diagnose 
prediabetes and diabetes.  It is also used to monitor people with diabetes”. 
Glycosylated hemoglobin testing: (HbA1C testing) is a test measuring an individual’s average 
blood glucose levels for the past 2 to 3 months (ADA, 2014, 2016).  The hemoglobin 
(HEE-mo-glo-bin) is the part of a red blood cell that carries oxygen to the cells and 
sometimes joins with the glucose in the bloodstream.  This test is called hemoglobin A1C 
or glycosylated (gly-KOH-sih-lay-ted) hemoglobin, and represents the percentage of red 
blood cells with glucose attached to the A1c component, which is proportional to the 
amount of glucose in the blood. 
Heart rate variability: Heart rate variability (HRV) is a measureable, physiological phenomenon 
involving the variation of intervals of time between successive heart beats and is 
measured in beat to beat intervals. 
High frequency (HF) component: Refers to a primarily parasympathetic dominant pathway in the 
autonomic nervous system (Heathers, 2014; Lieb, Parson, Mamikunian, & Vinik, 2012). 
Low frequency (LF) component: Refers to low frequency component of HRV; often reflected in 
literature as a sympathetically dominant component; however, debate exists on the 





Oral glucose tolerance testing: This is a test used to diagnose prediabetes and diabetes.  The oral 
glucose tolerance test is given by a health care professional after an overnight fast.  A 
blood sample is taken, then the patient drinks a high-glucose beverage provided by the 
health care professional.  Blood samples are taken at intervals for 2 to 3 hours and the 
results are compared with a standard and show how the body uses glucose over time 
(ADA, 2014, 2016). 
Prediabetes: Prediabetes is considered to be a condition of elevated but not yet clinically 
diagnosable diabetes blood glucose or HbA1C levels (ADA, 2014, 2016). 
Prediabetes Identification Criteria: Prediabetes may be defined with an HbA1C value of 5.7–
6.4% or a fasting glucose of > 100–125 mg/dL (7.0 mmol/L) (ADA, 2014, 2016; Zhou & 
Zhou, 2014).  These individuals should be considered to be in a place of increased risk 
for both CVD and diabetes development.  HbA1C values > 6.0 should be considered very 
high risk for the development of diabetes and aggressive interventions are advised. 
RMSSD: The square root of the mean of the sum of the squares of differences between 
successive NN intervals; a measure primarily of parasympathetic activity (American 
Heart Association Inc.; European Society of Cardiology, 1996; Vinik & Ziegler, 2007). 
SDNN: Refers to the standard deviation of NN intervals (normal R to R intervals); a measure 
that reflects both sympathetic and parasympathetic pathways within the autonomic 
nervous system; is a reflection of cyclic components that are responsible variability 
during the period of recording (American Heart Association Inc.; European Society of 
Cardiology, 1996; Lieb et al., 2012). 
Subclinical: Subclinical refers to a condition in terms of being elevated but not yet clinically 





diabetes symptomology (Mustafa et al., 2012). 
Valsalva Ratio: Evaluates sympathetic adrenergic pathways by utilizing HR and BP responses; 
evaluates parasympathetic pathways in the form of HR responses; involves timed, 
dynamic breathing patterns which create a dynamic, active exhalation against pressure 
(Gulichsen et al., 2012). 
30:15 Ratio: A ratio derived from the duration of inspiration to the duration of exhalation; taken 
from the lowest heart rate after position change (standing) in relationship to the fastest 
heart rate.  Typically, the ratio is derived from the 30th and 15th heart beats. 
 
Expected Outcomes 
We expect that melatonin will have a positive effect on the ANS, attenuating some of the 
effects of T2D pathophysiology demonstrated in altered baseline HRV measures and disrupted 
sleep patterns.  We expect that individuals will likely experience better sleep during the 
melatonin part of the trial and that sleep will likely remain the same during the four-week period 







REVIEW OF THE LITERATURE 
This purpose of this chapter is to review the pertinent literature relating to neuropathy 
detection, screening, and treatment.  Chapter II Part A, Neuropathy Screening Tools, discusses 
diabetic peripheral neuropathy (DPN), its pathophysiological basis, and examines the diagnostic 
accuracy of specific tools for the assessment of DPN, including the 128-Hz tuning fork, 1-g and 
10-g monofilaments, the QOL-DN, the NC-Stat DPN Check and HbA1C testing.  Chapter II Part 
B, Neuropathy Quality of Life Tools, discusses health-related quality of life (HQOL) within the 
context of T2D and DPN, and examines neuropathy specific QOL instruments of interest, 
including the QOL-DN, the PN-QOL-97, and the NeuroQOL-28 in conjunction with the NC-Stat 
DPN Check and HbA1C testing.  Each of these modules of the study (Part A and B) will present 
research findings and synthesize the current literature relating to reliability and validity for the 
aforementioned diagnostic tools, questionnaires, and testing methods within the context of 
screening for and identifying neuropathy in healthy, PD and T2D populations. 
Chapter II Part C, Melatonin and the Autonomic Nervous System, discusses melatonin 
and its effect on autonomic nervous system function in T2D, symptoms of cardiovascular 
autonomic neuropathy (CAN) in diabetes, symptoms and measurement of cardiac dysfunction.  
This section presents research findings and synthesizes the current literature relating to these 
concepts and instruments, including their reliability and validity.  The focus of the literature 







PART A: NEUROPATHY SCREENING TOOLS 
Diabetic Peripheral Neuropathy 
 The International Diabetes Federation (IDF) estimates the global problem of diabetes to 
have reached 387 million people as of 2014, and estimate the reach of diabetes to increase to 592 
million by the year 2035 (International Diabetes Federation, 2014).  With such significant 
impact, it is easy to understand why the complications of T2D draws significant attention.  DPN 
is one of the most common and troublesome complications that T2D patients may encounter as it 
is both a silent and damaging opponent, even in early stages (Divisova, 2012; Mustafa et al., 
2012; Papanas & Ziegler, 2012).  Chronic or acute hyperglycemia, microvascular insufficiency, 
oxidative and nitrosative stress, defective neurotropism or autoimmune-related nerve destruction 
all may contribute to the destruction of nerve cells or structures, and produce damage to key 
organs and systems, such as the kidneys, retina or neurons (Marcovecchio, Lucantoni, & 
Chiarelli, 2011; Vinik et al., 2013).  Such damage may lead to diabetic cardiac autonomic 
neuropathy (CAN), retinopathy, diabetic nephropathy, damage to various organs, or our focus, 
DPN. 
 Evaluating DPN is not a simple task, and physicians generally rule out other possible 
causes for any presenting symptoms before assigning a DPN diagnosis (Tesfaye, 2010; Tesfaye, 
2015; Vinik et al., 2013).  Diagnosis is difficult, and misdiagnosis is common as many specialists 
are not trained to recognize the signs and symptoms of the disease, and this ultimately aids in the 
progression of DPN without treatment (Herman & Kennedy, 2005).  DPN is also viewed in 





symmetric polyneuropathies and sensorimotor polyneuropathy (DSPN), further elaborating the 
scenario for proper diagnosis.  DSPN presents as the most commonly occurring neuropathy to 
date, manifesting with length-dependent, symmetrical sensorimotor polyneuropathy, often 
developing in patients with a history of extended hyperglycemia (Marcovecchio et al., 2011; 
Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, Lauria, Malik, Spallone, & Vinik, 2010).  
Glycemic control, therefore, is an important prevention implementation or risk covariate, and is 
dependent on the history of the patient and whether stabilization is achievable.  The damage 
caused is microvascular by nature, linking this manifestation to similar diabetes complications 
such as retinopathy and nephropathy (Tesfaye, 2010).  
Literature is divided relating to the true prevalence of DPN, with variability in reporting 
ranging from 30–90% (Dixit & Maiya, 2014; Duby, Campbell, Setter, & Rasmussen, 2004; 
Vinik, 1999; Vinik et al., 2013).  Reporting rates vary based on the testing methods used, with 
the highest rates of reporting associated with sophisticated testing equipment such as nerve 
conduction studies (NCS) or in research reporting, neuropathic pain syndromes (Rota, 2005, 
2007).  Both type 1 diabetes (T1D) and T2D patients are affected by the disease, and may or may 
not present with neurologic signs or symptoms (Boulton, 2015; Singh, Armstrong, & Lipsky, 
2005; Vinik et al., 2013).  Strong community reporting indicates rates of DPN prevalence at 
25%, with DPN contributing to 30% of diabetes related hospitalizations, and some research 
reports that as many as one out of four diabetes patients will develop foot ulcers within the 
course of their lifetime (Lipsky et al., 2006; Vinik et al., 2013; Zgonis, Stapleton, Girard-Powell, 
& Hagino, 2008). 
DPN has been commonly reported as a late complication of diabetes, and described as a 





2013).  A lack of universal classification makes DPN especially difficult to diagnose, even for 
seasoned professionals (McKinlay, Piccolo, & Marceau, 2013).  This is even more true for the 
untrained eye, as physicians will offer competing diagnoses with great levels of certainty 
(McKinlay et al., 2013).  DN affects distinct areas of the nervous system in a singular or 
combined fashion, and may do so silently for quite some time (Vinik et al., 2013).  Conversely, 
DPN may present with very distinct symptoms that are diagnosable or, nonspecific, difficult to 
diagnose symptoms and, therefore, these symptoms may be confused with other illnesses.  While 
symptoms vary, common complaints may include burning, tingling, or numbness in the lower 
extremities (Dixit & Maiya, 2014), see Table IIA.1. 
When classifying sensation loss, there are several fiber types, including small, large, and 
sensory fiber involvement.  Small fiber sensation loss generally affects thermal and pain 
perception while large fiber dysfunction will result in dysfunction related to touch and vibration 
sensations (Vinik et al., 2013).  Sensory fiber involvement causes variations of pain or abnormal 
sensations such as tingling, pins and needles or prickly sensations. 
 
Neuropathy Screening & Assessment 
 The clinical assessment of DPN is recommended when receiving a T2D diagnosis or 
within five years of receiving a T1D diagnosis, and a detailed examination is key in order to 
reveal the presence of DPN (ADA, 2016; Baraz, Zarea, Shahbazian, & Latifi, 2014; Dixit & 
Maiya, 2014; Katon, Reiber, & Nelson, 2013).  Screening should include an examination of 
ankle reflexes and sensory tests associated with DPN, along with a full examination of feet.  
Sensory function may be evaluated in a number of ways, including the Wartenberg Pinwheel 





monofilament applied at the distal halluces.  It is recommended for examinations to utilize more 
than one test during screenings, as previous research indicates an 87% sensitivity for the 
detection of DPN when two tests are combined (Boulton et al., 2005; Vinik et al., 2013; Vinik, 
Suwanwalaikorn, et al., 1995). 
 Small fiber neuropathy may be examined with Neurotips, which evaluates nociceptors for 
pain and warmth, or a cold tuning fork, which evaluates cold thermoreceptors (see Table IIA.2; 
Vinik et al., 2013).  Large fiber neuropathy may be evaluated via vibration distributed through a 
128-Hz tuning fork, which tests the mechanoreceptors and Ruffini corpuscle, or alternatively one 
may choose to implement a wisp of cotton, which evaluates Meissner corpuscles through light 
touch (see Table IIA.2, Vinik at al., 2013).  Pacinian corpuscle may be tested via 1-g or 10-g 
monofilament, which ultimately tests pressure and large fiber sensitivity. 
 The staff of the Strelitz Diabetes Center, which is part of the Eastern Virginia Medical 
School in Norfolk, VA has compiled the following definitions for the diagnostic assessment of 
DPN: 
1. “Possible DSPN.  The presence of symptoms or signs of DSPN and may include the 
following: symptoms—decreased sensation, positive neuropathic sensory symptoms (e.g., 
“asleep numbness”, prickling or stabbing, burning or aching pain) predominantly in the 
toes, feet, or legs; or signs—symmetric decrease of distal sensation or unequivocally 
decreased or absent ankle reflexes. 
2. Probable DSPN.  The presence of a combination of symptoms and signs of neuropathy 
including any two or more of the following: neuropathic symptoms, decreased distal 
sensation, or unequivocally decreased or absent ankle reflexes. 





or symptoms, or a sign or signs, of neuropathy confirm DSPN.  If nerve conduction is 
normal, a validated measure of small fiber neuropathy (SFN) (with class one evidence) 
may be used.  To assess for the severity of DSPN, several approaches can be 
recommended: for example, the graded approach outlined (see Table IIA.3); various 
continuous measures of sum scores of neurologic signs, symptoms, or nerve test scores; 
scores of function of activities of daily living; or scores of predetermined tasks of 
disability. 
4. Subclinical DSPN.  The presence of no signs or symptoms of neuropathy are confirmed 
with abnormal nerve conduction or a validated measure of DSPN (with class 1 evidence).  
Definitions 1, 2, or 3 can be used for clinical practice, and definitions 3 or 4 can be used 
for research studies. 
5. Small fiber neuropathy (SFN).  SFN should be graded as follows: (1) possible: the 
presence of length-dependent symptoms and/or clinical signs of small-fiber damage; (2) 
probable: the presence of length-dependent symptoms, clinical signs of small-fiber 
damage, and normal sural nerve conduction; and (3) definite: the presence of length-
dependent symptoms, clinical signs of small-fiber damage, normal sural nerve 
conduction, and altered intra-epidermal nerve fiber (IENF) density at the ankle and/or 
abnormal thermal thresholds at the foot” (Vinik at al., 2013, p.755–756). 
 As previously mentioned, presentation of neuropathy differs based on the type of 
neuropathy present.  Vinik & Mehrabyan (2004) prepared a simple, clear figure to represent this 
(see Figure IIA.1).  Neuropathy is a worldwide concern, with many organizations making great 
efforts to not only advance research, but also classify the disease.  Accepted testing parameters 





options for staging neuropathy as presented in Table IIA.4. 
The Tuning Fork.  The 128-Hz tuning fork has been effectively used in research to test 
for vibration sensation loss (Divisova et al., 2012; Perkins, Olaleye, Zinman, & Bril, 2001; 
Robinson, Balbinot, Silva, Achaval, & Zaro, 2013) by detecting the loss of sensation in the 
associated Ruffini mechanoreceptors of the large nerve fibers (Vinik et al., 2013).  It is a low 
cost means of assessing vibration thresholds (VT), easily accessible and has been widely used in 
the assessment of the diabetic foot for diagnosing polyneuropathy (Meijer et al., 2005). 
The Canadian Diabetes Association clearly outlines practices for the rapid screening of 
diabetic neuropathy and includes exact methodology for the tuning fork on/off test, including test 
scoring, site application and reproducible familiarization details ("Rapid Screening for Diabetic 
Neuropathy," 2013).  This method, within research, has presented as one of the most clearly 
defined methodologies and has been recommended by clinical practitioners. 
 Jayaprakash et al. (2011) investigated the validation of bedside testing methods 
specifically for the evaluation of DPN (Jayaprakash et al., 2011).  Vibration perception 
thresholds (VPT) were measured via a biothesiometer probe and compared to the 10–g 
monofilament, and the 128-Hz tuning fork.  Detailed histories were taken from 1044 patients 
with DM, questionnaires were filled out relating to Diabetic Neuropathy Symptom scoring, with 
a score greater than 1 being considered as significant.  Results indicated that tuning fork testing 
and 10-g monofilament testing resulted in lower sensitivity (62.5 and 62.8%); however, more 
desirable specificity (95.3 and 92.8%).  Accuracy was relatively high for both instruments (78.9 
and 77.9%) for tuning fork testing and monofilament screening, respectively.  The final 
interpretations of the study indicate these tools as useful in the assessment of DPN (Jayaprakash 





 Pourhamidi evaluated clinical tools and their diagnostic usefulness in detecting distal 
symmetric polyneuropathy and found sensitivity to be relatively low in the tuning fork compared 
to electronic measures such as the biothesiometer (Pourhamidi, Dahlin, Englund, & Rolandsson, 
2014).  In contrast to the study, other research has found the tuning fork to be quite useful for 
detecting large fiber related sensation loss, even when compared to a neurothesiometer 
(Kastenbauer, Sauseng, Brath, Abrahamian, & Irsigler, 2004). 
The 1-g and 10-g Monofilaments.  While monofilaments have been widely used for PN 
detection (Gregg et al., 2004; Katon et al., 2013), literature indicates a lack of continuity in 
testing across studies and debate regarding which monofilament methods (sites, grams, number 
of trials) are the most effective and reliable for detecting early sensation loss (Dros, Wewerinke, 
Bindels, & van Weert, 2009).  Studies suggest numerous site testing possibilities ranging from 
one to ten, including four-site SWM testing (Dixit & Maiya, 2014), three-site (Katon et al., 
2013), two-site (Lee et al., 2003), or one-site monofilament testing (Bourcier et al., 2006).  Baraz 
et al. chose multiple tests to evaluate with their research, testing at three, four, eight and ten sites, 
and found that three and four sites were significantly accurate and that adding additional points 
did not increase accuracy (Baraz et al., 2014).  Varying approaches have been established, with 
some studies utilizing full kits and multiple sites for testing, and others relying solely on one site, 
while utilizing the 1-g and 10-g for testing. 
The 10-g monofilament has been widely used in neuropathy screening both as a simple 
bedside screening tool and during general diabetes exams, and in the United States is considered 
a target tool for the evaluation of “loss of protective sensation” (Lavery & Gazewood, 2000; 
"Rapid Screening for Diabetic Neuropathy," 2013).  The Canadian Diabetes Association 





screening methods that physicians have utilized and approved ("Rapid Screening for Diabetic 
Neuropathy," 2013).  This standardized screening method highlights protocols for the 10-g 
monofilament and the 128-Hz tuning fork on/off method. 
As research literature points out, monofilaments are highly desirable for their portability, 
ease of use, and non-invasiveness in detecting developing problems within the insensate foot, 
and more recently have been used in subclinical neuropathy screening efforts (Divisova, 2012; 
Lavery & Gazewood, 2000).   Monofilaments have been used to help define DPN previously in 
literature: for example, Katon, Reiber, and Nelson (2013) utilized the 10-g monofilament data 
from the NHANES study (1999–2004), which used this screening tool to detect insensate sites 
on the foot in a massive study that examined 7818 individuals (Gregg et al., 2004; Katon et al., 
2013).  DPN was defined as one or more insensate sites on the foot.  Relative risks were 
calculated relating to diabetes and DPN, and results indicated modest increases in risk and DPN 
for those with PD and undiagnosed diabetes and a 74% higher risk of DPN for those with 
diagnosed diabetes.  Such ventures in literature demonstrate the usefulness of the 10-g for simple 
screening in large populations. 
 The precision and accuracy of the 10-g monofilament may come into question when used 
in a repeated loading fashion, without rest (Lavery et al., 2012).  This factor should be taken into 
consideration in how testing is administered by limiting testing loads per day.  If high volume 
testing is to take place, monofilament loading force should be regularly checked during research 
testing and clinical exams, as high repeated (200 cycles per day, 15 consecutive days) use will 
shorten the service life of this instrument.  Lavery et al. (2012) endorses the use of this unique 
instrument, but recommends seeking a quality manufacturer and combining this tool with other 






 Other issues which must be addressed are age, temperature and humidity, as 
monofilaments are affected by all three (Haloua, Sierevelt, & Theuvenet, 2011).  Age had a 
relatively minor effect within this research; however, temperature and humidity both 
significantly contributed to buckling force changes, as much as 39%.  When unaccounted for, 
this has the potential to mislead the examiner regarding the levels of sensation detected. Haloua 
et al. (2011) recommends awareness regarding the environmental effects of temperature and 
humidity (Haloua et al., 2011).  Controlling for environmental factors and screening with 
multiple bedside tests to confirm lack of sensation seems prudent. 
The Norfolk Quality of Life Diabetic Neuropathy Tool.  The Norfolk Quality of Life 
Diabetic Neuropathy Tool (QOL-DN) was developed as a neuropathy screening tool, aiming to 
differentiate between typical features that present in DPN (Vinik, Hayes, Oglesby, & Vinik, 
2004; Vinik et al., 2005), particularly issues related to changes in sensation in small and large 
fibers, as well as typical alterations to autonomic nervous system functioning (see Appendix B) 
(Vinik et al., 2005).  Twenty-eight questionnaire items were developed through 1000 structured 
patient interviews and combined with activities of daily living (ADLs), general health and status 
items of interest and tested on DPN patients. Initial testing revealed that the QOL-DN 
successfully identified domains of a fiber–specific nature relating to DPN with reliability, and 
discriminates between individuals who do and do not have DPN in an English-speaking 
population. 
The QOL-DN instrument is comprised of a Total QOL score, and five subscale items 
(symptoms, ADLS, small fiber, large fiber, autonomic), each targeting to measure a specific area 





fiber-specific QOL tool in this new population in 2014 (Vinik, Paulson, Ford-Molvik, & Vinik, 
2008).  This research demonstrated the tool’s ability to cross language barriers, and confirmed 
prior findings relating to the same factors as previously identified in the English version. 
Important findings include the Norfolk QOL-DN’s ability to detect levels of neuropathy within 
and across different populations (Vinik, Vinik, et al., 2014).  This fiber specific, self-report 
questionnaire was translated into Romanian and effectively revealed a high prevalence of 
undisclosed neuropathy in 25,000 Romanian patients (Veresiu et al., 2015).  The QOL–DN 
effectively and accurately determined the QOL of the participants, while also establishing its 
ability to operate within a new language and population to ferret out undisclosed neuropathy 
(Veresiu et al., 2015; Vinik et al., 2008). 
 The QOL-DN has also been used to assess baseline and improved QOL in randomized, 
double-masked, placebo-controlled, clinical studies and was sensitive enough to differentiate 
where improvement developed within fiber types (Boyd, Casselini, Vinik, & Vinik, 2011; 
Casellini, 2007).  The questionnaire has been successfully used in research to detect both the 
severity and impact of neuropathy on the QOL experiences in 61 patients diagnosed with 
transthyretin familial amyloid polyneuropathy (TTR-FAP) (Coelho et al., 2012; Coelho et al., 
2013; Vinik, Vinik, et al., 2014) and in patients with neuroendocrine tumors (Vinik, Silva, & 
Vinik, 2010).   This questionnaire has been effectively utilized to perform cost analyses of the 
financial impact of DPN within research and used within postal surveys within research efforts 
(Currie et al., 2006; Happich, John, Stamenitis, Clouth, & Polnau, 2008).   
Smith et al. analyzed the QOL-DN in relationship to other available measures in 2012 
and recommended it for DN screening (Smith et al., 2012).  Furthermore, this research points out 





fiber-specific, demonstrating test/re-test reliability and emphasizes the strong clinical 
background that serves as the foundation for the instrument.  The time to complete the 
instrument is unknown and criterion validity had not yet been assessed when the article was 
written. 
NC-Stat DPN Check.  The NC-Stat DPN Check (Neurometrix Inc., Waltham, MA) is a 
point-of-care nerve conduction device that has been developed with the intent to serve as a 
substitute for more advanced nerve conduction study (NCS) devices (Lee et al., 2014).  It is a 
simple, portable device that was made to be both user and patient friendly.  This method of 
evaluation of the sural nerve allows for a quick assessment (less than 10 minutes), with results 
that are easily uploaded to a laptop computer for evaluation.  The NC-Stat DPN Check has been 
proposed as being able to serve as a potential substitute for the more expensive and less 
accessible clinic driven NCS (Lee et al., 2014) and provides an opportunity for accessibility in 
community health care that has not been previously available.  This point of care device (POCD) 
requires limited training and supplies to operate it and flexible options for testing, thus enabling a 
low-cost and short time investment to screen for potential nerve damage in the lower leg in order 
to determine if further evaluation is warranted at a more complex facility. 
 The NC-Stat DPN Check was tested as a POCD across multiple sites with 72 patients in 
order to determine its potential as an alternative to traditional NCS (Perkins et al., 2008).  
Patients underwent extensive testing that included neurological examination and NCS.  
Spearman correlation coefficients indicated a relationship between the POCD and other 
measures ranging from .76 to .91, confirming reasonable accuracy for the device to serve as an 
alternative.  Lee et al. (2014) continued the validation of this device when his research team 





(Lee et al., 2014).  The sural nerve conduction velocity (SNCV) and sural nerve action potential 
(SNAP) were recorded.  Reliability and validity were evaluated via intraclass correlation 
coefficients, Bland-Altman analysis, and receiver operating characteristic curves and results 
indicated.  Two trained testers were utilized and interrater reproducibility ICC values were .97 
for SNAP (interrater value, .83) and .94 for SNCV (interrater value, .79), with 88% sensitivity 
and 94% specificity for SNAP reference values and 94% sensitivity and 71% specificity.  
Excellent reliability and acceptable accuracy was demonstrated by the device, and POCD 
normative threshold values were validated. 
 This validated POCD has been shown to be a reliable and accurate alternative to 
traditional NCS through successful evaluation of the sensory nerve action potential (SNAP) and 
sensory nerve conduction velocity (SNCV) of the sural nerve in multiple research studies (Lee et 
al., 2014; Perkins, Grewal, Ng, Ngo, & Bril, 2006; Perkins et al., 2008).  Multiple methodologies 
have been employed in its validation within these studies, including unilateral and bilateral 
applications, with one to two trials. 
Glycohemoglobin Testing.  Glycohemoglobin testing, or HbA1C, testing has been 
reliably used to categorize BG values within research and has been proven as a simple, portable 
method of screening for diabetes that is accurate, relatively quick to perform on-site (10 
minutes), and results are easily relayed (Feng, Schlosser, & Sumpio, 2009; Sumpio et al., 2013).  
This method of screening also provides the unique caveat of accessible health care upon demand 
to individuals that might not otherwise engage in or be able to afford more expensive tests such 
as oral glucose tolerance testing (OGTT).  When considering the validity of HbA1C screening 
for diabetes, it should be noted that the Canadian Task Force on Preventive Health Care, 





screening and diagnosis of diabetes (American Diabetes Association, 2012; Canadian Task 
Force, 2012; World Health Organization, 2011).  In a clinical setting, if positive results are 
obtained, results should be confirmed with repeated testing. 
 HbA1C testing has been shown in research to be strongly associated as an accurate 
predictor of glycemic control, especially when compared to fasting plasma glucose (FPG) (ADA, 
2016; Bernal-Lopez et al., 2011; Mannarino, Tonelli, & Allan, 2013).  While agreement is strong 
between HbA1C testing and FBG, issues arise with nonparallel findings between HbA1C and 
oral glucose tolerance testing (OGTT) (Farhan et al., 2012; Mannarino et al., 2013).  Studies 
independently performed by Mannarino et al. and Farhan et al. point out that there is discordance 
between OGTT and HbA1C regarding T2D diagnosis outcomes, with Farhan’s findings 
indicating discordance when cardiac autonomic neuropathy (CAN) is present.  Such issues may 
lower the incidence of diagnosis when using HbA1C as a determining test (Farhan et al., 2012). 
Additionally, HbA1C testing is not appropriate in situations with individuals who have 
hemoglobinopathies, as it may not be reliable (Hare, Shaw, & Zimmet, 2012).  Current 
recommendations by the American Diabetes Association, however, align HbA1C as a valid test 
in equal measure to other diagnostic tests that may be used and that one test is not preferred over 
the other (ADA, 2016). 
 The DCA Vantage from Siemens Corporation has been evaluated within research as a 
POCD for HbA1C testing and found to have good correlation with laboratory methods and 
acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al., 2011).  
Sanchez-Mora et al. examined 53 blood samples from diabetic patients over a wide range of 
HbA1C values (4–14%), with results examined by both a DCA Vantage Analyzer and a POCT 





correlated (r = 0.973) with clinical lab testing results. 
 HbA1C testing remains as a recommended test for the screening and diagnosis of 
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in 
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic 
populations.  The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values, 
with a proven wide range of testing capabilities that are clinically acceptable. 
 
Summary 
In summary, symptoms and testing results are reviewed in combination to present a 
background for which a determination may be made regarding the presence of neuropathy.  
Defining what types of sensory receptor deficiency is present aids in the determination of which 
fibers may be affected and ultimately, contributes to the determination of the type of neuropathy 
that the individual is experiencing.  The usefulness of these three tests have been well established 
in addition to their clinical diagnostic assessment applications in the literature.  Both large and 
small fiber deficiencies may be evaluated with simple bedside tests that have been repeatedly 
validated within research literature.  It would be beneficial to evaluate the effectiveness of three 
neuropathy screening tools with specific aims to determine early DPN detection.  Therefore, the 
purpose of the study was to evaluate the 128-Hz tuning fork, 1-g and 10-g monofilaments, and 
the QOL-DN for the purposes of DPN screening to determine which of the tools or combinations 
thereof would be the most effective for early DPN detection. 
 The potential for the study lies in investigating to what extent will the 128-Hz tuning 
fork, 1-g and 10-g monofilaments, and the QOL–DN detect DPN in an OOI, PD, and T2D 





DPN detection, specifically by fiber type, is a lofty, but worthy goal and an achievable aim for 
these tools.  Establishing which screening tools provide the greatest reliability and accuracy for 
detecting early or subclinical DPN is a promising hope for the study.  We hypothesized that the 
tuning fork will detect early sensation loss, indicating large fiber neuropathy, in OOI and PD.  
Furthermore, we hypothesized that the QOL–DN and the 128-Hz tuning fork would both provide 
excellent mechanisms for detecting early or subclinical DPN in HN and PD populations.  This 
being said, we believed the QOL–DN has the potential to detect DPN in a HN and PD 
populations with the greatest reliability and accuracy.  It is with these things in mind that we 
moved forward in discussion of our methods and how we executed the study (Alam, Ezhova, 
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Table IIA.2  
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Table IIA.3  
Advanced objective testing for diabetic neuropathy 
Neurologic Test 
Type of 
Neuropathy Measurement Advantages 
Quantitative 
sensory testing 
Small and large  
fiber 
neuropathies 











Small-caliber sensory nerves 
including somatic 
unmyelinated IENFS, dermal 
myelinated nerve fibers, and 
autonomic nerve fibers 
 
Quantitates small 







Detects small nerve fiber loss 
in the cornea 
Noninvasive technique 







Uses nociceptive heat as a 





Detects small fiber 
neuropathy in the 
absence of other indices 
Sudomotor 
function 
Distal small  
fiber 
neuropathy 
Assesses the sweat response 
by analyzing sweat production 










Small and large 
fiber 
neuropathy 
Measure the ability of nerves 
to conduct an electrical 
stimulus 
Standardized universal 
technique that is well 
documented and 
recommended 






Table IIA.4  
Stages in Diabetic Neuropathy   







0 No neuropathy No No 





3 Debilitating neuropathy Yes Yes 















PART B: NEUROPATHY QUALITY OF LIFE TOOLS 
Health Related Quality of Life (HRQOL) 
 HRQOL may be defined as subjective perceptions of how an illness and treatment for the 
illness is experienced, particularly in how it is perceived to affect physical, mental and social 
aspects, thereby providing an indication of the individuals perception of their overall well-being 
(Rajabally & Cavanna, 2015).  T2D, as an illness, represents a collection of challenges that may 
affect several different facts of an individual’s functioning, including physical, emotional, social, 
sexual, cognitive and self-perceptions surrounding health changes.  The health issues 
surrounding T2D are formidable, and a variety of HRQOL instruments have been used 
throughout the last two decades to gain insight relating to the health perceptions experienced by 
T2D patients (Luscombe, 2000).  Research conducted to determine associations between 
particular complications such as depression, HRQOL measures and ABC (HbA1C, BP, 
cholesterol) goal attainment in 808 adult T2D patients using the National Health and Nutrition 
Examination Survey (NHANES) (Shah, Mezzio, Ho, & Ip, 2015) found that longer disease 
duration and severe depression highly impacted individuals abilities to achieve health related 
goals.  Likewise, research by Ji et al. relates findings regarding the effect of elevated BMI in an 
examination of 2052 Chinese T2D patients, who were examined for the HRQOL relationships 
between BMI, complications, glycemic control and comorbidities (Ji et al., 2015).  Increased 
complications such as hypertension, dyslipidemia, and poorer HRQOL were associated with 





examples highlight the gravity and impact of disease duration, underlying psychological 
challenges and BMI on the exacerbation of T2D. 
HRQOL instruments have evolved over the last two decades, encompassing more 
domains, crossing language barriers and aiming to specialize in particular disease facets, such as 
in DPN  (Hogg, Peach, Price, Thompson, & Hinchliffe, 2012; Vickrey, Hays, & Beckstrand, 
2000; Vinik et al., 2004).  Hogg et al. reviewed HRQOL diabetes-related foot disease measures 
through a meta-analysis of scientific literature available from 1996 to 2011, ultimately 
examining 53 studies that used a structured manner to directly assess HRQOL relating to foot 
problems (Hogg et al., 2012).  Measures utilizing patient reported outcome measures (PROMs) 
to self-evaluate general diabetes topics were excluded.  The NeuroQOL-28 was assessed as a 
disease specific instrument, providing proficiency in the assessment of advancing neuropathy 
and impact on HRQOL, but poor sensitivity to diabetic foot ulcers (DFU).  The QOL-DN was 
discussed as an assessment of diabetes oriented neuropathy, with intentions for aiding in 
diagnosis and monitoring; however, Hogg et al. reports a lack of specificity for PN, thereby 
limiting the instrument to health impacts of a diabetes foot disease related nature (Hogg et al., 
2012).  This research further advises that the utilization of two tools would be more promising in 
detailing outcomes, but impractical in a clinical setting (Jeffcoate et al., 2009).  After careful 
evaluation, Hogg et al. advises that each diabetes foot-specific PROM has some validity for 
measuring HRQOL, but also has limitations that are unique and specific to each tool and that 
these limitations should be considered when choosing an instrument.  According to this research, 
no one specific PROM could be viewed as a gold standard measure. 
 Smith, Lamping and MacLaine reviewed HRQOL related to DPN in a systematic review 





2012).  After a review of reliability, validity, content, language, development and prior use in 
research, this team concluded that all three instruments warranted support for their use in a DPN-
specific manner based on evidence, to some degree; however, limitations exist.  The NeuroQOL-
28 lacks test-retest reliability, while the QOL-DN possesses this component as a strength.  This 
being said the QOL-DN lacks content to assess the emotional and psychological impact of DPN, 
such as anxiety or depression components (Smith et al., 2012).  Language variability is available 
with the QOL-DN, but the PN-QOL-97 is a valid option for assessing PN if language diversity is 
not a necessity.  The authors suggest future research to compare the psychometric properties of 
all three instruments. 
What once was only thought to be able to be accomplished by a specialist during an exam 
has now become a target for specific screening development in the form of self-reported QOL 
measures (Vinik et al., 2005).  Efforts have been rewarded, as QOL measures relating to DN 
have successfully targeted and differentiated between small and large fiber deficits and levels of 
neuropathy severity (Vinik et al., 2004; Vinik et al., 2008).  Such efforts allow more individuals 
to be screened and in a variety of locations, with or without clinical personnel, providing the 
ability to detect advancing disease at earlier stages with the hopes of earlier disease assessment 
and intervention.  Earlier assessment of the debilitating effects of DN allows for the potential to 
grasp the impact and scope of accumulating pathophysiological processes in an individual, the 
formulation of targeted medical support plans and pre and post evaluations for T2D interventions 
(Wong et al., 2015).  Such evaluations of physical, mental, emotional, social, and sexual 
functioning in additional to health perceptions, helps care providers in their efforts to effectively 





Research indicates that obese individuals experience reduced HRQOL, with findings 
indicating a more significant impact on physical functions relating to health rather than mental 
capacity (Kolotkin, Crosby, & Williams, 2002).  Kolotkin et al. examined HRQOL in 3353 
patients of varying ethnicities in a geographically diverse study over a wide age range, 18 to 90 
years of age, and found that higher BMIs, Caucasian status and women experienced obesity 
related reductions in HRQOL.  Such results are not uncommon, as a meta-analysis of research 
examining 43,086 study participants indicated that increased BMI status relates to significant 
reductions in physical QOL, with the highest impact relating to individuals who were class III 
obese (Ul‐Haq, Mackay, Fenwick, & Pell, 2013).  At-risk individuals for T2D include those who 
are inactive.  Hakkinen et al. (2009) evaluated 132 individuals for physical activity/inactivity 
patterns in relationship to HRQOL using the SF-36, and found that inactive individuals had a 
lower HRQOL in the pain and general health domains (Hakkinen et al., 2009).  HRQOL 
decreased in a linear fashion in relationship to physical inactivity and increased in individuals 
who had higher physical activity levels.  Individuals who were more active reported better 
subjective health and weight control, while researchers reported that high activity levels reduced 
the risk of T2D onset and associated complications. 
Norfolk Quality of Life Diabetic Neuropathy Instrument (QOL–DN).  The Norfolk 
Quality of Life Diabetic Neuropathy Tool (QOL-DN) was developed as a neuropathy-screening 
tool, aiming to differentiate between typical features that present in DN (see Appendix B) (Vinik 
et al., 2004; Vinik et al., 2005).  Twenty-eight questionnaire items were developed through 1000 
structured patient interviews, combined with ADLs, general health and status items of interest 
and tested on DN patients.  Initial testing revealed that the QOL-DN successfully identified 





individuals who do and do not have DPN in an English-speaking population.  The QOL-DN is 
unique due to its ability to detect issues that arise related to changes in sensation in small and 
large fibers, typical alterations to autonomic nervous system functioning and neuropathy severity 
(Vinik et al., 2008; Vinik, Stansberry, Ruck, & Vinik, 2003). 
The QOL-DN instrument is comprised of a Total QOL score, and five subscale items 
(symptoms, ADLS, small fiber, large fiber, autonomic), each measuring a specific area of 
interest.  Furthering its impact and validation, it was translated into German and was successfully 
tested as a fiber-specific QOL tool in this new population (Vinik et al., 2008).  This research 
demonstrated the QOL-DN’s ability to cross language barriers, and confirmed prior findings of 
the same five factors previously identified in the English version.  Important findings include the 
Norfolk QOL-N’s ability to detect levels of neuropathy within and across different populations 
(Vinik, Vinik, et al., 2014).  This fiber specific, self-report questionnaire was utilized in a 25,000 
person Romanian population, effectively revealing a high prevalence of undisclosed neuropathy 
in 25,000 Romanian patients (Veresiu et al., 2015).  The QOL–DN effectively and accurately 
determined the QOL of the participants, while also establishing its ability to operate within a new 
language and population to ferret out undisclosed neuropathy (Veresiu et al., 2015; Vinik et al., 
2008). 
 The QOL-DN has also been used to assess baseline and improved QOL in randomized, 
double-masked, placebo-controlled, clinical studies and was sensitive enough to differentiate 
where improvement developed within fiber types (Boyd et al., 2011; Casellini, 2007).  The 
questionnaire has been successfully used in research to detect both the severity and impact of 
neuropathy on the QOL experiences in 61 patients diagnosed with transthyretin familial amyloid 





and in patients with neuroendocrine tumors (Vinik et al., 2010).  This questionnaire has been 
effectively utilized to perform cost analyses of the financial impact of DPN within research and 
used within postal surveys within research efforts (Currie et al., 2006; Happich et al., 2008).  
Smith et al. (2012) analyzed the QOL-DN in relationship to other available measures in 
2012 and recommended it for DPN screening (Smith et al., 2012).  Furthermore, this research 
points out the strengths of the QOL-DN as being able to serve effectively in multiple languages 
as a fiber-specific tool, demonstrating test/re-test reliability and emphasizing the strong clinical 
background that serves as the foundation for the instrument.  The time to complete the 
instrument is unknown at the time of the writing of the article. 
The Peripheral Neuropathy Quality of Life Instrument (PN-QOL-97).  Vickrey, 
Hays and Beckstrand (2000) also developed a questionnaire to evaluate peripheral neuropathy 
(see Appendix C) (Vickrey et al., 2000).  The instrument was formed from items from the Rand-
36, a widely used HRQOL PROM measure (Hays & Morales, 2001), and responses from focus 
group material, and evaluated in 80 patients at 3 and 6 month follow up evaluations in a clinical 
setting.  The instrument was re-evaluated, and in the process, pared down from 162 items to 97 
items during the study through examination of construct validity, reliability, and comparisons to 
HRQOL measures.  Findings resulted in strong associations between the instrument’s results and 
reported DN symptoms and support for reliability and validity for use in adults with DN.  The 
revisions ultimately arrived at an instrument that is made of two base components, a physical 
component and a mental component, both of which are scored through a complex set of 
calculations provided by the author. 
 The PN-QOL-97 was utilized in a study aiming to determine the effectiveness of  





participants who had skin biopsies performed on the lower leg (Bakkers et al., 2009).  The PN-
QOL-97, along with a Symptoms Inventory Questionnaire (SIQ), were administered to 
participants and results were compared to IENFD values.  The resulting comparisons of the PN-
QOL-97 and SIQ helped to establish a validated realm of normative values for IENFD.  A study 
examining the effect of social support on QOL was examined in 154 patients with 
polyneuropathy (Maxwell et al., 2013).  The PN-QOL-97 and the Medical Outcome Study-
Social Support Survey (MOSS-SSS) were utilized to determine QOL and social support.  Results 
indicated that pain and autonomic symptoms strongly related to physical and mental components 
of QOL while social support only weakly correlated with the emotional/mental health 
components. 
 Research examining the characteristics of muscle cramps in individuals over the age of 
18 with polyneuropathy utilized the PN-QOL-97 as a validated measure of QOL (Maxwell et al., 
2014).  Nerve conduction studies, the Toronto Clinical Neuropathy Score, the PN-QOL-97 and a 
demographic questionnaire assessing qualities of the symptoms and cramps were administered to 
225 patients.  Of the participating patients, 63% experienced muscle cramps, and nearly 44% 
described cramps of a disabling nature.  This study confirmed that patients who experienced a 
disabling level of pain reported a lower QOL on the PN-QOL-97 than patients without disabling 
cramps and that muscle cramps were a common factor in individuals with polyneuropathy.   
The PN-QOL-97 was reviewed by a research team in comparison to other QOL measures (Smith 
et al., 2012).  Researchers pointed out that there are several strengths of the PN-QOL-97, such as 
expert review of focus group material, multi-dimensional design, psychological and emotional 





least 20 minutes to complete according to previously published materials and this QOL 
instrument represents one of the longest instruments available for use to assess DN today. 
Neuropathy-and Foot Ulcer-Specific Quality of Life Instrument (NeuroQOL-28).  
The NeuroQOL-28 was developed to measure patient related QOL perceptions as they are 
impacted by DN and foot ulcers (see Appendix D) (Vileikyte et al., 2003).  This research related 
to the development of an instrument designed to assess symptomology of DN, QOL and 
psychometric properties by working with 418 patients across U.K. and U.S. diabetes centers.  
Researchers found that the NeuroQOL-28 was able to reliably determine three measures relating 
to physical symptoms and two measures relating to psychosocial aspects of functioning 
(Vileikyte et al., 2003).  When compared to the SF-12, results indicated stronger associations 
with neuropathic severity, DN’s relationship to QOL, and was able to better explain variances in 
QOL when compared to the SF-12. 
 Vileikyte and fellow collaborators utilized the NeuroQOL-28 in a slightly differently 
research effort in 2005, as their team examined the associations between DN and symptoms of 
depression, in an attempt to develop associations that would lead to potential targets for 
interventions in future research (Vileikyte et al., 2005).  The research successfully utilized the 
NeuroQOL-28 to evaluate this relationship while also using the Hospital Anxiety and Depression 
Scale (HADS) and demonstrated a link between neuropathy symptoms and depressive 
symptoms.  Related research was performed in 2011, by Bergis, Hulman and Kulzer when they 
evaluated the effectiveness of the NeuroQOL-28 to detect psychological and neuropathic 
symptoms in 211 diabetic patients (Bergis, Hermanns, & Kulzer, 2011).  Individuals were 
examined and tested by a physician and subsequently administered the NeuroQOL-28 





reliable to assess neuropathy symptoms and to relay emotional problems arising from 
neuropathy-related symptoms. 
With DPN rising as both a common and painful complication of diabetes, Davies et al. 
employed a study which examined the severity of symptoms in individuals with PN (Davies, 
Brophy, Williams, & Taylor, 2006).  Surveys were sent out through the mail to known T2D 
patients in order to screen and determine the presence or absence of symptomology, followed by 
a more detailed neurological history collection through the Toronto Clinical Scoring System.  PN 
or painful PN individuals were also administered a Neuropathic Pain Scale measure and the 
NeuroQOL-28.  This research utilized the NeuroQOL-28 to establish that individuals with PN 
experience negative effects from the disease and are more likely to develop painful PN at a later 
point in time. 
 Further support for the validation of the NeuroQOL-28 developed with a study performed 
by Vileikyte and fellow researchers in 2007, when they examined NeuroQOL-28 scores in 295 
DN patients in the U.S. and U.K. over a 9-month time period in comparison to the Neuropathy 
Disability Score (NDS) (Vileikyte et al., 2007).  Results revealed continued validity for the 
NeuroQOL-28 through detecting changes in the severity of DN. 
 The use of the NeuroQOL-28 in DN related research is diverse, with efforts to measure 
improvements in sensation through at home light therapy among them (Lavery, Murdoch, 
Williams, & Lavery, 2008).  Sixty-nine individuals participated in a study where they received 
sham or active treatments, with the active treatment consisting of 40 minutes of anodyne light 
therapy.  The MNSI was utilized in conjunction with the NeuroQOL-28, SWM and nerve 
conduction studies in a repeated-measures evaluation and determined that there were no 





 Finally, the translation of the NeuroQOL-28 into Brazilian Portuguese and evaluation of 
this translation in a 50 person Brazilian neuropathic population validated the NeuroQOL-28 as a 
reliable foot and ulcer specific instrument across different languages (Xavier et al., 2011).  The 
NeuroQOL-28 was evaluated in conjunction with the SF-36, and found to be reliable and valid as 
a tool that could be utilized in DM populations by Brazilian medical staff. 
 A review of HRQOL instruments examined the NeuroQOL-28 in comparison to several 
other measures, detailing its strengths and weaknesses (Smith et al., 2012).  This research 
determined that the NeuroQOL-28’s target population was adults with DN through self-report 
measures and that at the time of the research, it was available in the US and UK, and in 10 
different languages.  The validation of the additional language versions was unclear despite 
personal communication from the author.  Upon evaluation, Smith et al. determined that the DN 
version of the NeuroQOL-28 has 28 items that represent three physical domains, two 
psychosocial domains and one overall measure of QOL.  Researchers commented that the time 
required to complete the NeuroQOL-28 was unknown.  Test-retest reliability and criterion 
validity was not assessed in the main validation study. 
NC-Stat DPN Check.  The NC-Stat DPN Check (Neurometrix Inc., Waltham, MA) is a 
point-of-care nerve conduction device that has been developed with the intent to serve as a 
substitute for more advanced nerve conduction study (NCS) devices (Lee et al., 2014).  It is a 
simple, portable device that was made to be both user- and patient-friendly.  This method of 
evaluation of the sural nerve allows for a quick, easy assessment (less than 10 minutes), with 
results that are easily uploaded to a laptop computer for evaluation.  The NC-Stat DPN Check 
has been proposed as being able to serve as a potential substitute for the more expensive and less 





community health care that has not previously been available.  This POCD requires limited 
training and supplies to operate it and flexible options for testing, thus enabling a low-cost and 
short time investment to screen for potential nerve damage in the lower leg in order to determine 
if further evaluation is warranted at a more complex facility. 
 The NC-Stat DPN Check was tested as a POCD across multiple sites with 72 patients in 
order to determine its potential as an alternative to traditional NCS (Perkins et al., 2008).  
Patients underwent extensive testing, which included neurological examination and NCS.  
Spearman correlation coefficients indicated a relationship between the POCD and other 
measures ranging from .76 to .91, confirming reasonable accuracy for the device to serve as an 
alternative. 
 Lee et al. (2014) evaluated 44 T1D and T2D subjects with the NC-Stat DPN Check 
POCD and standardized NCS (Lee et al., 2014).  The sural nerve conduction velocity (SNCV) 
and action potential (SNAP) were recorded.  Reliability and validity were evaluated via 
intraclass correlation coefficients, Bland-Altman analysis, and receiver operating characteristic 
curves and results indicated.  Two trained testers were utilized and interrater reproducibility ICC 
values were .97 for SNAP (interrater value, .83) and .94 for SNCV (interrater value, .79), with 
88% sensitivity and 94% specificity for SNAP reference values and 94% sensitivity and 71% 
specificity.  Excellent reliability and acceptable accuracy was demonstrated by the device, and 
POCD normative threshold values were validated.  This validated POCD has been shown to be a 
reliable and accurate alternative to traditional NCS through successful evaluation of the sensory 
nerve action potential (SNAP) and sensory nerve conduction velocity (SNCV) of the sural nerve 





methodologies have been employed in its validation within these studies, including unilateral and 
bilateral applications, with one to two trials. 
Glycohemoglobin Testing.  Glycohemoglobin testing or HbA1C testing has been 
reliably used to categorize BG values within research and has been proven as a simple, portable 
method of screening for diabetes that is accurate, relatively quick to perform on-site (10 
minutes), and results are easily relayed (Feng et al., 2009; Sumpio et al., 2013).  This method of 
screening also provides the unique caveat of accessible health care upon demand to individuals 
that might not otherwise engage in or be able to afford more expensive tests such as oral glucose 
tolerance testing (OGTT).  When considering the validity of HbA1C screening for diabetes, it 
should be noted that the Canadian Task Force on Preventive Health Care, American Task Force 
and WHO recommendations all support HbA1C testing of > 6.5 for the screening and diagnosis 
of diabetes (ADA, 2016; Siu, 2015; World Health Organization, 2012).  In a clinical setting, if 
positive results are obtained, the results should be confirmed with repeated testing. 
 HbA1C testing has been strongly associated as an accurate predictor of glycemic control, 
especially when compared to fasting plasma glucose (FPG) (ADA, 2016; Bernal-Lopez et al., 
2011; Mannarino et al., 2013).  While agreement is strong between HbA1C testing and FBG, 
issues arise with nonparallel findings between HbA1C and oral glucose tolerance testing (OGTT) 
(Farhan et al., 2012; Mannarino et al., 2013).  Studies independently performed by Mannarino et 
al. and Farhan et al. point out that there is discordance between OGTT and HbA1C regarding 
T2D diagnosis outcomes, with Farhan’s findings indicating particularly discordant results when 
cardiac autonomic neuropathy (CAN) is present.  Such issues may lower the incidence of 
diagnosis when using HbA1C as a determining test (Farhan et al., 2012).  Additionally, HbA1C 





not be reliable (Hare et al., 2012).  Current recommendations by the American Diabetes 
Association, however, align HbA1C as a valid test in equal measure to other diagnostic tests that 
may be used and that one test is not preferred over the other (ADA, 2016). 
 The DCA Vantage from Siemens Corporation has been evaluated within research as a 
point of care analyzer for HbA1C testing and found to have good correlation with laboratory 
methods and acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al., 
2011).  Within this research effort, 53 blood samples from diabetic patients over a wide range of 
HbA1C values (4–14%), were examined with both a DCA Vantage Analyzer and a POCT 
Analyzer and compared to on-site lab testing, and both were found to be clinically acceptable. 
 HbA1C testing remains as a recommended test for the screening and diagnosis of 
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in 
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic 
populations.  The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values, 
with a proven wide range of testing capabilities that are clinically acceptable. 
 
Summary 
 HRQOL relating to DPN is an important field of study, allowing for the assessment of 
disease impact for the potential early intervention and offers unique caveats to physicians to aid 
them in the diagnosis and treatment of DPN.  HRQOL instruments vary greatly, ranging from 
general to disease specific, and researchers and clinicians both must be aware of the individual 
strengths and weaknesses of each instrument before utilizing them.  Three HRQOL DN-specific 
instruments in particular stand out as points of interest: the QOL-DN, the PN-QOL-97 and the 





valuable in relationship to diabetes foot related disease or neuropathy.  Researchers who have 
examined these instruments have recommended further evaluation, to compare certain aspects, 
such as the psychometric properties of these tools.  Overweight and obese individuals experience 
reduced HRQOL, and are at risk for developing T2D, which makes them a unique population of 
interest.  Activity status has been shown to be linked to risk for the development of T2D.  
Therefore, an overweight, obese, inactive population (OOI) is likely to be at increased risk for 
PD, T2D and potentially, early complications such as DPN.  While limited studies have 
evaluated individuals with metabolic syndrome and obese populations, an OOI population has 
not been well investigated.  The primary focus in literature has been on the utilization of 
HRQOL measures to assess individuals who have been diagnosed with disease, such as T2D. 
We examined these three instruments to determine how to best detect early sensation loss 
and signs of neuropathy in an HbA1C categorized OOI, PD and T2D population, allowing for a 
beneficial appraisal of the instruments, an evaluation of potential early onset of disease and the 
timing of the instruments being employed.  Furthermore, we compared the three instruments 
with the NC-Stat DPN Check POCD device, as a means of employing a criterion standard 
measure of determining the accuracy of the instruments themselves. 
We hypothesized that the QOL–DN and PN-QOL-97 would more clearly identify signs 
of early or subclinical DPN when compared to the criterion standard of the NC-Stat DP Check, 
that all three instruments would correlate with our criterion standard at .60 or higher, with the 
QOL–DN yielding the strongest relationship and that the NeuroQOL-28 would be quickest to 
complete, followed by the QOL–DN and PN-QOL-97.  These investigational concepts laid the 






PART C: MELATONIN & AUTONOMIC NERVOUS SYSTEM FUNCTION 
Melatonin 
 When attempting to develop treatments for the dysfunction that arises in T2D, the 
potential benefits of melatonin have just begun to be evaluated.  Melatonin is a hormone that is 
made by the pineal gland in the human body (Claustrat, Brun, & Chazot, 2005).  Produced in 
circadian patterns, this particular hormone has been found to regulate sleep and wake cycles and 
the circadian rhythms within healthy humans by means of hypothalamus receptors located in the 
suprachiasmatic nucleus (SCN) (Spadoni, Bedini, Rivara, & Mor, 2011).  The hypothalamus acts 
as a dominant brain region, taking responsibility for sensing and responding to the levels of 
blood glucose within the body, and managing control of blood glucose during circadian rhythms 
(Cailotto et al., 2005; Page et al., 2009; Reiter et al., 2007; Vriend & Reiter, 2015). 
 Impairment of melatonin synthesis may have serious consequences related to 
hyperglycemia, as documented recently by Amaral et al., 2014.  Rat studies involving sustained 
hyperglycemia-induced detrimental effects in melatonin synthesis, in vivo and in vitro, which 
suggest that given melatonin’s antioxidant effects and roles in energy homeostasis, deficiencies 
in its release likely contribute toT2D progression (Amaral et al., 2014).  Individuals with T2D 
often suffer the consequences of disrupted sleep processes, with reduced hypothalamic activity, 
and when tested, have been found to have decreased melatonin levels with phase delays (Kreier 
et al., 2007).  Such process interruptions contribute to increased nocturnal liver glucose 
production (Radziuk & Pye, 2006), further indicating defects relating to glucose homeostasis. 





metabolic research (Goyal et al., 2014) and improved glycemic control (Greico, Colberg, 
Somma, Thompson, & Vinik, 2013).  Recent research documented protective effects on the 
cardiovascular system in older populations (Paredes, Forman, Vara, Escames, & Tresguerres, 
2014) and reduced electrical instability after epinephrine application, suggesting positive roles 
for this easily accessible supplement (Vazan & Ravingerova, 2015).  A similar study evaluated 
two major neurotransmitters of the sympathetic nervous system (SNS), plasma norepinephrine 
and dopamine levels, in the supine position, and found that after 60 minutes of melatonin 
administration, measured norepinephrine and dopamine levels were lower (Nishiyama et al., 
2001), suggesting that melatonin administration influences cardiac vagal tone, potentially 
exerting suppressive effects on sympathetic influences from the ANS. 
 Dysfunction within the hypothalamus, particularly related to SCN output, may be 
particularly troublesome for T2D sufferers, creating irregular sleep and wake cycles, and making 
it difficult for them to avoid the exacerbation of the disease (Kreier et al., 2007).  These deficits 
related to hypothalamic activity may contribute to the further development of T2D and cause 
individuals to progress further into the complications of diabetes.  Melatonin has been researched 
as a synchronizer of the body’s biological clock and has demonstrated a restorative ability within 
the SCN output context (Scheer, Kalsbeek, & Buijs, 2003).  It is within this context that 
melatonin has the potential to improve ANS balance, inflammation, oxidative stress, and 
glycemic control within the T2D patient (Hussain et al., 2006; Kedziora-Kornatowska et al., 
2009; Paskaloglu, Sener, & Ayangolu-Dulger, 2004; Reiter, 1995; Scheer et al., 2003; Tutuncu 
et al., 2005).  It also lowers production of free radicals within the mitochondria (Okatani, 
Wakatsuki, Reiter, & Miyahara, 2002) and attenuates inflammation by inhibiting NF-κB (Jung et 





while potentially increasing parasympathetic function, culminating in reduction in activation of 
the neuroinflammatory reflex arc. 
 The SNS is a powerful force, enabling the body to essentially push the gas pedal when it 
needs to gain momentum for a task; however, the system is often out of balance in patients with 
T2D, leaving the body in gear, so to speak.  Parasympathetic nervous system (PNS) influences 
bring a more calming, and balance to the SNS, effectively representing the opposite end of the 
spectrum within the ANS.  T2D patients experiencing cardiac autonomic neuropathy (CAN) in a 
progressive state, appear to be left in variations of full throttle or vacillating dysfunction, when 
every engine needs a period of rest in order to maintain reasonable performance levels.  
Melatonin appears to potentially have the ability to positively influence the ANS in such a way 
that it brings balance to the functions of the SNS and PNS by attenuating excessive SNS 
dominance dysfunction that is frequently found in T2D individuals. 
 
Cardiovascular Autonomic Neuropathy & Diabetes 
 Neuropathy comes in many forms, including those that more specifically affect the 
cardiovascular system termed as cardiovascular autonomic neuropathy (CAN) (Vinik & Erbas, 
2001).  Incidence of the disease is incredibly high, with reported rates as high as 100% in some 
research findings (Ziegler, Gries, Spuler, & Lessmann, 1992).  Microvascular damage occurring 
within the ANS exhibit itself in the form of CAN dysfunction, placing great risk to the individual 
being affected, as ANS dysfunction is a strong predictor of sudden death with intensive glycemic 
control  (Vinik, Maser, & Ziegler, 2011).  Mortality rates are significantly higher for individuals 
experiencing CAN compared to patients without this particular pathology (Ewing & Clarke, 





A unique T1D case proves the point, as Pop-Busui (2010) discussed the sudden death of a 
26-year-old woman with severe CAN (Pop-Busui, 2010).  Poor glycemic control over a 16-year 
period, with hyperglycemic unawareness is believed to have contributed to persistent orthostatic 
hypotension with BPs ranging in the 30 to 60 mmHg range.  This case study revealed classic 
signs of the disease upon her last clinical visit, yet sadly this case is not isolated.  T2D is often 
characterized by early damage to the ANS as well, which likely occurs prior to its onset 
(Laitinen et al., 2011). 
 CAN dysfunction and its relationship to diabetes is not clearly defined, although 
hyperglycemia appears to play a role, with glycation end products playing a significant role in 
creating inflammation in microvascular processes (Lieb et al., 2012).  A proinflammatory state 
has been associated with ANS damage in diabetes (Lieb et al., 2012), and sympathovagal 
imbalance may either result from or be the cause of an increased state of inflammation (Lieb et 
al., 2012), which plays a key role in the development of both T2D and atherosclerosis. 
 This inflammatory response is controlled by the neural circuitry of the ANS. The afferent 
arc consists of nerves that sense injury and infection and, in turn, activate a cholinergic anti-
inflammatory pathway that modulates the response (Vinik, 2012).  The lymphoid organs of the 
immune system are innervated by cholinergic, catecholaminergic, dopaminergic, and peptidergic 
neurons, and neurotransmitters can alter the level of function of immune cells.  In addition, 
sensory neurons detect inflammation and can lead to the release of dopamine and 
norepinephrine, causing depolarization of the vagal sensory fibers and initiation of a motor 
efferent arc in the brainstem (i.e. the cholinergic anti-inflammatory pathway) (Vinik, 2012).  It is 
the loss of autonomic control with reduction of parasympathetic activity (a hallmark of T2D) that 





Symptoms.  Symptoms associated with the disease include reduced resting heart rate 
variability (HRV), elevated HR at rest (tachycardia), exercise intolerance, orthostatic 
hypotension, abnormal circadian BPs, painless myocardial ischemia and intraoperative 
cardiovascular lability, leading to a two to three-fold increase in mortality in diabetic patients 
(Maser & Lenhard, 2005; Purewal & Watkins, 1995; Vinik & Ziegler, 2007).  Others link CAN 
to lower survival rates post myocardial infarction (Vinik et al., 2013). 
Resting tachycardia and fixed HR or blunted HR response tend to be late symptoms of 
CAN, likely due to vagal impairments that have developed over time (Vinik et al., 2013).  
Abnormal HR response is a simple, yet powerful marker of CAN, identifying individuals at 
higher risk.  Hage et al. (2013) successfully identified blunted HR response to adenosine in 
otherwise asymptomatic diabetics (Hage et al., 2013).  Results indicated that individuals with 
both abnormal MPI and HR were associated with the highest increased risk for cardiovascular 
events, further substantiating the stealth of CAN, and necessity of screening and treatment.  
Unique cases of dysfunction exist in the literature, as in the case of a 19 year old T1D 
experiencing palpitations, elevated HR, and postural orthostatic hypotension (POTS) (Meyer et 
al., 2015).  Further examination resulted in hypotheses that related to PTSD in combination with 
T1D contributed to altering autonomic balance, thus inferring that altered mental states due to 
extreme stress may contribute to HR related autonomic dysregulation.  Patients with POTS may 
also experience fatigue and sleeping disturbances, warranting intervention.  Mallien et al. 
examined 38 POTS patients and 31 controls utilizing the Pittsburg Sleep Quality Questionnaire 
and the Epworth Sleepiness Scale (Mallien et al., 2014).  Participants were examined at a sleep 
laboratory, where HRV analysis and other autonomic activity were recorded.  POTS participants 





researchers found dysregulation of autonomic function relating to increased sympathetic activity 
during rest and lowered sympathetic response to stimuli in 39 age matched females that 
underwent autonomic testing (De Wandele et al., 2014).  Orthostatic intolerance, postural 
tachycardia and lowered sympathetic responses to stimuli suggested dysautonomia relating to 
CAN in these participants.  A host of other symptoms are associated with CAN, including 
gastrointestinal, genitourinary, metabolic, Sudomotor, and pupillary dysfunction, yet these are 
not the focus of this research and are listed elsewhere (Vinik, Maser, et al., 2003). 
Measuring Cardiac Autonomic Dysfunction.  Several means exist to evaluate CAN, 
and most have been described in clinical and research literature (Vinik, Maser, et al., 2003; Vinik 
et al., 2013).  Clinical and research evaluation and confirmation of CAN differ, however (see 
Table IIC.1).  Research literature lists the following as acceptable means to evaluate CAN: heart 
rate response to deep breathing (an indication of beat-to-beat variations within the heart), heart 
rate response to standing, Valsalva maneuver, power spectral analysis (HRV analysis), 24 hour 
electrocardiogram (ECG) monitoring, systolic blood pressure (SBP) response to standing, 
diastolic blood pressure (DBP) responses sustained handgrip, and hemodynamic responses to tilt 
table tests (Poanta, Cerghizan, & Pop, 2010; Tarvainen, Laitinen, Lipponen, Cornforth, & 
Jelinek, 2014; Vinik, Maser, et al., 2003; Vinik et al., 2013). 
 HR, cardiovascular testing, and orthostatic hypotension testing have been evaluated and 
found to be acceptable measures for both research and clinical diagnosis of CAN (Vinik et al., 
2013), and heart rate variability (HRV) has been used as a measure of CAN dysfunction.  
Tarvainen et al. (2014) performed work with these measures with 92 T2D patients, investigating 
time-domain, frequency-domain, and non-linear methods (Tarvainen et al., 2014).  The 





when compared to healthy controls, providing relative evidence of CAN pathology within the 
first 5-10 years of T2D.  Research is broad concerning the use of HRV, with power spectral 
analysis being endorsed as a primary means of evaluating and diagnosing CAN (Spallone, 2011; 
Vinik et al., 2013). 
 Baroreflex sensitivity measures have been used to evaluate coronary artery involvement 
related to impaired endothelial function, relating to patients with IGT (Wykretowicz, 2005), with 
vasodilator responses significantly being impaired in patients with IGT or diabetes.  Rolim, de 
Souza, & Dib (2013) and Spallone (2011) endorse baroreflex sensitivity testing as a primary 
means of evaluating CAN and in response to the Toronto Consensus panel on Diabetic 
Neuropathy guidelines (Rolim, de Souza, & Atala Dib, 2013; Spallone, 2011).  
 More recently, Sudoscan has been introduced into research to evaluate the microvascular 
complications associated with neuropathy via electrochemical skin conduction (Eranki et al., 
2013; Freedman, Bowden, Smith, Xu, & Divers, 2014; Smith, Lessard, Reyna, Doudova, & 
Singleton, 2014).  This noninvasive skin conductive measurement evaluates sweat that is 
stimulated by a gentle electrical current (undetectable) that is passed quite gently through the 
soles of the feet and palms of the hands.  Sudoscan is a measure of microvascular complications 
included in the study. Ease-of-use makes this tool a target for screening.  Yajnik et al., 2012 
discusses Sudomotor dysfunction testing as a simple means of alerting clinicians to both 
peripheral and cardiac dysfunction (Yajnik, Kantikar, Pande, & Deslypere, 2012), but advises 
additional research and clinical outcomes. 
 The presence of one abnormal cardiac vagal result indicates possible early CAN, while 





Orthostatic hypotension combined with an abnormal HR should be considered severe or 
advanced CAN disease. 
Glycohemoglobin Testing.  Glycohemoglobin, or HbA1C, testing has been reliably used 
to categorize BG values within research (Feng et al., 2009; Sumpio et al., 2013) and has been 
proven as a simple, portable method of screening for diabetes that is accurate, relatively quick to 
perform on-site (10 minutes), with results that are easily relayed.  This method of screening also 
provides the unique caveat of accessible health care upon demand to individuals that might not 
otherwise engage in or be able to afford more expensive tests such as oral glucose tolerance 
testing (OGTT).  When considering the validity of HbA1C screening for diabetes, it should be 
noted that the Canadian Task Force on Preventive Health Care, American Task Force and WHO 
recommendations all support HbA1C testing of > 6.5% for the screening and diagnosis of 
diabetes (American Diabetes Association, 2012; Canadian Task Force, 2012; World Health 
Organization, 2011).  In a clinical setting, if positive results are obtained, results should be 
confirmed with repeated testing. 
 HbA1C testing has been shown in research to be strongly associated as an accurate 
predictor of glycemic control, especially when compared to fasting plasma glucose (FPG) (ADA, 
2016; Bernal-Lopez et al., 2011; Mannarino et al., 2013).  While agreement is strong between 
HbA1C testing and FBG, issues arise with nonparallel findings between HbA1C and oral glucose 
tolerance testing (OGTT) (Farhan et al., 2012; Mannarino et al., 2013).  Studies independently 
performed by Mannarino et al. and Farhan et al. point out that there is discordance between 
OGTT and HbA1C regarding T2D diagnosis outcomes, with Farhan’s findings indicating 
particularly discordant when cardiac autonomic neuropathy (CAN) is present.  Such issues may 





Additionally, HbA1C testing is not appropriate in situations with individuals who have 
hemoglobinopathies, as it may not be reliable (Hare et al., 2012).  Current recommendations by 
the American Diabetes Association, however, align HbA1C as a valid test in equal measure to 
other diagnostic tests that may be used and that one test is not preferred over the other (ADA, 
2016). 
 The DCA Vantage from Siemens Corporation has been evaluated within research as a 
point of care analyzer for HbA1C testing and found to have good correlation with laboratory 
methods and acceptable precision (Lenters-Westra & Slingerland, 2010; Sanchez-Mora et al., 
2011).  Within this research effort, 53 blood samples from diabetic patients over a wide range of 
HbA1C values (4–14%), and results were examined with both a DCA Vantage Analyzer and a 
POCT Analyzer to be compared to on-site lab testing, and both were found to be clinically 
acceptable. 
 HbA1C testing remains as a recommended test for the screening and diagnosis of 
diabetes. Increased accuracy over FPG, high portability, and financial accessibility in 
comparison to OGTT make it an excellent screening test, despite limitations with certain diabetic 
populations.  The DCA Vantage Analyzer provides quality, on-site testing for HbA1C values, 
with a proven wide range of testing capabilities that are clinically acceptable. 
 
Summary 
 Melatonin has been shown in research to have a positive effect on ANS function through 
a variety of studies, many of which have addressed epinephrine, norepinephrine and glycemic 
control.  It is postulated that melatonin may have a significant effect on circadian rhythms in 





The potential for the study lies in investigating to what extent the ANS is altered in T2D 
individuals at baseline testing, followed by to what extent melatonin would improve baseline 
study measures of ANS function.  We hypothesized that the ANS is misconducting, causing a 
neuroinflammatory response, leading to impairment and that the proposed study would evaluate 
this phenomenon.  We further postulated that ANS function would improve in participants with 
melatonin supplementation. 
 The overall purpose of this research was to investigate whether the underlying central, 
cardiac, and peripheral defects that are observed in T2D could be improved or reversed by a 
known chronotropic hormone, melatonin, given as a supplement.  The physiological impact was 
evaluated through the effects of a high dose supplemental melatonin on autonomic balance in 






Table IIC.1    
Cardiovascular autonomic tests and suggested indications for their use 
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PROJECT I: NEUROPATHY SCREENING TOOLS 
INTRODUCTION 
 Diabetes is known for its complications, with one of the most common being 
microvascular damage that leads to diabetic neuropathy (DN), an insidious pathology which 
comes in many forms, affecting various systems within the body, increasing a person’s risk for 
amputation (Veresiu et al., 2015; Vinik et al., 2013).  A common form of DN is diabetic 
peripheral neuropathy (DPN), which is a primary cause for balance issues (Schwartz et al., 2008; 
Vinik, Vinik, Colberg, & Morrison, 2015) and loss of sensation in the feet (Lamparter et al., 
2014); it is also a major contributor to non-traumatic lower limb amputations (Vinik et al., 2013).  
DPN is a particularly significant problem for individuals with diabetes as it is relatively 
common, and often leads to disability, but is difficult to diagnose due to frequent asymptomatic 
onset or unusual presentation (Dixit & Maiya, 2014; Herman & Kennedy, 2005; McKinlay et al., 
2013; Veresiu et al., 2015; Vinik et al., 2013).  This complication affects the nerve endings in the 
feet, hands, and other regions of the body after an individual has experienced extended or acute 
hyperglycemia or other pathologies that lead to the destruction of various forms of sensation 
(Goh & Cooper, 2008; Goodarzi, 2014; Marcovecchio et al., 2011). 
Earlier detection of such complications in at-risk individuals and in those with type 2 
diabetes (T2D) or prediabetes (PD) allows for the best-case health and cost reduction scenarios 
for all concerned, including optimal intervention and lifestyle changes (Papanas & Ziegler, 2012; 
Phillips et al., 2014; Tabák, Herder, Rathmann, Brunner, & Kivimäki, 2012).  Limited research 





units, but research aiming to discover early changes in sensation using readily accessible, 
portable tools has not been a primary focus (Mustafa et al., 2012; Papanas & Ziegler, 2012; 
Smith & Singleton, 2006).  DPN often develops silently, during early hyperglycemic processes, 
yet many find out far too late in the process to effectively intervene (Monnier, Hanefeld, Schnell, 
Colette, & Owens, 2013; Nichols et al., 2006; Phillips et al., 2014; Ruterbusch, 2014).  Earlier 
intervention in the DPN disease process would allow individuals time to respond with 
appropriate choices to better direct their health, and low-cost tools to detect symptomology 
before T2D or PD has been diagnosed may be useful in this effort.  Several tools, such as the 1-g 
and 10-g monofilaments and the 128-Hz tuning fork, have been successfully used within 
research, effectively serving PD and T2D populations for screening and disease assessment 
(Baraz et al., 2014; Bourcier et al., 2006; Divisova, 2012; Dros et al., 2009; Feng et al., 2009; 
Robinson et al., 2013; Tracey, Greene, & Doty, 2012).  The Norfolk Quality of Life Diabetic 
Neuropathy Screening Tool (QOL-DN), the NC-Stat DPN Check, and hemoglobin A1C testing 
(HbA1C) have been validated within T2D and limited PD populations as well, making them 
likely candidates for success in early screening efforts (Boyd et al., 2011; Casellini, 2007; Lee et 
al., 2014; Perkins et al., 2006; Veresiu et al., 2015; Vinik, Vinik, et al., 2014). 
While each measure has been shown to be reliable and valid in T2D and PD populations, 
overweight, obese and inactive (OOI) populations have not been a primary focus of studies using 
these measures; however, they are at high risk for the development of T2D and associated 
complications.  Evaluation and screening for early signs of dysfunction in an OOI, PD and T2D 
population allows for the development of the appropriate refinement of methods for earlier 





screening tools, the 128-Hz tuning fork, 1-g and 10-g monofilaments, and QOL–DN, in these 









 Sampling.  This study included a total of 34 adults of both sexes and varying ethnicities, 
divided into three groups: 10 overweight, obese and inactive normoglycemic adults (OOI) (6 
females, 4 males; 59.6 + 13.0 years), 13 with prediabetes (11 females, 2 males; 56.4+ 12.2 
years), and 11 with T2D (7 females, 4 males; 59.6 + 12.1 years).  Individuals with T1D, active 
tobacco use, presence of hepatitis B, hepatitis C, HIV, pregnancy, damage to the lower 
extremities, history of nerve disease (other than neuropathy), history of peripheral arterial 
disease, lower limb amputations, or foot ulcers were excluded from participation.  Any 
individual possessing a serious medical condition that would compromise the subject’s safety or 
the integrity of the study was also excluded. 
Selection and Assignment.  Volunteer subjects were recruited by flyers, email, word of 
mouth and university announcements.  Subjects were screened by phone for exclusionary factors 
prior to reporting for testing.  Assignment to groups was based on current HbA1C testing values 
obtained onsite during study procedures.  This research was approved by the Old Dominion 
University Institutional Research Board and subjects participated in informed, signed consent 
procedures before participating (ODU IRB ID: 15-197). 
 
Procedures  
 Subjects reported to the Old Dominion University Wellness Institute to be screened and 
participate in informed consent procedures prior to participation.  Once they completed the 





QOL-DN Questionnaires.  The QOL-DN, a validated method instrument of assessing 
neuropathy, and differentiating between autonomic, large and small fiber impairment (Boyd et 
al., 2011; Veresiu et al., 2015; Vinik, Vinik, et al., 2014) and was utilized with each participant.  
Individuals were given the questionnaire in a quiet area of the testing facility where they could 
work undisturbed at their own pace (see Appendix B).  Incomplete questionnaires were 
completed before proceeding further with the study (Boyd et al., 2011; Casellini, 2007; Veresiu 
et al., 2015; Vinik, Vinik, et al., 2014). 
HbA1C Testing.  Individuals were instructed prior to their appointment to drink several 
glasses of water within 2–3 hours prior to the study to avoid POCD errors, such as high total 
hemoglobin errors.  Hydration instructions were assigned for the 24-hour period beforehand.  
Finger-stick testing was performed with a Siemens DCA Vantage 2000 Analyzer (Lenters-
Westra & Slingerland, 2010) and DCA Vantage HbA1C test kits utilizing sterile techniques.  
HbA1C values and prior diagnoses were utilized to screen and categorize subjects as follows: 
OOI 4.0–5.6%; PD, 5.7–6.4%, T2D, 6.5% and above (Mannarino et al., 2013; Mustafa et al., 
2012; Selvin, Steffes, Gregg, Brancati, & Coresh, 2011). 
NC-Stat DPN Check.  Nerve conduction study procedures utilized the POCD NC-Stat 
DPN Check (DPN-Check, NeuroMetrix Inc., Waltham, MA) and followed previously outlined 
methods as performed in Lee et al., 2014.  The POCD test method involved a bilateral 
examination of the lower extremity with the focus of obtaining sural nerve amplitude potential 
(SNAP) and conduction velocity (SNCV) to assess large myelinated nerve fibers (Lee et al., 
2014; Perkins et al., 2006; Perkins et al., 2008).  The device allows for evaluation of the SNCV 
and SNAP by nonclinical personnel, assisting in DPN detection at a significantly earlier stage 





Vas, & Rayman, 2015).  The unit utilized biosensor technology paired with 2 probes coated in 
conductive gel and was applied directly to the skin posterior to the lateral malleolus.  The single 
press of a button distributed 100 mA of current, which was detected by a single patient use 
disposable biosensor.  A built-in thermometer accounted for variances in temperature between 
23oC and 30 oC and notified the operator of skin temperatures too cold for testing, preventing 
testing until appropriate temperatures were present.  Up to five attempts were utilized to collect 
three sets of SNCV and SNAP values, per leg.  Device errors were not recorded; however, zero 
readings were recorded by hand and reattempts were made up to the 5-trial limit, as individuals 
permitted.  When individuals could not tolerate the acquisition of 3 data points per leg, last 
observation carried forward (LOCF) methods were employed to complete the trial set (Vinik, 
Shapiro, et al., 2014).  The validity and effectiveness of the NC-Stat DPN Check system has 
been confirmed in prior research (Perkins et al., 2006; Sharma et al., 2015).  This test served as a 
criterion standard for the study and all other testing was compared to this measure. 
Tuning Fork Testing.  A 128-Hz tuning fork was used to assess vibration perception 
(Abbott et al., 2002; Shin, Seong, Lee, Kim, & Park, 2000) (See Figure III.1).  Familiarization, 
the site and method of testing, and all procedures for the “On/Off” method followed standardized 
protocols as outlined by the Rapid Screening for Diabetic Neuropathy using the 128-Hz turning 
fork (Abbott et al., 2002; Divišová et al., 2012; Meijer et al., 2005; Perkins et al., 2001; "Rapid 
Screening for Diabetic Neuropathy," 2013; Shin et al., 2000).  The timed tuning fork method was 
employed in the same manner as Perkins et al., 2001, bilaterally (Perkins et al., 2001).  The 
procedural execution of  both sets of tuning fork tests for peripheral neuropathy were performed 
with the subjects lying in the supine position, with eyes closed during testing (Perkins et al., 





Monofilament Testing.  Commercially produced 1-g and 10-g monofilaments were used 
(North Coast Medical, San Jose, CA) with a standard lab testing table to evaluate sensation 
perception.  Monofilament storage and testing took place in a temperature controlled 
environment, within the published parameters established by previous research (Haloua et al., 
2011; Lavery et al., 2012).  Testing loads were limited to appropriate testing and rest periods.  
Scheduling was spaced out over a period of six weeks, less than 10 subjects per day, followed by 
a 1-day rest period before subsequent use.  Monofilaments were utilized to assess sensation 
according to previously published standardized guidelines (Baraz et al., 2014; Kafa et al., 2015; 
"Rapid Screening for Diabetic Neuropathy," 2013).  Procedures for familiarization and testing 
followed the Canadian Diabetes Association for the Rapid Screening of Diabetic Neuropathy as 
laid out for 10-g monofilament testing at the dorsum of the great toe, just proximal to the nail 
bed (see Figure III.2).  These procedures were applied to testing for the 4.17/1-g and 5.07/10-g 
monofilaments and included standardized procedures for familiarization procedures, subject 
response patterns, sites tested, number of stimuli and score assignment based off of prior 
literature (Perkins et al., 2001; "Rapid Screening for Diabetic Neuropathy," 2013; Shin et al., 
2000).  Monofilament testing was performed with the subject lying supine, eyes closed on a 
laboratory testing table.  The 4.17 (1-g) and 5.07 (10-g) monofilaments from a full kit of North 
Coast Medical (North Coast Medical, San Jose, CA) monofilaments were utilized to assess 
sensation according to previously published standardized guidelines (Baraz et al., 2014; Kafa et 
al., 2015; "Rapid Screening for Diabetic Neuropathy," 2013).  Individuals were allowed to keep 
shoes and socks on until the time of testing in order to maintain normal body temperature, but 







 Statistical analyses were performed using SPSS version 22.0 for Windows (SPSS, 
Chicago, IL).  Participant, group characteristics, SNAP and SNCV are presented in raw form.  
Criterion and dependent variable data were logarithmically transformed to best achieve 
normality for statistical analysis.  Correlations were analyzed using Spearman’s coefficients for 
the tuning fork, 1-g and 10-g monofilaments, QOL-DN and NC-Stat DPN Check results, and 
accounted for age, HbA1c and waist measurement (in cm).  Kruskal-Wallis H tests were used to 
determine if there were differences between the three groups with pairwise comparisons using 









Our population included 10 males and 24 females of Caucasian and African American 
ethnicity, with HbA1C ranges varying from 4.4–14.0% (Tables III.1 and III.2).  Fifteen of the 34 
individuals reported no prior diagnosis or knowledge of hyperglycemia.  Five out of 15 had PD 
HbA1C values and were grouped accordingly.  Without specific recruitment for OOI, 33 of the 
34 subjects were overweight or obese.  Twenty-eight individuals reported having no prior 
neuropathy diagnosis or knowledge.  Medication usage varied, with 10 of 34 participants 
reporting T2D specific medication usage as part of their personal medical plan.  Two individuals 
with T2D reported a combination of T2D and neuropathy medication. 
 
Sural Nerve Conduction Amplitude and Velocity Results 
 Overall group means for SNAP and SNCV characteristics did not significantly vary by 
HbA1C level (Table III.3).  Kruskal-Wallis H testing revealed no significant differences among 
OOI, PD and T2D groups for SNAP and SNCV values (SNAP: R, H(2) = 1.460, p = .482; L, 
H(2) = 2.369, p = .306; SNCV: R, H(2) = 1.874, p = .392, L, H(2) = 1.880, p = .391).  Raw data 
means and standard deviations are presented (Table III.3).  Twenty-seven individuals obtained 
confirmed, individualized, abnormal NCS results, of which 25 were bilateral and symmetrical 
(Table III.4).  Twenty-four participants presented with a combination of abnormal distal signs 
bilaterally, of which two also reported altered ADLs and four reported autonomic symptoms.  
Only two of the twenty-four reported changes in both ADLs and autonomic features.  One 
individuals presented with no signs or symptoms.  Seven cases presented with normal NCS 





Tuning Fork Testing, Monofilaments & QOL-DN Results 
The tuning fork on/off test did not correlate with our criterion variables (see Table III.5); 
however, the tuning fork achieved a sensitivity of 53.8% and specificity of 75.0%. (Table III.5), 
Timed tuning fork testing yielded no significant correlations or relationships within the study, 
bilaterally.  The 1-g total scores moderately correlated with both SNAPs [R, rs(34) =.364, p = 
.024; L, rs(34) =.312, p = .047], and left 1-g scores demonstrated a moderate relationship to both 
SNAPs [R, rs(34) =.393, p = .016; L, rs(34) =.301, p = .053] of the NC-Stat DPN Check.  
Sensitivity for the 1-g monofilament was 73.1% and specificity was low, at 25.0%.   
The 10-g monofilament did not significantly correlate to our criterion variables.  
Sensitivity for the 10-g was 46.2% and specificity was 62.5%.  Total QOL-DN scores negatively 
correlated with both SNAPs [R, rs(34) = -.317, p = .044; L, rs(34) = -.311, p = .047], as did the 
Symptoms subscale (both SNAPs) [R, rs(34) = -.332, p = .036; L, rs(34) = -.375, p = .021].  The 
small fiber subscale of the QOL-DN correlated with the RSCV [R, rs(34) = -.311, p = .047] and 
the ADLS subscale correlated with the RSNAP both SNAPs [R, rs(34) = -.354, p = .028]. QOL-







The integration of these testing methods provided an excellent framework to develop a 
better understanding of the onset of dysfunctional physiological processes within PD and OOI 
individuals during the beginning of disease onset and examination of relationships between 
symptoms and disease.  This study compared the effectiveness of the 128-Hz tuning fork, 1-g 
and 10-g monofilaments, and the QOL-DN as screening measures for early DPN detection to 
established NCS criterion values as measured by the NC-Stat DPN Check.  Our evaluation 
utilized the NC-Stat DPN Check and associated NC-Stat software to account for the age, height 
and weight of the subjects in conjunction with 3 bilateral sural NCS readings to assess the 
function of large myelinated nerve fibers, and thus we did not directly assess small fiber 
neuropathy associated deficits.  This study offers a nonclinical analysis based off of the criteria 
required by Tesfaye et al. (2010) aiming to achieve minimal definition requirements for 
confirmed and subclinical DSPN classification, with the intent of developing early screening 
measures for DPN prone populations (Tesfaye, Boulton, Dyck, Freeman, Horowitz, Kempler, 
Lauria, Malik, Spallone, & Vinik, 2010). 
Sural nerve conduction and amplitude values are validated quantitative physiological 
markers that assist in the assessment and confirmation of DPN status with, or without the 
presence of signs or symptoms.  Twenty-six of 34 individuals had abnormal NCS, 24 of whom 
reported symptoms and bilateral symmetrical signs upon examination (1-g, 10-g monofilaments, 
128-Hz tuning fork), meeting the requirements for confirmed DSPN according to some literature 
(Tesfaye et al., 2010); however, we find that this is a significant percentage of study participants 
in comparison to other research conducted with this device (Perkins et al., 2006).  In addition, 





potentially indicating pathology that is not the focus of this study, while one individual with 
abnormal NCS reported no symptoms or signs, confirming the likelihood of subclinical 
neuropathy.  Six individuals obtained normal NCS studies, but had the presence of signs and 
reported symptoms, while one individual had normal NCS, but the presence of signs and no 
reported symptoms. 
Perkins et al. 2006 experienced significant findings, yet their study only evaluated 
individuals with diagnosed diabetes (T1D and T2D), whereas our study examined a wide range 
of individuals, including “healthy” individuals that were recruited for our OOI population that 
we believed might be prone to DPN, as well as PD and T2D individuals.  The fact that we report 
bilateral, abnormal findings in 71% of the individuals we tested, leaves room for questions.  We 
applied rigorous testing preparation and methods, and while it is possible that there is an error we 
are unaware of, our findings may be questioned as valid.  It is also possible that the NC-Stat 
DPN Check’s current software components and algorithms are too sensitive for the subject 
population.  For clarification, we compared our SNAPs to Perkins et al. and found that, overall, 
our SNAP values for our groups (see Table III.3) contained values ranging from 2–25μV, with 
means ranging from 6.6 to 10.5μV, compared to Perkins et al., who contained means of 5.6μV.  
Many of their participants (16) had undetectable levels, whereas we were able to achieve three 
readings on all but 4 individuals to whom LOCF was applied.  At present, we interpret our 
readings as valid given that we acquired three readings on each leg, across a diverse collection of 
individuals, all of whom were likely to develop DPN.  In support of our findings, the individuals 
with abnormal findings self-reported symptoms via QOL-DN and had documented distal 
sensation loss via 128-Hz tuning fork, and 1-g or 10-g monofilaments.  It is, however, possible 





In an attempt to offer specific recommendations of normal or abnormal findings based on 
applied individual characteristics, our assessment differed from previous research by evaluating 
each individual participant according to age, height and weight and determining appropriate 
cutoffs for normal and abnormal findings, thereby individualizing results to each participant with 
the built-in NC-Stat software.  This method of analyses seemed particularly appropriate given the 
nature of the potential impact of overweight, obese status within our population.  Having noted 
discrepancies between the two in the study he performed that analyzed both measures, Lee et al. 
2014 notes that the SNCV values tend to be lower with a traditional NCS when compared to the 
NC-Stat DPN Check (Lee et al., 2014).  This would prove to an interesting point to consider, if 
the same type of error were true, as it would likely boost the number of individuals who had 
abnormalities even higher. 
To detect early DPN in normoglycemic OOI individuals, we had postulated that the 128-
Hz tuning fork and QOL-DN would provide the best mechanisms for detection; however, our 
results only indicated partial support for this theory.  The tuning fork on/off test did not correlate 
well with our NC-Stat DPN Check SNAP criterion variables, however, the QOL-DN, on several 
measures, did.  This finding is different than some prior research, as the QOL-DN has not always 
been found to correlate with electrophysiological measures (Vinik et al., 2005; Vinik et al., 
2008). 
The QOL-DN ranged in sensitivity (0–65.4%) and specificity (12.5–87.5%), differing 
from previous research that resulting in high specificity and sensitivity.  While there is no 
definitive answer for this, plausible considerations for this finding include the unusual 
distribution of our population, and our small pilot size across three groups in our attempts to 





QOL-DN: Hogg et al., 2012 reported the QOL-DN as a means to aid in diagnosis and 
monitoring, but expressed a lack of specificity for PN, stating that it may be limited its use to 
health impacts of a diabetes foot disease related nature (Hogg et al., 2012).  We did not find this 
to be true in our study as QOL-DN measures not only correlated, but also provided vital 
standardized data relating to self-reported symptoms, ultimately contributing to our goal of the 
early identification of DPN. 
Detecting such diabetes complications is an unfolding evolution that involves multiple 
dynamics.  DPN may present in a completely silent manner, without pain, burning or symptoms 
of annoyance.  In such cases, individuals will not disclose physical symptoms that they aren’t 
currently experiencing.  Individuals with early DPN may experience the disease in a varied 
manner, with some individuals experiencing asymptomatic disease patterns, ultimately requiring 
hands on screening to identify the silent progression of the disease.  Future research should likely 
continue to examine the QOL-DN for early DPN detection, as several subscales indicate 
correlations. 
The 1-g monofilament proved to be useful within our study, with (30) individuals 
experiencing abnormal findings.  This measure indicated high sensitivity (73.1%) and poor 
specificity (25.0%), yielding concerns.  However, validation of 1-g physical findings was seen 
through moderate correlations back to our criterion SNAP variables.  Our results relate to 
previous research efforts that reported high sensitivity and low specificity, as is the case of 
Takasande et al. 2011 and reviews performed by Feng et al. (Feng et al., 2009; Taksande, Ansari, 
Jaikishan, & Karwasara, 2011). 
The 10-g monofilament testing lacked significant correlational relationships, yet the 





research.  Our correlational findings did not add support for its use in normoglycemic obese 
populations, but insensate feet relate to neuropathy in later stages and this research focused 
instead on early detection.  In contrast, Ylitalo et al. examined cardiometabolic and neuropathy 
factors in obese individuals and found that the 10-g monofilament was a useful tool for such 
research (Ylitalo, Sowers, & Heeringa, 2011). 
We had hypothesized that the QOL-DN would be the most sensitive measure to detect 
undisclosed DPN in our population, and sensitivity results did not support this.  The most 
sensitive tools for early DPN detection was the 1-g monofilament, which was reasonably 
sensitive at 73.1% but poorly specific at 25.0%, and the tuning fork on/off test, which was less 
sensitive (53.8%) and more specific (75.0%) in nature.  Despite low sensitivity and specificity, 
the Total QOL-DN, Symptoms, ADLS and Small Fiber component aspects of the QOL-DN 
measure, should be considered, as this questionnaire proved to be invaluable to the study.  The 
QOL-DN and its subscales are likely to be more successful in a more balanced study that is 
seeking both small and large fiber deficits related to early DPN detection, as this measure has 
been previously validated to detect both.  Our criterion measure, the NC-Stat DPN Check was 
targeted towards screening for large fiber, and thus may not correlate as well with a well-rounded 
screening measure that targets multiple areas of neuropathy, such as the QOL-DN. 
Finally, our results reflect a strong indication of neuropathy in this population, 
suggesting that careful screening of individuals at earlier stages may be quite beneficial in the 
early detection of DPN, even prior to hyperglycemia diagnosis.  Smith and Singleton found 
elevated HbA1C status in such populations to be a concern for the development of large fiber-
related neuropathy complications, as was found in our cohort (Smith & Singleton, 2013).  





velocities, may arise out of acute bouts of hyperglycemia experienced though postprandial 
excursions, which may be best reflected by HbA1C values (Marcovecchio et al., 2011). 
Our study certainly has some limitations.  As it is a pilot study, generalizations of 
findings may not be made to large populations.  Lack of random assignment and use of 
volunteers for subjects created potential selection bias, with clinical population research targeting 
and low available funding heavily influencing this method.  The HbA1C testing machine that 
was used within the study is a validated machine, yet oral glucose tolerance testing is preferred 
by some researchers, particularly for individuals with cardiac autonomic neuropathy (CAN) 
(Farhan et al., 2012).  We did not test for CAN and, therefore, cannot account for unknown 
discrepancies.  Temperature and humidity have been found to affect monofilament results, by 
affecting the potential validity of the instrument in extremely high temperatures as well as high 
testing volumes in short periods of time (Booth & Young, 2000; Haloua et al., 2011).  
Temperature was accounted for by limiting monofilament storage and use to normal climate 
controlled room temperatures and monitored these values.  Humidity was monitored, but not 
controlled beyond what the laboratory air-conditioning and heating systems accounted for.  
Preparation for monofilament usage followed previously stated guidelines and recommendations, 
with testing amounting to far less than 100 compressions per day per instrument (Booth & 
Young, 2000).  The NC-Stat DPN Check device was used solely to test the sural nerve; 
therefore, deficits in nerve function relating to other nerves of the lower leg were not confirmed 
through this device and two nerves were not evaluated, as some literature advises.  The QOL-DN 
has been previously validated for individuals with diabetes and neuropathy, yet its specific 
validation to effectively target OOI individuals has not been performed and, therefore, this 






This study aimed to detect DPN signs and symptomology prior to PD diagnosis in 
overweight, obese, and inactive adults using low-cost, established tools and compared these tools 
to a validated measure of nerve conduction.  The 1-g monofilament was more useful for 
detection in this population than the 10-g monofilament.  The tuning fork on and off test 
demonstrated reasonable use for this population, although it did not correlate with our criterion 
standard.  The QOL-DN correlated on Total QOL and several subscales, providing valuable, 
standardized symptom information which may be incorporated into community screening 
models.  Future research should continue to aim to refine and develop low-cost screening 







Table III.1  
Participant Characteristics 
Variable Frequency Percent 
Gender   
Male 10 29.4 
Female 24 70.6 
Ethnicity   
Caucasian 22 64.7 
African American 12 35.3 
Diabetes Diagnosis   
None 15 44.1 
Prediabetes 8 23.5 
T2D 11 32.4 
Neuropathy Diagnosis   
No Prior Diagnosis 28 82.4 
Prior Diagnosis 6 17.6 
Medication   
No Medication 8 23.5 
Not T2D Specific 14 41.2 
T2D Specific 10 29.4 
T2D and Neuropathy 2 5.9 
HbA1C Category   
OOI 10 29.4 
PD 13 38.2 
T2D 11 32.4 
BMI Category   
Normal 1 2.9 
Overweight 9 26.5 






Table III.2  
Gender and Group Characteristics 
  N Min Max Mean Std. Err Std. Dev 
Age             
Males 10 37.00 79.00 61.00 4.279 13.532 
Females 24 35.00 74.00 57.20 2.364 11.581 
Height       
Males 10 1.58 1.85 1.745 0.024 0.078 
Females 24 1.48 1.74 1.66 0.013 0.064 
Wt.       
Males 10 83.18 133.10 105.86 6.520 20.618 
Females 24 65.36 122.73 89.40 3.083 15.103 
Wt. By Group       
OOI 10 76.60 106.60 87.93 3.460 10.940 
PD 13 65.90 133.10 98.03 7.350 23.260 
T2D 11 78.40 127.70 101.29 5.590 17.680 
BMI       
Males 10 28.20 41.50 34.85 1.570 4.966 
Females 24 24.70 43.90 32.99 1.156 5.664 
BMI by Group       
OOI 10 27.2 35.6 30.9 1.003 3.170 
PD 13 24.7 43.9 34.2 1.860 6.707 
T2D 11 27.0 41.5 35.1 1.516 5.029 
HbA1C by Gender      
Males 9 4.4 7.1 6.0 0.289 0.915 
Females 21 5.2 14.0 6.5 0.365 1.790 
HbA1C by Group      
OOI 10 4.4 5.6 5.3 0.114 0.362 
PD 13 5.6 6.4 5.9 0.06 0.218 
T2D 11 6.5 14.0 7.8 0.632 2.095 
Wt. = Weight in kg; OOI = Overweight, obese, inactive; T2D = Type 2 diabetes;  






Table III.3  
NCS Results By Group     
NC-Stat DPN Check - Sural Nerve 





SNAP-R (μV)       
OOI 10 2.0 14.3 6.631 1.444 4.567 
PD 13 2.0 24.7 7.691 1.674 6.037 
T2D 11 2.0 25.0 9.875 2.133 7.076 
SNAP-L (μV)       
OOI 10 2.3 21.7 7.129 1.834 5.798 
PD 13 3.0 21.7 7.277 1.186 4.277 
T2D 11 3.0 21.7 10.572 2.064 6.847 
SNCV-R (μV)       
OOI 10 35.3 55.7 46.2 1.902 6.016 
PD 13 30.0 57.0 48.2 1.871 6.747 
T2D 11 35.3 57.0 45.5 1.816 6.022 
SNCV-L (μV)       
OOI 10 41.3 55.0 47.265 1.519 4.803 
PD 13 43.0 55.0 49.637 1.072 3.865 
T2D 11 37.3 57.0 46.876 1.946 6.455 
*Displayed in untransformed form, as raw data 








Sural NCS, Signs and Symptoms 
  Variable Total 
Group 
OOI PD T2D 
Sural NCS         
N = 34 
Normal 7 1 4 3 
Abnormal* 27 10 9 8 
Signs                  
N = 34 
Tuning Fork         
Normal 13 3 5 5 
Abnormal* 21 7 7 6 
Monofilaments      
1-g     
Normal 3 1 0 2 
Abnormal* 31 9 12 9 
10-g     
Normal 3 1 0 2 
Abnormal* 31 9 13 9 
Symptoms          
N = 34 
None Reported 11 7 1 4 
Reported** 23 3 12 7 
Autonomic          
N =34 
None Reported 21 7 8 6 
Reported** 13 3 5 5 
ADLS            
N = 34 
None Reported 26 8 10 8 
Reported** 8 2 3 3 





17 3 9 5 
AbNCS, Signs 
or Symptoms 




1 1 0 0 
NNCS, Signs & 
Symptoms 
7 1 3 3 
*Bilateral testing; abnormal findings on at least one limb; 
**Self-reported on QOL-DN 
AbNCS = Abnormal nerve conduction study; NNCS = 






Table III.5  
Spearman's Partial Correlations (Log Transformed) 
NC-Stat DPN Check - Sural Nerve 
  SNAP-R SNAP-L SNCV-R SNCV-L 
Tuning Fork N = 34 N = 34 N = 34 N = 34 
On/Off  0.221 0.137 0.235 -0.089 
Sig 0.121 0.235 0.106 0.319 
Timed–R -0.066 -0.019 -0.019 -0.099 
Sig 0.365 0.461 0.459 0.302 
Timed–L -0.063 -0.052 -0.018 -0.081 
Sig 0.371 0.392 0.463 0.355 
Monofilaments N = 34 N = 34 N = 34 N = 34 
Total 1-g 0.364* 0.312* -0.060 -0.141 
Sig 0.024 0.047 0.377 0.229 
1-g R 0.229 0.206 0.024 0.077 
Sig 0.112 0.138 0.451 0.342 
1-g L 0.393* 0.301* -0.191 -0.313 
Sig 0.016 0.053 0.155 0.046 
Total 10-g 0.098 0.088 0.032 0.030 
Sig 0.304 0.321 0.432 0.438 
10-g R 0.096 0.160 0.005 -0.066 
Sig 0.306 0.200 0.489 0.364 
10-g L 0.137 0.070 0.031 0.054 
Sig 0.235 0.356 0.436 0.388 
QOL-DN  N = 34 N = 34 N = 34 N = 34 
Total -0.317* -0.311* 0.162 -0.117 
Sig 0.044 0.047 0.197 0.269 
Symptoms -0.332* -0.375* 0.213 -0.003 
Sig 0.036 0.021 0.129 0.493 
Large Fiber -0.297 -0.284 0.107 -0.163 
Sig 0.056 0.064 0.286 0.195 
Small Fiber -0.241 -0.187 -0.311* -0.366 
Sig 0.099 0.161 0.047 0.023 
ADLS -0.354* -0.263 0.104 -0.065 
Sig 0.028 0.080 0.293 0.366 
Autonomic -0.236 -0.245 0.149 -0.044 
Sig 0.105 0.096 0.216 0.408 







Figure III.1  128-Hz Tuning Fork 
 
Reproduced with permission by the Canadian Diabetes Association. April 2016 ("Rapid 






Figure III.2 Monofilament Application 
 
Reproduced with permission by the Canadian Diabetes Association. April 2016 ("Rapid 







PROJECT II: NEUROPATHY QUALITY OF LIFE TOOLS  
INTRODUCTION 
Diabetes is an overwhelming disease that places significant demands on individuals, 
often leading to distress and ultimately degradation of consistent self-care behaviors (Guo et al., 
2015; Karlsen, Oftedal, & Bru, 2012).  Such stressors and inconsistent monitoring behaviors 
invite damage caused by extended or acute hyperglycemia (Vinik et al., 2013).  Hyperglycemia 
promotes early microvascular complications related to diabetic neuropathy (DN), including 
altered eyesight, kidney and psychosocial functioning, all of which may bring significant impact 
on an individual.  An individual’s outlook on life, how he or she experiences it, interacts with 
others, and chooses activities may be affected by a DN diagnosis and individual symptomology.  
Such adverse outcomes on an individual body system, and the ability to perform tasks and 
psychosocial functioning is referred to as health-related quality of life (HRQOL) (Luscombe, 
2000).  HRQOL is an important concept within diabetes care management, particularly due to 
the rising impact of the disease itself, as projected estimations for 2035 indicate diabetes will 
impact over 592 million individuals worldwide across the globe (Guariguata et al., 2013). 
Research over the past several decades has made great strides in developing several 
HRQOL assessments that specialize in assessing DN-related measures and address HRQOL as a 
significant factor (Bredfeldt, Altschuler, Adams, Portz, & Bayliss, 2015; Smith et al., 2012; 
Vickrey et al., 2000; Vileikyte et al., 2003; Vinik et al., 2004).  Within the realm of HRQOL, DN 
has been of particular interest, with individuals dedicating significant research effort to the 





should be promptly screened in order to facilitate optimal health outcomes (Marrero et al., 2014; 
Sinclair, Dunning, & Rodriguez-Mañas, 2015). 
 DN is often experienced in T2D and PD, raising questions as to when DN develops 
(Marrero et al., 2014; Papanas & Ziegler, 2012) and how soon it affects QOL.  Furthermore, 
overweight, obese, or inactive status (OOI) places an individual at increased risk for disease, 
including potential progression to PD and T2D and other forms of physiological dysfunction, yet 
sparse research is available relating to how these individuals may or may not experience DN 
(Miscio et al., 2005).  Neuropathy screening is considered a standard care for individuals 
diagnosed with T2D, but not for OOI individuals.  Therefore, the purpose of this study was to 
compare three measures of QOL, the NQOL–DN, the PN-QOL-97, and the NeuroQOL-28, in 
OOI, PD and T2D adults to determine which instrument is the most effective at detecting DN at 
various stages while comparing the findings back to a criterion standard, the NC–Stat DPN 








Sampling.  This study included a total of 34 adults of both sexes and varying ethnicities, 
divided into three groups: 10 overweight, obese and inactive normoglycemic individuals (OOI) 
(6 females, 4 males; 59.6+ 13.0 years), 13 individuals with prediabetes (11 females, 2 males; 
56.4+12.2 years), and 11 individuals with T2D (7 females, 4 males; 59.6+12.1 years).  
Individuals with T1D, active tobacco use, presence of hepatitis B, hepatitis C, HIV, pregnancy, 
damage to the lower extremities, history of nerve disease (other than neuropathy), history of 
peripheral arterial disease, lower limb amputations, or foot ulcers were excluded from 
participation.  Any individual possessing a serious medical condition that would compromise the 
subject’s safety or the integrity of the study was also excluded. 
Selection and Assignment.  Volunteer subjects were recruited by flyers, email, word of 
mouth and university announcements.  Subjects were screened by phone for exclusionary factors 
prior to reporting for testing (see Appendix A).  Assignment to groups was based on current 
HbA1C testing values obtained onsite during study procedures.  
Protection of Subjects.  Participants were closely monitored during the study. Sterile 
techniques were used to collect blood samples and perform HbA1C testing.  This research was 
approved by the Old Dominion University Institutional Research Board and subjects participated 
in informed, signed consent procedures before participating (ODU IRB ID: 15-197). 
 
Procedure 
Questionnaires were filled out after individuals were screened and consented into the 





times were tracked for each instrument, allowing a comparison of the time investment needed to 
utilize each chosen method.  Individuals were placed in a quiet room within the Wellness 
Institute with a volunteer research assistant who timed their completion of each instrument in 
minutes and seconds.  Questionnaires were checked by volunteer research assistants and 
investigators for completeness before proceeding to HbA1C testing.  Incomplete questionnaires 
were completed before proceeding with the study.  Digital copies of all questionnaires were 
acquired directly from the authors (QOL–DN, PN-QOL-97 and NeuroQOL-28) via email 
correspondence, including scoring rubrics.  Printed copies were used with each participant and 
are attached as appendices (see Appendices B, C and D). 
 Norfolk Quality of Life Diabetic Neuropathy Tool.  The Norfolk Quality-of-Life 
Diabetic Neuropathy tool (QOL-DN) has been found to be reliable across different populations 
and sensitive to both small and large fiber impairment and improvements in neuropathy (see 
Appendix B) (Boyd et al., 2011; Casellini, 2007; Veresiu et al., 2015; Vinik, Vinik, et al., 2014). 
 PN-QOL-97.  This instrument has been identified as a validated measure for identifying 
DPN and successfully used in research (Maxwell et al., 2013; Maxwell et al., 2014; Vickrey et 
al., 2000).  It is a PN-specific HRQOL measure that offers multiple psychometric properties to be 
considered (see Appendix C) (Smith et al., 2012; Vickrey et al., 2000). 
NeuroQOL-28.  The NeuroQOL-28 questionnaire instrument has been validated as a 
neuropathy-and foot ulcer-specific QOL tool and subsequently utilized in myriad studies 
evaluating QOL identifying key factors involved in the DPN experience (see Appendix D) (Dixit 
& Maiya, 2014; Vileikyte et al., 2003). 
HbA1C Testing. Hemoglobin A1C (HbA1C) finger-stick testing was performed with a 





HbA1C test kits utilizing sterile techniques.  HbA1C values were utilized to screen and 
categorize subjects as follows: OOI 4.0–5.6%; PD, 5.7–6.4%, T2D 6.5% and above (Mannarino 
et al., 2013; Mustafa et al., 2012; Selvin et al., 2011) HbA1C finger-stick testing followed a 
standardized protocol determined from Selvin et al. (2011) and Lenters-Westra and Slingerland, 
(2010) (Lenters-Westra & Slingerland, 2010; Selvin et al., 2011).  HbA1C testing was performed 
after individuals have been screened, and consented into the study, and after all other paperwork 
has been filled out.  Individuals were instructed prior to their appointment to drink several 
glasses of water within 2–3 hours prior to the study to avoid errors on the test, such as high total 
hemoglobin errors.  Individuals were also instructed to stay well hydrated for the 24-hour period 
beforehand. 
NC-Stat DPN Check.  NC-Stat DPN Check (DPN-Check, NeuroMetrix Inc., Waltham, 
MA) procedures followed previously outlined methods as performed in Lee et al. (2014) (Lee et 
al., 2014).  The POCD test method involved a bilateral examination of the lower extremity with 
the focus of obtaining sural nerve amplitude potential (SNAP) and conduction velocity (SNCV) 
(Lee et al., 2014; Perkins et al., 2006; Perkins et al., 2008).  The device allows for evaluation of 
the SNCV and SNAP by nonclinical personnel, assisting in DPN detection at a significantly 
earlier stage when compared to bedside tests (Pambianco et al., 2011; Sharma et al., 2015).  The 
unit utilized biosensor technology paired with 2 probes was applied directly to the skin posterior 
to the lateral malleolus.  A single press of a button distributed 100 mA of current, which was 
detected by a one use disposable biosensor.  A built-in thermometer accounted for variances in 
temperature between 23oC and 30oC and notified the operator if skin temperatures were too cold 
for testing.  Thee SNCV and SNAP values were attempted for each leg with up to five attempts 





hand and re-attempts we made up to the 5 trial limit, as individuals permitted.  The validity and 
effectiveness of the NC-Stat DPN Check system has been confirmed in prior research (Perkins et 
al., 2006; Sharma et al., 2015).  This test served as a criterion standard for the study and all other 
testing was compared to this measure. 
 
Data Analyses 
 Statistical Evaluation.  Questionnaires were considered valid if complete biographic 
information, including age and sex was provided (Veresiu et al., 2015).  Summary statistics, in 
the form of continuous data is presented with means and standard deviations.  Pertinent 
Spearman’s partial correlations are presented.  NC-Stat DPN Check, measuring (3 trials) the 
right sided sural nerve amplitude potential (RSNAP) served as the comparable criterion standard, 
determining confirmed DSPN or subclinical DSPN. 
Multiple regressions were run to attempt to predict the right SNAP criterion through 
modeling that accounted for HbA1C, age, BMI and selected correlated predictor variables from 
each questionnaire.  Comparisons involved running separate multiple regression analyses with 
limited covariate and predictor variables with the aim to predict DPN.  Covariates and predictors 
were entered at once, including accounting for known factors such as HbA1C, age, and BMI as a 
substitute measure for weight and height, in order to best preserve the regression model DOF 
(Herrera-Rangel, Aranda-Moreno, Mantilla-Ochoa, Zainos-Saucedo, & Jáuregui-Renaud, 2014).  
Selected neuropathy-related components were entered into each regression model based on 
potential relationships presented in Spearman’s partial correlations and appropriate choices that 





Selections were first made from the highest correlations, with additional predictors options if 
multicollinearity issues could not be effectively resolved within the model. 
Linearity was assessed by scatterplot analyses, partial regression plots and a plot of 
studentized residuals against the predicted values.  Homoscedasticity, independence of 
observations (research design and Durbin-Watson), linear relationships, outliers (+3 std. dev.), 
influential leverage cases, and multi-collinearity components (correlations, tolerance, VIF 
values) were evaluated and addressed for each model independently. 
 Regression results were compared via confidence intervals, standard errors and 
regression coefficients in an effort to determine if one survey could be named as the optimal 
predictor survey with post hoc testing as necessary.  All analyses were performed using SPSS 








Our population included 10 males and 24 females of Caucasian and African American 
ethnicity, with HbA1C ranges varying from 4.4–14.0% for all subjects (Tables IV.1 and IV.2).  
Fifteen of 34 individuals reported no prior diagnosis or knowledge of T2D or PD.  Five of 15 
individuals had PD HbA1C values and were grouped accordingly.  A total of 33 out of 34 
individuals were overweight or obese.  Twenty-eight individuals reported having no prior 
neuropathy diagnosis or knowledge.  Medication usage varied, with 10 of 34 participants 
reporting T2D specific medication usage as part of their personal medical plan.  Two individuals 
with T2D reported a combination of T2D and neuropathy medication. 
 
Sural Nerve Conduction Amplitude and Velocity Results 
 Overall group means for SNAP and SNCV characteristics did not significantly vary by 
HbA1C level (Table IV.3).  Kruskal-Wallis-H testing revealed no significant differences among 
OOI, PD and T2D groups for SNAP and SNCV values (SNAP: R, H(2) = 1.460, p = .482; L, 
H(2) = 2.369, p =.306; SNCV: R, H(2) = 1.874, p =.392, L, H(2) = 1.880, p =.391).  Raw data 
means and standard deviations are presented (Table IV.5).  Twenty-seven individuals obtained 
confirmed, individualized, abnormal NCS results, of which 25 were bilateral and symmetrical 
(Table IV.4).  Twenty-four participants presented with combinations of abnormal distal signs 
bilaterally, meeting criteria for confirmed DSPN, and one case presented with no signs or 
symptoms, indicating the presence of subclinical neuropathy.  Seven cases presented with normal 







 Spearman’s partial correlations were run between NC-Stat DPN Check criterion standard 
variables, which were the right and left SNAP and SNCV values and all questionnaire data 
components while accounting for age and HbA1C values.  Significant correlations were 
identified and are presented (Table IV.5).  The QOL-DN symptom component moderately 
correlated with the right SNAP criterion [R, rs(34) -.365, p = .044].  The PN-QOL-97 physical 
component score moderately correlated with both the right and left SNAP criterions [R, rs(34) 
=.375, p = .038; L, rs(34): .366, p = .043], as did the mental component scores; however, the 
relationship was considerably stronger [R, rs(34) = .522, p = .003; L, rs(34) = .451, p = .011].  
NeuroQOL-28 neuropathy specific components moderately strongly correlated to the left SNAP 
[ rs(34) = -.426, p = .017], and the NeuroQOL-28 overall QOL judgment score strongly 
[RSNAP, rs(34) =.541, p = .002] and moderately correlated [LSNAP, rs(34) =.396, p = .028] to 
our criterion SNAP values. 
 
Completion Times 
Completion times analyses revealed that the QOL-DN (M = 5.17; SD = 1.83) was the 
quickest, on average to complete, followed by the NeuroQOL-28 (M = 5.58; SD = 3.56) and 
QOL-97 (M = 13.23; SD = 3.606) (Table IV.6). 
 
QOL-DN Questionnaires 
A multiple regression was run to attempt to predict the right SNAP criterion with a 
regression model that accounted for HbA1C, age, BMI, QOL-DN Symptoms and Total QOL 





value, F(5,28) = 6.118, p <.001, adj. R2 = .52.  Age (p =.000) and Total QOL (p = .019) 




A multiple regression was run to attempt to predict the right SNAP criterion with a 
regression model that accounted for HbA1C, age, BMI, and PN-QOL-97 Physical and Mental 
Scores as predictors.  This model significantly predicted the right SNAP value, F(5,25) = 7.465, 
p < .0005, adj. R2 = .52.  Age (p =.000) and HbA1C (p = .025) significantly added to the 
prediction.  Regression coefficients and standard errors can be found in Table IV.8. 
 
NeuroQOL-28 Questionnaires 
A multiple regression was run to attempt to predict the right SNAP criterion with a 
regression model that accounted for HbA1C, age, BMI, and the NeuroQOL-28 Neuropathy 
Specific Component and Overall QOL Judgment as predictors.  The multiple regression model 
significantly predicted the right SNAP value, F(5,28) = 7.238, p < .0005, adj. R2 = .49.  Age (p = 
.000) and Overall QOL Judgment (p = .017) significantly added to the prediction.  Regression 







Although the QOL-DN, PN-QOL-97 and NeuroQOL-28 have been validated for use in 
research as neuropathy instruments to detect DPN, further analysis of these instruments has been 
recommended (Bredfeldt et al., 2015; Smith et al., 2012).  We sought to determine which of 
three instruments, the QOL-DN (Vinik et al., 2005), the PN-QOL-97 (Vickrey et al., 2000) or the 
NeuroQOL-28 (Vileikyte et al., 2003) would be the best predictor of neuropathy when compared 
to our criterion standard measurements in OOI, PD and T2D populations.  The QOL-DN 
Symptoms component correlated with our LSNAP, but not with the RSNAP, thus the fact that 
the regression results revealed a predictor relationship between the Total QOL and RSNAP was 
not surprising.  Examination of bilateral results will be reported elsewhere. 
We had anticipated that our first hypothesis would likely be supported, with the QOL-DN 
more clearly identifying early, or subclinical PN, and the Total QOL-DN (p = .019) component 
supports this hypothesis.  Our results indicate that QOL-DN, but not the PN-QOL-97, predicted 
our criterion standard RSNAP value within our regression models, although the PN-QOL-97’s 
Mental Score was relatively close to significance (p = .073).  The NeuroQOL-28 Overall 
Judgment of QOL (p = .017) demonstrated significant predictive qualities for early detection, 
giving further validation to this short questionnaire, yet asymmetry existed in its correlational 
relationship across the RSNAP and LSNAP variables.  Normal variants within our target 
population could account for such asymmetries.  Twenty-six of 34 individuals had abnormal 
NCS.  Of these 26, 24 reported symptoms (recorded via QOL-DN) and the presence of bilateral 
symmetrical signs as evidenced by 1-g and 10-g monofilaments, 128-Hz tuning fork, and 





In hypothesizing which instrument would be most effective to detect DPN in our OOI, 
PD and T2D population, we had predicted correlation of .60 or higher between these tools and 
the NC-Stat DPN Check criterion SNAP and SNCV values.  However, our results indicate that 
all three measures failed to meet this level; although they correlated to our criterion, the 
association was not as strong as clinically desirable.  Correlations revealed significant 
relationships between the RSNAP and the Neuropathy Overall Judgment QOL (rs = .523), and 
PN-QOL-97 Mental Scores (rs = 505) for the RSNAP, but not for the QOL-DN. 
Early detection is considered critical, yet is difficult to accomplish with currently 
available methods. Papanas and Ziegler (2012) emphasize the importance of early DPN detection 
in their research, advising small fiber evaluation as a means to catch the pathophysiological 
process in the earliest stages (Herrera-Rangel et al., 2014; Papanas, Vinik, & Ziegler, 2011; 
Papanas & Ziegler, 2012).  Clinical exams readily identify small fiber pathology, often using 
Neurotips (pain and warmth detection), or a cold 128-Hz tuning fork (thermoreceptor evaluation) 
(Vinik et al., 2013).  Large fiber neuropathy, which is the primary focus of the NC-Stat DPN 
Check tool, may also be evaluated through hands-on measures (NC-Stat DPN-Check, 1-g, 10-g 
monofilaments, 128-Hz tuning fork) in clinical or on site applications to test pressure and large 
fiber sensitivity changes.  Small fiber dysfunction, however, is difficult to detect, often requiring 
skin biopsy for confirmed status, paired with abnormal QST and clinical exams, requiring 
clinical appointments.  Such clinical tests are useful, if one can get individuals to report for 
testing at a clinical site or participate in on-site screening that utilizes them.  However, we 
emphasize the necessity of research to develop easy-to-use screening tools that may be utilized in 
short time commitment community screening efforts.  The often silent beginnings of small fiber 





pathology.  Unless experiencing symptoms, such as brief pins-and-needles, pricks, or shock 
sensations, they have little to move them towards clinical evaluation. 
While we knew that each instrument had its strengths and weaknesses as we entered this 
study, one thing we did not fully consider was that each may pick up on different components of 
fiber loss, meaning one may be more adept at detecting small fiber, another identifies with large 
fiber loss and another may do well with both of these and autonomic as well.  Our criterion 
focused on large fiber measurement, and future study designs may want to incorporate multiple 
means to assess the effectiveness of these QOL tools, ones that address small, large and 
autonomic neuropathy components, to better detect the abilities of each individual instrument for 
screening.  This might include simple bedside tests, such as a cold tuning fork and Neurotips, in 
order to evaluate small fiber components. 
The further development of paper questionnaires to effectively screen for small fiber 
component dysfunction should be a priority, as much of the general public does not seek medical 
attention until symptoms have become obvious.  Ultimately, the focus of patient reported 
outcomes such as the QOL-DN, PN-QOL-97 and the NeuroQOL-28 is DPN screening and 
detection, thus evaluating these instruments for different facets of the targeted disease population 
and determining each tool’s viability in that subset was a useful objective of the current study.  
Both the QOL-DN and NeuroQOL-28 likely identified key subjective measures that align well 
with objective screening measure in early hyperglycemic processes within our small pilot 
population.  The QOL-DN was effectively employed to identify key symptomology necessary 
for the diagnosis of DPN, aiding and assisting in a patient centered, cumulative approach.  Both 
of these instruments are available in US and UK versions, with the NeuroQOL-28 reported to be 





indicating widespread availability for use in research and screening efforts.  Additional strengths 
of the QOL-DN are highlighted in research efforts by Vinik et al. (2005), where the QOL-DN 
demonstrates a well-rounded approach, uncovering multiple neuropathy-related components, 
including complications, medication use, autonomic factors, fiber specific domains and validated 
use for revealing undisclosed neuropathy (Veresiu et al., 2015; Vinik et al., 2005).  Our study 
showed similar results, disclosing DPN in individuals who were unaware of their deteriorating 
physiological state, revealing promise for the QOL-DN in revealing disease in diverse population 
settings.  The NeuroQOL-28 focuses on painful symptoms, reduced sensation, ADLS, overall 
diffused sensory and motor changes, emotional changes and overall QOL, which likely explains 
its usefulness in our study (Vileikyte et al., 2003).  These facets relate to our research, as the 
completion of results reflect a strong indication of neuropathy in this population, suggesting that 
careful screening of individuals at earlier stages may be quite beneficial in the DPN detection 
process, even prior to acute hyperglycemia diagnosis.  Elevated HbA1C status in such 
populations is associated with the development of decreased motor and sensory nerve conduction 
velocities, which may arise out of acute bouts of hyperglycemia experienced though postprandial 
excursions (Marcovecchio et al., 2011; Smith & Singleton, 2013).  Our participants were likely 
to report a variety of component changes, including psychometric properties that are evaluated 
and reported by this measure.  Currently, each questionnaire has its strengths and should be 
applied accordingly. 
Previous research has reported unknown completion times for the NeuroQOL-28 and 
QOL-DN (Smith et al., 2012).  Our study, therefore, is the first to document time to completion 
for all three measures.  Our finding that completion times were shorter for the QOL-DN and 





screening efforts, as evaluations will need to take these times into account for optimal 
participation.  Both instruments can be employed within a short time, and the choice between 
which measure to use in future early DPN investigations is a difficult one, as these instruments 
are typically applied in populations that are likely further along in their disease process than the 
ones in this pilot work.  On a practical note, quickly completed PROMs provide more leeway for 
integration into community screenings, but the measure also must be able to be quickly scored to 
be of immediate use to the individual.  Of the 3 measures, the scoring is easiest for the 
NeuroQOL-28, which can be done by hand in a face-to-face setting as necessary within less than 
5 minutes.  The QOL-DN requires scoring, that although simple, requires additional time to 
provide feedback, likely needing contact information or a second reporting to disseminate 
results.  The PN-QOL-97, while thorough, requires more elaborate scoring and calculations 
accomplished through programs such as Excel, and same day reported outcomes would not be 
realistic without the cooperation of multiple researchers with designated roles.  Although not 
done in this study, examining these measures directly in the field, within whatever screening 
context they are being honed for, would have allowed for evaluation of these measures within the 
context of administering the instruments in a less controlled atmosphere and should be 
considered for future evaluations. 
Our study has limitations that should be considered.  We performed a pilot study, and 
generalizations may not be made to large populations.  Lack of random assignment and use of 
volunteers for subjects created potential selection bias, with clinical population research targeting 
and low available funding heavily influencing this method.  The HbA1C machine that was used 
within the study is a validated machine (Lenters-Westra & Slingerland, 2010), yet oral glucose 





autonomic neuropathy (CAN) (Farhan et al., 2012).  We did not test for CAN and, therefore, 
cannot account for unknown discrepancies.  The NC-Stat DPN Check device was used solely to 
test the sural nerve; therefore, deficits in nerve function relating to other nerves of the lower leg 
were not confirmed through this device.  Previous research has not investigated the validity of 
the QOL-DN, PN-QOL-97 and the NeuroQOL-28 within an overweight, obese and inactive 
population and, therefore, this should be taken this into account when interpreting our findings.  
Furthermore, each of these instruments detects particular types of neuropathy, and we only 







Both the QOL-DN and NeuroQOL-28 significantly predict neuropathy criterion standard 
components in OOI, PD and T2D subjects, adding validity to their use as screening measures as 
early DPN detection tools.  The PN-QOL-97 effectively identified multiple DPN-related issues; 
however, its ability to predict our criterion standard was not statistically significant.  Time 
completion studies revealed that the QOL-DN and NeuroQOL-28 may be posed as excellent 
short screening measures, completed in approximately 6 minutes or less, with reasonable scoring 
for both; however, if immediate feedback is needed, the NeuroQOL-28 is likely to be a better fit 
with time constraints and limited staff.  Consideration should be given to adding fiber specific 
domains to the NeuroQOL-28 and psychological measures assessing the impact of depression to 
the QOL-DN, thus adding potential to both instruments to more closely align with different 
facets potentially experienced by the target population, hopefully increasing the power of their 
constructs.  Asymmetry in NCS findings warrants proposing that future research consider how 
falls and injuries may contribute to the uneven pathogenesis of SNAP values in subacute and 
acute hyperglycemic populations and to further explore other options for effective screening for 
early DPN.  Priority should be given to investigations seeking to evaluate the effectiveness of 
these tools to detect DN within early, DN prone, predefined populations, providing new 
opportunities to increase the effectiveness of these and other instruments in subclinical 









Variable Frequency Percent 
Gender   
Male 10 29.4 
Female 24 70.6 
Ethnicity   
Caucasian 22 64.7 
African American 12 35.3 
Diabetes Diagnosis   
None 15 44.1 
Prediabetes 8 23.5 
T2D 11 32.4 
Neuropathy Diagnosis   
No Prior Diagnosis 28 82.4 
Prior Diagnosis 6 17.6 
Medication   
No Medication 8 23.5 
Not T2D Specific 14 41.2 
T2D Specific 10 29.4 
T2D and Neuropathy 2 5.9 
HbA1C Category   
OOI 10 29.4 
PD 13 38.2 
T2D 11 32.4 
BMI Category   
Normal 1 2.9 
Overweight 9 26.5 







Gender and Group Characteristics 
  N Min Max Mean Std. Err Std. Dev 
Age             
Males 10 37.00 79.00 61.00 4.279 13.532 
Females 24 35.00 74.00 57.20 2.364 11.581 
Height       
Males 10 1.58 1.85 1.745 0.024 0.078 
Females 24 1.48 1.74 1.66 0.013 0.064 
Wt.       
Males 10 83.18 133.10 105.86 6.520 20.618 
Females 24 65.36 122.73 89.40 3.083 15.103 
Wt. By Group       
OOI 10 76.60 106.60 87.93 3.460 10.940 
PD 13 65.90 133.10 98.03 7.350 23.260 
T2D 11 78.40 127.70 101.29 5.590 17.680 
BMI       
Males 10 28.20 41.50 34.85 1.570 4.966 
Females 24 24.70 43.90 32.99 1.156 5.664 
BMI by Group       
OOI 10 27.2 35.6 30.9 1.003 3.170 
PD 13 24.7 43.9 34.2 1.860 6.707 
T2D 11 27.0 41.5 35.1 1.516 5.029 
HbA1C by Gender      
Males 9 4.4 7.1 6.0 0.289 0.915 
Females 21 5.2 14.0 6.5 0.365 1.790 
HbA1C by Group      
OOI 10 4.4 5.6 5.3 0.114 0.362 
PD 13 5.6 6.4 5.9 0.06 0.218 
T2D 11 6.5 14.0 7.8 0.632 2.095 
Wt. = Weight in kg; OOI = Overweight, obese, inactive; T2D = Type 2 diabetes;  







NCS Results By Group     
NC-Stat DPN Check - Sural Nerve 
  N Min Max Mean Std. Err 
Std. 
Dev 
SNAP-R (μV)       
OOI 10 2.0 14.3 6.631 1.444 4.567 
PD 13 2.0 24.7 7.691 1.674 6.037 
T2D 11 2.0 25.0 9.875 2.133 7.076 
SNAP-L (μV)       
OOI 10 2.3 21.7 7.129 1.834 5.798 
PD 13 3.0 21.7 7.277 1.186 4.277 
T2D 11 3.0 21.7 10.572 2.064 6.847 
SNCV-R (μV)       
OOI 10 35.3 55.7 46.2 1.902 6.016 
PD 13 30.0 57.0 48.2 1.871 6.747 
T2D 11 35.3 57.0 45.5 1.816 6.022 
SNCV-L (μV)       
OOI 10 41.3 55.0 47.265 1.519 4.803 
PD 13 43.0 55.0 49.637 1.072 3.865 
T2D 11 37.3 57.0 46.876 1.946 6.455 
*Displayed in untransformed form, as raw data 







Table IV.4      
Sural NCS, Signs and Symptoms 
  Variable Total 
Group 
OOI PD T2D 
Sural NCS         
N = 34 
Normal 7 1 4 3 
Abnormal* 27 10 9 8 
Signs                  
N = 34 
Tuning Fork     
Normal 13 3 5 5 
Abnormal* 21 7 7 6 
Monofilaments      
1-g     
Normal 3 1 0 2 
Abnormal* 31 9 12 9 
10-g     
Normal 3 1 0 2 
Abnormal* 31 9 13 9 
Symptoms          
N = 34 
None Reported 11 7 1 4 
Reported** 23 3 12 7 
Autonomic          
N =34 
None Reported 21 7 8 6 
Reported** 13 3 5 5 
ADLS            
N = 34 
None Reported 26 8 10 8 
Reported** 8 2 3 3 





17 3 9 5 
AbNCS, Signs 
or Symptoms 




1 1 0 0 
NNCS, Signs 
& Symptoms 
7 1 3 3 
*Bilateral testing; abnormal findings on at least one limb; **Self-
reported on QOL-DN 
AbNCS = Abnormal nerve conduction study; NNCS = Normal 






Table IV.5  
Spearman Partial Correlations 
    RSNAP LSNAP RSNCV LSNCV 
QOL-DN    N=34 N=34 N=34 N=34 
Total Score 
Corr. -0.289 -0.352 -0.004 -0.242 
Sig. 0.128 0.061 0.985 0.205 
Large Fiber 
Corr. -0.275 -0.322 -0.058 -0.290 
Sig. 0.149 0.088 0.765 0.127 
Small Fiber 
Corr. -0.251 -0.185 -0.340 -0.361 
Sig. 0.189 0.336 0.071 0.054 
Symptoms 
Corr. -0.291 *-0.417 0.047 -0.102 
Sig. 0.126 0.024 0.808 0.597 
ADLS 
Corr. -0.331 -0.260 0.066 -0.074 
Sig. 0.079 0.164 0.734 0.701 
Autonomic 
Corr. -0.188 -0.297 -0.091 -0.188 
Sig. 0.328 0.117 0.638 0.329 
PN-QOL-97 N=34 N=34 N=34 N=34 
Physical 
Corr. 0.350 *0.399 0.107 0.166 
Sig. 0.063 0.032 0.579 0.389 
Mental 
Corr. *0.505 *0.479 0.052 -0.101 
Sig. 0.005 0.009 0.791 0.603 
NeuroQOL-28 N=34 N=34 N=34 N=34 
Total Score 
Corr. -0.194 -0.334 -0.288 -0.279 
Sig. 0.314 0.077 0.129 0.142 
Neuropathy Specific 
Corr. -0.305 *-0.464 -0.177 -0.204 
Sig. 0.108 0.011 0.358 0.287 
Overall QOL Judgement 
Corr. *0.523 *0.426 0.194 0.025 
Sig. 0.004 0.021 0.312 0.897 
All correlations account for HbA1C, age, height and weight. 






Table IV.6  
Instrument Completion Times  
  N Mean Std. Dev. 
Std. 
Error 
QOL-DN 34 5.17 1.834 0.315 
NeuroQOL-28 34 5.58 3.566 0.612 






Table IV.7  

















(Constant) 28.084 7.291  3.852 .001 13.150 43.018 
Age -.311 .066 -.629 -4.738 .000 -.446 -.177 




-.110 .149 -.101 -.741 .465 -.416 .195 
Symptoms 3.613 2.523 .347 1.432 .163 -1.555 8.780 
Total 
QOL 
-2.719 1.096 -.550 -2.481 .019 -4.964 -.474 






Table IV.8  

















(Constant) -47.420 43.910  -1.080 .290 -137.853 43.014 
Age -.348 .077 -.730 -4.525 .000 -.507 -.190 
HbA1C 2.608 1.090 .374 2.392 .025 .362 4.853 
Body Mass 
Index 
-.207 .156 -.178 -1.326 .197 -.528 .114 
Physical 
Score 
4.470 11.653 .076 .384 .705 -19.529 28.470 
Mental 
Score 
12.102 6.456 .349 1.874 .073 -1.195 25.399 






Table IV.9  

















(Constant) -.235 18.513  -.013 .990 -38.157 37.688 
Age -.357 .067 -.721 -5.344 .000 -.494 -.220 
HbA1C .918 .549 .243 1.671 .106 -.207 2.042 
Body Mass 
Index 
.036 .151 .032 .236 .815 -.273 .345 
Neuropathy 
Specific 




15.748 6.180 .422 2.548 .017 3.089 28.406 







PROJECT III: MELATONIN AND THE AUTONOMIC NERVOUS SYSTEM  
INTRODUCTION 
 The complications relating to diabetes are numerous, potentially relating to most regions 
of the body as microvascular pathology develops over an extended period, yet no complication 
of the disease may be as dangerous as cardiac autonomic neuropathy (CAN) (Vinik & Erbas, 
2001; Ziegler et al., 1992).  Mortality rates are significantly higher for individuals experiencing 
CAN when compared to patients without this particular pathology (Ewing & Clarke, 1986; 
Vinik, Maser, et al., 2003; Vinik & Erbas, 2006).  CAN dysfunction and how it relates to 
diabetes is not clearly defined, although hyperglycemia appears to be related, with glycation end 
products playing a significant role in creating inflammation in microvascular processes 
(Hardeland, Cardinali, Brown, & Pandi-Perumal, 2015; Lieb et al., 2012; Tarvainen et al., 2014).  
A proinflammatory state has been associated with ANS damage in diabetes (Hardeland et al., 
2011; Lieb et al., 2012) and sympathovagal imbalance may either result from or be the cause of 
an increased state of inflammation (Lieb et al., 2012), which plays a key role in the development 
of both T2D and atherosclerosis. 
 Interest has developed in melatonin as a substance that may provide answers for elements 
of dysfunction that arise in T2D, particularly those associated with circadian disorders (Ferrell & 
Chiang, 2015; Scheer et al., 2003; Spadoni et al., 2011).  Melatonin regulates sleep patterns and 
wake cycles within healthy individuals, and is produced in circadian patterns (Claustrat et al., 





melatonin production is suspected, and thought to be related to the consequences of 
hyperglycemia (Reutrakul & Van Cauter, 2014). 
 Interruption in sleep and wake cycles may be particularly difficult for T2D patients, 
speeding along symptoms of the disease (Kreier et al., 2007).  Melatonin synchronizes the 
biological clock (Reiter et al., 2007; Scheer et al., 2003), increasing restorative capabilities, 
lowering inflammation (Jung et al., 2010), and attenuates neurotransmitters of the sympathetic 
nervous system (Nishiyama et al., 2001; Vazan & Ravingerova, 2015).  Thus, it has been 
hypothesized that melatonin may have promise to improve ANS balance, inflammation, 
oxidative stress, and glycemic control within the T2D patient (Hussain et al., 2006; Kedziora-
Kornatowska et al., 2009; Paskaloglu et al., 2004; Reiter, 1995; Scheer et al., 2003; Tutuncu et 
al., 2005). 
 Given melatonin’s effects on resetting the circadian clock of the ANS, we postulated that 
it might help improve ANS function in T2D patients.  Thus, the purpose of this research was to 
investigate whether the underlying central, cardiac, and peripheral defects observed in T2D could 








 Sampling.  A total of 10 adults of both sexes and varying ethnicities, 40–75 years of age, 
who had diagnosed T2D were recruited from a local population.  Exclusionary criteria included: 
congestive heart failure, recent myocardial infarction, unstable arrhythmia, any cardiovascular 
event in the previous year, liver or kidney disease, severe orthostatic hypotension, active tobacco 
use, type 1 diabetes, hepatitis B or C, presence of HIV, active malignancy (diagnosed or treated 
with in the last year), nighttime shift work, current or recent use of supplemental melatonin, 
pregnancy and/or breast-feeding, or other serious medical conditions that investigators believed 
would compromise the subject’s well-being or participation in the study. 
Protection of Subjects.  This research was approved by the Old Dominion University 
Institutional Research Board and Eastern Virginia Medical School’s Institutional Review Board, 
and subjects participated in informed, signed consent procedures before participating (ODU IRB 
ID: 15-260).  Documented, informed consent was obtained from each subject prior to 
participation.  Throughout the study, patients were evaluated by a medical professional at each 
visit (baseline, 4 and 8 weeks) to the Eastern Virginia Medical School (EVMS) Strelitz Diabetes 




 This study utilized a single over-the-counter daily dose of melatonin (10 mg) to 
determine its effect on both autonomic balance and baroreflex sensitivity.  Up to 10 mg doses are 





and even as little as 0.5 mg can affect circadian rhythm entrainment (Hack, Lockley, Arendt, & 
Skene, 2003).  Individuals were screened by phone as potential candidates for the study utilizing 
inclusion/exclusion criteria (see Appendix F) before scheduling volunteers to arrive in a fasted 
state for a 2-hour appointment at the EVMS Strelitz Diabetes Center, in Norfolk, VA.   During 
visit one, the inclusion/exclusion form was completed (see Appendix F), and individuals meeting 
study requirements were consented into the study prior to receiving an exam that included 
height, weight, an electrocardiogram, blood pressure measurements (supine, standing, seated), 
medication recording, health condition disclosure, basic diabetes screening and a neurological 
physical to determine the health of the individual to participate in the research study (see 
Appendix E).  Qualified candidates continued with testing, which included sleep questionnaires, 
HbA1C finger-stick testing, Sudoscan testing, HRV and baroreflex sensitivity testing (see 
Appendix G).  Each of the 3 visits followed the same pattern, with HbA1C testing on visits 1 and 
3, and 4-week melatonin or placebo assignment on visits 1 and 2. 
HbA1C Testing.  A Siemens DCA Vantage 2000 Analyzer (Lenters-Westra & 
Slingerland, 2010), DCA Vantage HbA1C test kits, alcohol prep pads, lancets, medical gloves, 
anti-bacterial wipes, and a Hazard Sharps container were utilized for finger-stick testing on visits 
1 and 3. 
 Melatonin.  After qualifying for the study and giving their informed consent, subjects 
were randomly assigned a tablet order.  Subjects received a single 4-week quantity of 10 mg 
melatonin capsules or placebo capsules and were instructed to consume one capsule every 
evening 30 minutes before bedtime.  The crossover dose (melatonin or placebo) was distributed 
to each subject after 4 weeks and compliance reassessed after the second 4 weeks until each 





(Life Extension, Ft. Lauderdale, FL) contained 10 mg each.  Placebo capsules contained white 
flour. 
Autonomic Nervous System Function Testing.  Before and after each of the two 4-
week trials (melatonin and placebo), the ANSAR device (ANSAR; ANX 3.0 software; ANSAR 
Group, Inc., Philadelphia, PA) was utilized to assess systemic (vagal) autonomic function and 
sympathetic balance (Vinik & Erbas, 2006).  Subjects underwent three tests of autonomic 
function (R-R intervals): 1) deep breathing (expiratory/inspiratory ratio; E/I); 2) Valsalva 
maneuver (breath holding); and 3) postural change (standing from a seated position).  All ANS 
testing was done at the same time of day both before and after supplementation to minimize 
individual diurnal variations of any residual melatonin following each overnight period. 
 Power Spectral Analysis.  Power spectral analysis of HRV was performed with 
previously validated methods (La Rovere, Pinna, Maestri, & Sleight, 2012) under resting 
conditions with the ANSAR device for determination of low frequency (LF) and high-frequency 
(HF) components.  The LF component of the power spectrum of HRV primarily is now 
considered to reflect baroreflex function.  The HF component primarily reflects parasympathetic 
activity. LF/HF ratios were calculated to provide a measure of ANS balance.  The total spectral 
power (TSP) was calculated, along with the standard deviation of all normal R-R intervals 
(SDNN), a measure of both sympathetic and parasympathetic action on HRV, and the root-mean 
square of the difference of successive R-R intervals (RMSSD), a measure primarily of 
parasympathetic activity (Vinik & Ziegler, 2007).  Abnormalities in SDNN and RMSSD precede 
inflammation in adults with newly-diagnosed T2D (Lieb et al., 2012).  All power spectral 






Baroreflex Sensitivity Testing.  IBSF was measured with the ANSAR device using 
validated methods (Dimitropoulos, Tahrani, & Stevens, 2014; La Rovere et al., 2012).  Sudoscan 
(Aspire Medical Solutions, NY) testing was also used to quantify changes in sudomotor and 
small nerve fiber function (i.e., peripheral sympathetic tone) and, together with BSF, to 
determine parasympathetic balance.  The physiological impact was evaluated through the effects 
of a high dose supplemental melatonin on autonomic balance in baroreflex sensitivity (BRS). 
 Sleep Quality.  Although melatonin supplements may or may not improve sleep quality 
in older adults (Baskett et al., 2003; Baskett et al., 2001; Wade et al., 2007), to account for any 
possible effects of changes in sleep quality alone due to exogenous melatonin, subjects 
completed the Pittsburgh Sleep Quality Index (PSQI), (Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989; Buysse et al., 1991; Lemoine, Wade, Katz, Nir, & Zisapel, 2012; Nunes et al., 
2008; Yu et al., 2011), a validated, self-rated questionnaire assessing sleep quality and 
disturbances over a 1-month time interval, before and after each 4-week supplementation period.  
Nineteen individual items generated seven “component” scores: subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, 
and daytime dysfunction (see Appendix G). 
 
Data Analyses 
 Statistical Evaluation.  Repeated measures analysis of variance (ANOVA) was used to 
compare pre- and post-supplementation values for melatonin and placebo.  Data were 
normalized.  Relationships among autonomic function, baroreflex sensitivity, sleep quality 
measures, and melatonin dose were determined with Spearman’s partial correlations.  





assessment variables were performed after age and HbA1C adjustment (Agelink et al., 2001; 






Ten individuals participated in a double blinded, randomized crossover study comparing 
4 weeks of placebo to 4 weeks of 10 mg of melatonin supplementation.  Participant 
characteristics are displayed in Table V.1.  HbA1C values did not significantly differ from visit 1 
to visit 3.  Careful logging was kept of all potential side effects and events during the study.  
After medical examination, the only side effect reported possibly related to melatonin 
administration was sleepiness, as reported by one subject.   
 
Autonomic Function & Power Spectral Analysis 
 Spearman’s partial correlations accounted for age and HbA1C, and key correlations of 
interest are included in Table V.2 for review.  Friedman’s ANOVA tests were run to determine if 
there were significant differences between baseline, placebo and melatonin time points relating 
to autonomic ratio tests (E/I Ratio, Valsalva Ratio, 30:15 Ratio) and for all HRV variables.  
Ratio testing results indicate that there were increases from the baseline condition to placebo and 
from baseline to melatonin; however, none were statistically significant (see Table V.3).  
Assessment of individual ANSAR results indicated that that nine of ten individuals presented 
with initial ANS dysfunction, ranging from mild to advanced, with the ninth specifically 
demonstrated what was likely to be sympathetic withdrawal.  Only one participant presented 
with no evidence of dysfunction at initial baseline evaluation.  Four of these individuals also had 
abnormal Sudomotor function, further validating ANSAR findings.   
Orthostatic hypotension (OH) testing revealed that none of our participants were 
experiencing it.  This was tested twice each visit; once with ANSAR BP testing values (seated to 





twice each visit for tachycardia (90–130 bpm) (Dimitropoulos et al., 2014), and none 
experienced tachycardia, or even notable HR elevation/events throughout testing.  All 
participants were within a normal or slightly bradycardic range at baseline, placebo and 
melatonin conditions.  BP values did not vary significantly from baseline to placebo or baseline 
to melatonin within the conditions of deep breathing, Valsalva or postural change (30:15), with 
the exception of SBP response to deep breathing and SBP response to Valsalva (reported in 
Baroreflex Sensitivity). 
Individual evaluation of frequency domain components, revealed that Valsalva LFnu was 
significantly different between the baseline, placebo and melatonin conditions (p = .045).  
Pairwise comparisons revealed significant differences between baseline and melatonin 
conditions (p = .042), but not between baseline and placebo (p =.353) or placebo and melatonin 
(p = .371) (see Table V.3).  Valsalva HFnu was significantly different between the baseline, 
placebo and melatonin conditions (p = .045).  Pairwise comparisons revealed significant 
differences between baseline and melatonin conditions (p = .042), but not between baseline and 
placebo (p = .353) or placebo and melatonin (p = .371).  Analysis of other power spectral 
analysis components (LF, HF and LF/HF ratio) did not reveal any significant differences across 
the conditions, at any time point. 
Standing SDNN, a time domain component, was significantly higher in the melatonin 
measurement (p = .032) than baseline or placebo time measurements.  Pairwise comparisons 
revealed significant differences between placebo and melatonin (p = .042), but not between 
baseline and placebo (p = .371) or baseline and melatonin (p = .353). There were no other 
significant interactions relating to time domain variables.  See Table V.3 for nonparametric 






BP and HR were examined across all conditions (deep breathing, Valsalva, 30:15) via 
Friedman’s ANOVA, and heart rates did not significantly differ across any of the tested 
conditions.  SBP response, however, significantly differed across two tests.  SBP changes related 
to deep breathing [X2 (2, N = 10) = 6.821, p = .033] with pairwise comparisons indicate 
differences between baseline and the melatonin condition (p = .042).  SBP changes during 
Valsalva [X2 (2, N = 10) = 7.947, p = .019] were also present, with pairwise comparisons 
indicating significant differences between the placebo and melatonin conditions (p = .030). 
A one-way repeated measures ANOVA examined differences in Sudoscan results at 
baseline, and after placebo and melatonin conditions.  There were no outliers and the data were 
normally distributed at each time point, with the assumption of sphericity met by Mauchly’s test 
of sphericity.  There were no statistically different changes between the conditions over time, 
F(2,18) = .055, p = .844, η2 = .006.  There were no statistically significant differences between 
the means at the different time points (p > .05). 
 
Sleep Quality 
A Friedman’s test was conducted to determine if there were significant differences 
between the baseline, placebo and melatonin Sleep Questionnaire scores.  Median Sleep Quality 
scores were generated for all sleep components (subjective sleep quality, sleep latency, sleep 
duration, sleep efficiency, sleep disturbances, sleep medication, daytime dysfunction, and global 
PSQI (see Appendix G.  Subjective sleep quality scores were significantly different between the 
baseline, placebo and melatonin scores, X2 (3, N = 10) = 12.929, p = .002.  Post hoc analysis 





evaluation of subjective sleep quality revealed significant differences between the groups (p < 
.002) (Table V.5).  Pairwise comparisons were performed with a Bonferroni correction for 
multiple comparisons and subjective sleep quality were significantly different between placebo 
(Mdn = .00) and melatonin (Mdn = 1.00) interventions (p < .011), not between the placebo and 
baseline or baseline and melatonin interventions (see Table V.6).  Friedman’s test was performed 
on sleep latency, sleep duration, sleep efficiency, sleep disturbances, sleep medication, daytime 
dysfunction, and global PSQI, to determine if there were differences between baseline, placebo 








This study aimed to determine baseline ANS function in individuals with T2D with the 
intent to investigate to what extent melatonin would improve individual measures.  We 
hypothesized that the ANS misconducts in T2D, causing a neuroinflammatory response and 
leading to impairment, and that ANS function would improve in participants through melatonin 
supplementation.  However, our results indicate unexpected significant changes from melatonin 
supplementation in the HRV variables of LFnu and HFnu.  LFnu significantly increased from 
baseline after melatonin supplementation (p =.042), as did HFnu (p =.032) during the Valsalva 
portion of ANSAR testing.  Heathers (2014) discusses the interpretation of HRV variables in 
great depth, explaining that the LF component’s dominance is an ongoing debate, with 
multifaceted points to consider (Goldstein, Bentho, Park, & Sharabi, 2011; Heathers, 2014) and 
not to be confused with HRV components with normalized units, such as LFnu and HFnu.  
Theoretically, Heathers submits that one may view that LFnu and HFnu are extremely close in 
nature, more clearly representing a continuum of outcomes, representative of not just a deviation 
or change but potential changes that happen over a period or continuum and represent small 
deviations of measurement rather than two separate variables (Heathers, 2014).  Such an 
explanation may be plausible over a dynamic activity, such as Valsalva conditions, where a 
continuum applies, yet only one specific reading is evaluated, suggesting that our results are 
worthy of additional exploration.  An interesting finding in our study was a decrease in SBP 
during the Valsalva melatonin condition.  When viewed collectively with HFnu and LFnu 
findings, it becomes of greater interest as we found a positive effect on lowering SBP during 
dynamic activity.  Likewise, SBP dropped during the DB portion of the melatonin condition 





intervention.  Although not measured in the present study, research relating to melatonin 
supplementation in T2D should likely utilize 24-hr halter monitors that would capture a range of 
values and continuums to evaluate, during sleep, ADLS and activities, paired with clinically 
controlled ANSAR testing protocols. 
We had hypothesized that ANS function would improve with melatonin supplementation, 
creating a positive effect and this was found to be partly true within our study.  Power spectral 
measures, such as LF, which is generally thought to represent a balance of both the 
parasympathetic and sympathetic branches of the ANS and HF, a reflection of parasympathetic 
balance, did not significantly change across any of our testing conditions, despite changes in 
other measures of consideration.  SDNN, however, which is a time domain component 
representing the standard deviation of normal RR intervals, rose in the standing condition in our 
population of T2D subjects.  Subbalakshmi, Adhikari, Poornima, and KN (2015) investigated 
correlates of SDNN in T2D and found that higher heart rates, DBP and Q-T dysfunction were 
related to a reduction in SDNN in such individuals (Subbalakshmi et al., 2015).  Our subjects 
were screened via ECG at each visit, and monitored for cardiac abnormalities throughout the 
study, and abnormal Q-T interval, DBP and elevated HR findings were not found in our cohort. 
Depressed or lowered values of SDNN have been associated with increases in risk of sudden 
death, particularly in patients with known heart issues (Farrell et al., 1991; Kleiger, Miller, 
Bigger, & Moss, 1987).  Previous research indicates that E:I Ratio and SDNN are valid markers 
for monitoring CAN, yet our study revealed no significant differences in the evaluation of these 
ratios across baseline, placebo and the melatonin conditions (Subbalakshmi, Adhikari, Rao, & 
Jeganathan, 2012).  Our findings suggest a potential positive effect on SDNN in a small pilot 





Range: 28.7-47.0), with 9 individuals with a BMI over 30, with most participants on BP 
lowering medications.  HRV parameters have been researched in similar cohorts with 
nonsignificant findings; however, this study indicates that individuals with overweight, obese 
status may benefit from melatonin supplementation to increase SDNN or impact key 
physiological processes, or potentially positively impact this HRV features before more extreme 
forms of dysfunction are diagnosed (Stuckey, 2013). 
Baroreflex sensitivity was evaluated in our study, yet HR responses to SBP did not reveal 
any significant relationships, indicating that vagal cardiac activity most likely did not 
significantly change in relationship to HR.  Some participants experienced mild bradycardia 
(58/59 BPM) during resting conditions, indicating higher parasympathetic tone and possible 
sympathetic withdrawal.  Of interest, SBP did change in relationship to DB when considering the 
baseline to placebo and baseline to melatonin conditions.  When examining the data, it is 
apparent that the placebo SBP rose higher during the placebo condition in comparison to 
baseline, whereas the melatonin SBP dropped significantly, moving the opposite direction.  We 
cannot explain the rise in SBP across our participants, but it appears that the melatonin had a 
positive effect on SBP during DB.  In a similar manner, SBP for Valsalva relating to the placebo 
and melatonin condition moved the same directions, with the melatonin SBP dropping and the 
placebo elevating, although neither was significant in relationship to baseline, the resulting SBPs 
were significantly different when compared to each other.  Our results are similar to Cavallo, 
Daniels, Dolan, Bean, and Khoury (2004) who performed BP research with T1D individuals who 
utilized ambulatory BP monitors and took 10 mg  of melatonin daily (Cavallo et al., 2004).  This 
research documented decreases in SBP during sleep; however, our research differs in that they 





Our evaluation of Sudoscan measures to assess small fiber and autonomic nerve activity 
(baroreflex) found no significant differences between baseline, placebo and melatonin 
conditions, yet Sudoscan has become a validated and useful tool for measuring sudomotor 
changes at the microvascular level (Calvet, Dupin, Winiecki, & Schwarz, 2013).  Our results 
suggest that a 4-wk 10 mg melatonin intervention does not impact measurable small fiber and 
baroreflex changes, although the potential effects of longer supplementation or different 
melatonin doses were not evaluated. 
Subjective sleep quality significantly improved between the baseline and melatonin 
conditions, with 80% of subjects reporting improvements in sleep quality that were likely related 
to taking melatonin.  While other measures (sleep latency, daytime dysfunction, global PSQI) 
improved from baseline to melatonin condition, the effect was not statistically significant. 
Similar research has indicated positive results in various PSQI sleep scores while utilizing 4 mg 
of melatonin supplementation one hour before bedtime over a 21-day time period, which differs 
from our methodology of administering 10 mg 30 minutes prior to bedtime over a 4-week period 
(Nunes et al., 2008).  As observed in our subjects, 10 mg of melatonin at bedtime likely induces 
a positive, measurable effect on sleep quality in individuals with T2D. 
 Given that melatonin is secreted in the brain in all mammals, with primary synthesis 
rising from the pineal gland in a circadian manner orchestrated by the superchiasmatic nucleus, 
our introduction of a 10 mg supplementation of melatonin aimed to assist in what would, 
naturally be processes that are regulated by light and dark; however, how melatonin is used and 
orchestrated within the body can also be affected by medication usage.  Our subjects had 
numerous health comorbidities and took numerous prescribed and over-the-counter medications 





depression is common in T2D, for example, and have debatable brain interactions (Härtter et al., 
2001).  BP medications have varying interactions with melatonin, as melatonin has been found to 
lower BP nocturnally in beneficial ways and NSAIDS are known to reduce the efficacy of or 
suppress melatonin synthesis, which may have contributed to a type II error in our study (Aygün, 
Kaplan, Odaci, Onger, & Altunkaynak, 2012; Grossman et al., 2006; Murphy, Myers, & Badia, 
1996; Reiter, Guerrero, Escames, Pappolla, & AcuÑA-Castroviejo, 1997).  Melatonin may 
protect against neurotoxicity, and combats oxidative effects. We did not, however, account for 
potential effects of other medications in this pilot study, although individuals with major 
psychotic conditions were excluded from participation.   
 For the future, a larger cohort, with stricter medication parameters for admission to the 
study would be recommended.  While our testing measures were rigorous, an additional A1C 
value would be advantageous, as would a longer trial period, including a minimum time period 
of 8 weeks on 10 mg melatonin in order to evaluate potential positive effects.  There are a 
number of limitations to consider with this study.  We did not control the medications of 
individuals participating in the study and do not know how their individual medications relate to 
our melatonin intervention.  We used HbA1C to check diabetes status, despite literature that 
indicates that it is not ideal for working with individuals that might have CAN; however, our 
participants did have a prior medical history to confirm their diagnoses.  Melatonin and placebo 
tablets were distributed to the participants, and although compliance was monitored, we also 
trusted that they would regularly participate in the study measures by being responsible to 







Some beneficial effects on autonomic nervous system function, such as improved SDNN 
HRV measures, decreased SBP during deep breathing and Valsalva maneuvers, may result from 
supplementation with 10 mg of melatonin at bedtime over a 4-week time period in adults with 
T2D who have signs of CAN dysfunction.  Its effect on other HRV parameters (LFnu and HFnu) 
warrants additional investigation to evaluate the backdrop of dynamics activities, such as 
Valsalva breathing maneuvers.  Its positive impact on sleep quality is promising, but sleep 
quality studies involving T2D individuals should measure the effects of different doses over 
longer periods of time and possibly include control groups without diabetes.  Future research 
should focus on examining melatonin’s potential impact on SDNN in T2D individuals who 
exhibit normal BP and HR status, in an effort to determine how protective mechanisms may be 







Table V.1  
Participant Characteristics      10 




Error Min Max 
Age Cohort 10 62.8 6.030 1.907 54 70 
Weight 
Baseline 10 218.340 31.134 9.845 172.600 277.800 
Placebo 10 218.600 30.592 9.674 174.200 280.400 
Melatonin 10 217.620 31.156 9.852 171.600 276.400 
BMI 
Category 
Overweight 1 28.700 - - - - 




7.0% 0.865 0.274 
- - 






Table V.2  
Spearman's Partial Correlations 
Variable  Correlation/Significance Value 
Melatonin Valsalva  
LF/HF  
Melatonin Valsalva LFnu  
.976, p =.000                        
Melatonin Valsalva HFnu  
-.976, p =.000 
Melatonin Valsalva  
TSP 
Time Domain SDNN 
Baseline.693, p =.026               
Time Domain SDNN Placebo 
.729, p =.017                       
Time Domain SDNN Melatonin 
.891, p =.001 
Placebo Valsalva  
TSP 
Time Domain RMSSD 
Baseline.697, p =.025               
Time Domain RMSSD Placebo 
.867, p =.001                       
Time Domain RMSSD Melatonin 






Table V.3  
Log10 Transformed Nonparametric Friedman’s ANOVA Results 
 Mean Rank Test Statistics 
  Baseline Placebo Melatonin N Sig. 
Test 
Statistic DOF 
ANSAR Testing        
E/I Ratio 1.600 2.300 2.100 10 0.273 2.600 2 
Valsalva Ratio 1.850 2.150 2.000 10 0.794 0.462 2 
30:15 Ratio 1.450 2.450 2.100 10 0.071 5.282 2 
Deep Breathing        
LF/HF 1.800 1.800 2.400 10 0.301 2.400 2 
LF nu 1.800 1.800 2.400 10 0.301 2.400 2 
HF nu 2.200 2.200 1.600 10 0.301 2.400 2 
TSP 1.700 2.100 2.200 10 0.497 1.400 2 
SDNN 1.600 1.900 2.500 10 0.122 4.200 2 
RMSSD 1.750 2.050 2.200 10 0.575 1.105 2 
Valsalva Ratio        
LF/HF 1.500 2.000 2.500 10 0.082 5.000 2 
LF nu 1.400 2.100 2.500 10 *0.045 6.200 2 
HF nu 2.600 1.900 1.500 10 *0.045 6.200 2 
TSP 2.100 1.900 2.000 10 0.905 0.200 2 
SDNN 2.100 2.000 1.900 10 0.905 0.200 2 
RMSSD 2.450 1.500 2.050 10 0.097 4.667 2 
30:15        
LF/HF 2.500 1.800 1.700 10 0.150 3.800 2 
LF nu 2.500 1.600 1.900 10 0.122 4.200 2 
HF nu 1.850 2.150 2.000 10 0.794 0.462 2 
TSP 2.200 1.900 1.900 10 0.741 0.600 2 
SDNN 1.900 1.500 2.600 10 *0.032 6.889 2 
RMSSD 2.100 1.900 2.000 10 0.889 0.235 2 






   
Table V.4  
Log10 Transformed Nonparametric Pairwise Comparisons   
Variables & 
Comparisons Rank Test Statistics 
Valsalva Baseline Placebo Melatonin N Sig. 
Test 
Statistic DOF 








Statistic N  Sig. 
Adj. 
Sig.  
Baseline/Placebo -0.700 0.447 -1.565 10 0.118 0.353  
Baseline/Mel -1.100 0.447 -2.46 10 0.014 *0.042  
Placebo/Melatonin -0.400 0.447 -0.894 10 0.371 1.000  
Valsalva Baseline Placebo Melatonin N Sig. 
Test 
Statistic DOF 








Statistic N  Sig. 
Adj. 
Sig.  
Melatonin/Placebo 0.400 0.447 0.894 10 0.371 1.000  
Baseline/Melatonin 1.100 0.447 2.46 10 0.014 *0.042  
Placebo/Baseline 0.700 0.447 1.565 10 0.118 0.353  
30:15 Baseline Placebo Melatonin N Sig. 
Test 
Statistic DOF 








Statistic N  Sig. 
Adj. 
Sig.  
Baseline/Placebo 0.400 0.447 0.894 10 0.371 1.000  
Placebo/Melatonin -1.100 0.447 -2.46 10 0.014 *0.042  
Baseline/Melatonin -0.700 0.447 -1.565 10 0.118 0.353   






Table V.5  
Friedman’s ANOVA Sleep Questionnaire Results 
 Mean Rank Test Statistics 
  Baseline Placebo Melatonin N Sig. 
Test 
Statistic DOF 
Sleep Questionnaire       
Subjective Sleep 
Quality 1.800 1.450 2.750 10 *0.002 12.929 2 
Sleep Latency 2.200 2.100 1.790 10 0.393 1.867 2 
Sleep Duration 1.850 1.850 2.300 10 0.368 2 2 
Sleep Efficiency 1.750 2.250 2.000 10 0.210 3.125 2 
Sleep Disturbances 2.000 2.000 2.000 10 1.000 0.000 2 
Sleep Medication 1.700 2.000 2.300 10 0.135 4.000 2 
Daytime Dysfunction 2,25 1.900 1.850 10 0.368 2.000 2 
Global PSQI 2.400 1.850 1.750 10 0.130 4.083 2 






        
Table V.6  
Nonparametric Pairwise Comparisons    
Variables & 
Comparisons Rank Test Statistics 












Statistic N  Sig. 
Adj. 
Sig.  
Baseline/Placebo 0.350 0.447 0.783 10 0.434 1.000 2 
Placebo/Melatonin -1.300 0.447 -2.907 10 0.004 0.011 2 
Baseline/Melatonin -0.950 0.447 -2.124 10 0.034 0.101 2 






      
Table V.7  
Sudoscan Results      








Feet Mean ESC 1.748 0.142 1.761 0.173 1.746 0.186 10 
Feet Mean 
Asymmetry 
0.679 0.142 0.825 0.325 0.679 0.436 10 
Hands Mean ESC 1.704 0.166 1.631 0.233 1.682 0.121 10 
Hands Mean 
Asymmetry 








The impact of T2D is significant, affecting increasing numbers of individuals within the 
United States and across the globe in the range of 390−392 million and beyond at the present 
time.  Despite current efforts, diabetes diagnoses have dramatically increased over the past two 
decades, rising from 7.6 million globally in 2004 to 21.9 million in 2014.  Estimated impact by 
the year 2035 is projected to be in the 590 million range globally.  Despite medical and research 
efforts, the disease has continued to increase in prevalence.  With such rising numbers and 
increasing health impact, the research community must continue to seek out new ways to prevent 
and effectively manage the disease. 
The research efforts within this dissertation include three distinct investigations related to 
neuropathy screening and treatment.  Project I investigated the effectivenss of the 128-Hz tuning 
fork, 1-g and 1-g monofilament and the QOL-DN as potential early screening tools while 
comparing each measure back to the portable NC-Stat DPN Check nerve conduction device.  
These screening tools have been reported to be effective for the screening of DPN in T2D 
populations when used together or in conjunction with other bedside tests.  Each screening tool 
has unique functions as to what type of sensation they are reported to detect and this should be 
considered when choosing screening options.  Previous research has focused on T2D and limited 
PD populations for their research; however, we utilized these screening options within a mixed 
population of OOI, PD and T2D subjects.  Our results indicated that the 1-g monofilament and 
the QOL-DN show promise for development for the screening of early DPN and each correlates 
well with the portable NC-Stat DPN Check device.  Additionally, the 128-Hz tuning fork 





HRQOL measurements have become an interest in research, with emphasis developing 
on unique subsets of health linked to particular diagnoses such as DN.  Several DN-related QOL 
instruments have been developed and implemented within research in the past several decades in 
an effort to detect DN-related health deficits, in hopes of revealing and treating related 
complications and improving QOL.  Research efforts, beyond meta-analyses, to compare which 
measures might be most effective in an active research population have not been prevalent thus 
far, nor have many instruments been compared to nerve conduction studies.  Portable nerve 
conduction units, such as the NC-Stat DPN Check have more recently come available; thus, in 
keeping with advancing neuropathy screening efforts, we sought to compare three accepted DN 
specific QOL measures in an OOI, PD and T2D population, while comparing our results back to 
the validated NC-Stat DPN Check device.  Our results indicate that the QOL-DN and 
NeuroQOL-28 effectively predicted our neuropathy derived criterion, making them effective 
tools to administer in an OOI, PD and T2D population for early screening and detection of DPN.  
Effectively administered in approximately 6 minutes or less, both instruments are research 
screening friendly.  The NeuroQOL-28 is the easiest to administer and score on site, making it 
ideal for community screening efforts. 
Research literature proposes that T2D disrupts circadian rythms, alters autonomic 
function and places individuals with diabetes at significant risk for cardiovascular events.  
Studies have evaluated the effect of melatonin and found it to be beneficial for resetting sleep 
patterns in healthy adults.  We sought to determine the effectiveness of resetting the ANS in 
individuals with T2D, with the hope of improving sleep patterns and positively altering HRV 
measures by adminisering a 10 mg dose of over-the-counter melatonin.  Our investigation 





HFnu in the Valsalva condition when comparing the baseline to melatonin and placebo 
treatments.  This indicates a unique phenomenon to be evaluated further in order to investigate 
the continuum of how dynamic movement HRV measures are affected by melatonin 
supplementation.  SBP in deep breathing and SBP in the Valsalva maneuver were significantly 
lowered following melatonin supplementation, indicating a positive effect. SDNN was 
signficantly different from baseline to melatonin and between the placebo and melatonin 
condition, also indicating a beneficial effect from a 4-wk 10 mg melatonin supplementation.  
Sleep quality measures showed significant changes in subjective sleep quality measures, 
suggesting that melatonin had a positive impact on perceived sleep quality. 
 While these pilots studies show promising results, more research in all of these areas is 
needed.  Future research should focus on the continued development of effective methods for 
early detection, disease assessment, management and reversal in DN prone populations to 








Abbott, C. A., Carrington, A. L., Ashe, H., Bath, S., Every, L. C., Griffiths, J., . . . Boulton, A. J. 
(2002). The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new 
diabetic foot ulceration in a community-based patient cohort. Diabet Med, 19(5), 377-
384.  
ADA. (2014). Common terms.  Retrieved from http://www.diabetes.org/diabetes-
basics/common-terms/?loc=db-slabnav 
ADA. (2016). Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes 
Care, 39 Suppl 1, S4-5. doi:10.2337/dc16-S003 
Agelink, M. W., Malessa, R., Baumann, B., Majewski, T., Akila, F., Zeit, T., & Ziegler, D. 
(2001). Standardized tests of heart rate variability: normal ranges obtained from 309 
healthy humans, and effects of age, gender, and heart rate. Clin Auton Res, 11(2), 99-108.  
Alam, A., Ezhova, N., Kotovskaya, Y., Dogotar, O., & Kobalava, Z. (2015). Determinants of 
arterial stiffness and central blood pressure in the very elderly. Journal of the American 
Society of Hypertension, 9(4, Supplement), e35. doi:10.1016/j.jash.2015.03.079 
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., & Donato, K. A. 
(2009). Harmonizing the metabolic syndrome: a joint interim statement of the 
International Diabetes Federation Task Force on Epidemiology and Prevention; National 
Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International Association for the Study of 





Alexander, C. M., Landsman, P. B., & Grundy, S. M. (2006). Metabolic syndrome and 
hyperglycemia: congruence and divergence. Am J Cardiol, 98(7), 982-985. 
doi:10.1016/j.amjcard.2006.04.046 
Amaral, F. G., Turati, A. O., Barone, M., Scialfa, J. H., Carmo Buonfiglio, D., Peres, R., . . . 
Cipolla-Neto, J. (2014). Melatonin synthesis impairment as a new deleterious outcome of 
diabetes-derived hyperglycemia. Journal of pineal research, 57(1), 67-79. 
doi:10.1111/jpi.12144 
American Heart Association Inc.; European Society of Cardiology. (1996). Heart rate variability: 
standards of measurement, physiological interpretation and clinical use. Task Force of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. Circulation, 93, 1043-1065. doi:10.1161/01.CIR.93.5.1043 
Aygün, D., Kaplan, S., Odaci, E., Onger, M. E., & Altunkaynak, M. E. (2012). Toxicity of non-
steroidal anti-inflammatory drugs: a review of melatonin and diclofenac sodium 
association. Histology and histopathology, 27(4), 417.  
Bakkers, M., Merkies, I., Lauria, G., Devigili, G., Penza, P., Lombardi, R., . . . Faber, C. (2009). 
Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology, 73(14), 
1142-1148.  
Baraz, S., Zarea, K., Shahbazian, H. B., & Latifi, S. M. (2014). Comparison of the accuracy of 
monofilament testing at various points of feet in peripheral diabetic neuropathy 
screening. J Diabetes Metab Disord, 13(1), 19. doi:10.1186/2251-6581-13-19 
Baskett, J. J., Broad, J. B., Wood, P. C., Duncan, J. R., Pledger, M. J., English, J., & Arendt, J. 
(2003). Does melatonin improve sleep in older people? A randomised crossover trial. Age 





Baskett, J. J., Wood, P. C., Broad, J. B., Duncan, J. R., English, J., & Arendt, J. (2001). 
Melatonin in older people with age-related sleep maintenance problems: a comparison 
with age matched normal sleepers. Sleep, 24(4), 418-424.  
Bergis, N., Hermanns, N., & Kulzer, B. (2011). Erfassung von symptomatik und lebensqualität 
bei diabetischer neuropathie. [The assessment of symptomatology and quality of life in 
diabetic neuropathy.]. Verhaltenstherapie & Verhaltensmedizin, 32(4), 365-375.  
Bernal-Lopez, M. R., Santamaria-Fernandez, S., Lopez-Carmona, D., Tinahones, F. J., Mancera-
Romero, J., Pena-Jimenez, D., . . . Gomez-Huelgas, R. (2011). HbA(1c) in adults without 
known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical 
practice. Diabet Med, 28(11), 1319-1322. doi:10.1111/j.1464-5491.2011.03317.x 
Booth, J., & Young, M. J. (2000). Differences in the performance of commercially available 10-
g monofilaments. Diabetes Care, 23(7), 984-988. doi:10.2337/diacare.23.7.984 
Boulton, A. J. (2015). The diabetic foot. Medicine, 43(1), 33-37.  
Boulton, A. J., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., . . . Ziegler, D. 
(2005). Diabetic neuropathies: a statement by the American Diabetes Association. 
Diabetes Care, 28(4), 956-962.  
Bourcier, M. E., Ullal, J., Parson, H. K., Dublin, C. B., Witherspoon, C. A., Ward, S. A., & 
Vinik, A. I. (2006). Diabetic peripheral neuropathy: how reliable is a homemade 1-g 
monofilament for screening? A case-control study of sensitivity, specificity, and 






Boyd, A., Casselini, C., Vinik, E., & Vinik, A. (2011). Quality of life and objective measures of 
diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and 
topiramate. Journal Of Diabetes Science And Technology, 5(3), 714-722.  
Bredfeldt, C., Altschuler, A., Adams, A. S., Portz, J. D., & Bayliss, E. A. (2015). Patient reported 
outcomes for diabetic peripheral neuropathy. J Diabetes Complications. 
doi:10.1016/j.jdiacomp.2015.08.015 
Burgess, H. J., Revell, V. L., & Eastman, C. I. (2008). A three pulse phase response curve to 
three milligrams of melatonin in humans. J Physiol, 586(2), 639-647. 
doi:10.1113/jphysiol.2007.143180 
Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2010). Human phase response 
curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab, 
95(7), 3325-3331. doi:10.1210/jc.2009-2590 
Buysschaert, M., & Bergman, M. (2011). Definition of Prediabetes. Medical Clinics of North 
America, 95, 289-297. doi:10.1016/j.mcna.2010.11.002 
Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The 
Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. 
Psychiatry Res, 28(2), 193-213.  
Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Hoch, C. C., Yeager, A. L., & Kupfer, D. J. 
(1991). Quantification of subjective sleep quality in healthy elderly men and women 
using the Pittsburgh Sleep Quality Index (PSQI). Sleep, 14(4), 331-338.  
Cailotto, C., La Fleur, S. E., Van Heijningen, C., Wortel, J., Kalsbeek, A., Feenstra, M., . . . 





glucose via the autonomic output to the liver: are the clock genes involved? Eur J 
Neurosci, 22(10), 2531-2540. doi:10.1111/j.1460-9568.2005.04439.x 
Calvet, J., Dupin, J., Winiecki, H., & Schwarz, P. (2013). Assessment of small fiber neuropathy 
through a quick, simple and non invasive method in a German diabetes outpatient clinic. 
Exp Clin Endocrinol Diabetes, 121(2), 80-83.  
Casellini, C. M. (2007). A 6-month, randomized, double-masked, placebo-controlled study 
evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin 
microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes 
Care, 30, 896-902.  
Cavallo, A., Daniels, S. R., Dolan, L. M., Bean, J. A., & Khoury, J. C. (2004). Blood pressure-
lowering effect of melatonin in type 1 diabetes. J Pineal Res, 36(4), 262-266. 
doi:10.1111/j.1600-079X.2004.00126.x 
Center for Disease Control and Prevention. (2014). National Diabetes Statistics Report.  .  
Retrieved from http://www.cdc.gov/diabetes/library/reports/surveillance.html 
Chen, H. J., Wang, Y., Zhu, X. Q., Li, P. C., & Teng, G. J. (2014). Classification of Cirrhotic 
Patients with or without Minimal Hepatic Encephalopathy and Healthy Subjects Using 
Resting-State Attention-Related Network Analysis. Plos One, 9, e89684. 
doi:10.1371/journal.pone.0089684 
Claustrat, B., Brun, J., & Chazot, G. (2005). The basic physiology and pathophysiology of 
melatonin. Sleep medicine reviews, 9(1), 11-24. doi:10.1016/j.smrv.2004.08.001 
Coelho, T., Maia, L. F., da Silva, A. M., Cruz, M. W., Planté-Bordeneuve, V., Lozeron, P., . . . 
Schmidt, H. H.-J. (2012). Tafamidis for transthyretin familial amyloid polyneuropathy A 





Coelho, T., Maia, L. F., Da Silva, A. M., Cruz, M. W., Planté-Bordeneuve, V., Suhr, O. B., . . . 
Kelly, J. W. (2013). Long-term effects of tafamidis for the treatment of transthyretin 
familial amyloid polyneuropathy. Journal of neurology, 260(11), 2802-2814.  
Courcoulas, A. P. (2015). NO rush to judgment for bariatric surgery. JAMA Surgery. 
doi:10.1001/jamasurg.2015.2222 
Currie, C. J., Poole, C. D., Woehl, A., Morgan, C. L., Cawley, S., Rousculp, M. D., . . . Peters, J. 
R. (2006). The health-related utility and health-related quality of life of hospital-treated 
subjects with type 1 or type 2 diabetes with particular reference to differing severity of 
peripheral neuropathy. Diabetologia, 49(10), 2272-2280. doi:10.1007/s00125-006-0380-
7 
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006). The prevalence, severity, and impact 
of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care, 29(7), 1518-
1522.  
De Wandele, I., Rombaut, L., Leybaert, L., Van de Borne, P., De Backer, T., Malfait, F., . . . 
Calders, P. (2014). Dysautonomia and its underlying mechanisms in the hypermobility 
type of Ehlers–Danlos syndrome. Seminars in Arthritis and Rheumatism, 44, 93-100. 
doi:10.1016/j.semarthrit.2013.12.006 
Dimitropoulos, G., Tahrani, A. A., & Stevens, M. J. (2014). Cardiac autonomic neuropathy in 
patients with diabetes mellitus. World Journal Of Diabetes, 5(1), 17-39. 
doi:10.4239/wjd.v5.i1.17 
Divišová, Š., Bednařík, J., Vlčková, E., Hnojčíková, M., Němec, M., Dubový, P., . . . Jarkovský, 
J. (2012). Prediabetes/early diabetes-associated polyneuropathy is predominantly 





Divisova, S., Vlckova, E., Hnojcikova, M., Skorna, M., Nemec, M., Dubovy, P., . . . Bednarik, J. 
(2012). Prediabetes/early diabetes‐associated neuropathy predominantly involves sensory 
small fibres. Journal of the Peripheral Nervous System, 17(3), 341-350.  
Divisova, S., Vlckova, E., Hnojcikova, M., Skorna, M., Nemec, M., Dubovy, P., Dusek, L., 
Jarkovsky, J., Belobradkova, J., and Bednarik, J. (2012). Prediabetes/early diabetes-
associated neuropathy 
predominantly involves sensory small fibre. Journal of the Peripheral Nervous System, 17, 341-
350. doi:10.1111/j.1529-8027.2012.00420.x 
Dixit, S., & Maiya, A. (2014). Diabetic peripheral neuropathy and its evaluation in a clinical 
scenario: A review. Journal of Postgraduate Medicine, 60(1), 33. doi:10.4103/0022-
3859.128805 
Dros, J., Wewerinke, A., Bindels, P. J., & van Weert, H. C. (2009). Accuracy of Monofilament 
Testing to Diagnose Peripheral Neuropathy: A Systematic Review. Annals of Family 
Medicine, 7(6), 555-558. doi:10.1370/afm.1016 
Duby, J. J., Campbell, R. K., Setter, S. M., & Rasmussen, K. (2004). Diabetic neuropathy: an 
intensive review. American Journal of Health-System Pharmacy, 61(2), 160-173.  
Eikenberg, J. D., & Davy, B. M. (2013). Prediabetes: a prevalent and treatable, but often 
unrecognized, clinical condition. J Acad Nutr Diet, 113(2), 213-218. 
doi:10.1016/j.jand.2012.10.018 
Eranki, V. G., Santosh, R., Rajitha, K., Pillai, A., Sowmya, P., Dupin, J., & Calvet, J. H. (2013). 
Sudomotor function assessment as a screening tool for microvascular complications in 






Ewing, D. J., & Clarke, B. F. (1986). Diabetic autonomic neuropathy: present insights and future 
prospects. Diabetes Care, 9(6), 648-665.  
Farhan, S., Jarai, R., Tentzeris, I., Kautzky-Willer, A., Samaha, E., Smetana, P., . . . Huber, K. 
(2012). Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in 
patients with coronary artery disease. Clin Res Cardiol, 101(8), 625-630. 
doi:10.1007/s00392-012-0435-3 
Farrell, T. G., Bashir, Y., Cripps, T., Malik, M., Poloniecki, J., Bennett, E. D., . . . Camm, A. J. 
(1991). Risk stratification for arrhythmic events in postinfarction patients based on heart 
rate variability, ambulatory electrocardiographic variables and the signal-averaged 
electrocardiogram. J Am Coll Cardiol, 18(3), 687-697.  
Feng, Y., Schlosser, F. J., & Sumpio, B. E. (2009). The Semmes Weinstein monofilament 
examination as a screening tool for diabetic peripheral neuropathy. J Vasc Surg, 50(3), 
675-682, 682 e671. doi:10.1016/j.jvs.2009.05.017 
Ferrannini, E., Gastaldelli, A., & Iozzo, P. (2011). Pathophysiology of prediabetes. Med Clin 
North Am, 95(2), 327-339, vii-viii. doi:10.1016/j.mcna.2010.11.005 
Ferrell, J. M., & Chiang, J. Y. L. (2015). REVIEW: Circadian rhythms in liver metabolism and 
disease. Acta Pharmaceutica Sinica B, 5, 113-122. doi:10.1016/j.apsb.2015.01.003 
Freedman, B. I., Bowden, D. W., Smith, S. C., Xu, J., & Divers, J. (2014). Relationships between 
electrochemical skin conductance and kidney disease in Type 2 diabetes. J Diabetes 
Complications, 28, 56-60. doi:10.1016/j.jdiacomp.2013.09.006 
Goh, S. Y., & Cooper, M. E. (2008). Clinical review: The role of advanced glycation end 






Goldstein, D. S., Bentho, O., Park, M. Y., & Sharabi, Y. (2011). Low-frequency power of heart 
rate variability is not a measure of cardiac sympathetic tone but may be a measure of 
modulation of cardiac autonomic outflows by baroreflexes. Exp Physiol, 96(12), 1255-
1261. doi:10.1113/expphysiol.2010.056259 
Golomb, I., Ben David, M., Glass, A., Kolitz, T., & Keidar, A. (2015). LOng-term metabolic 
effects of laparoscopic sleeve gastrectomy. JAMA Surgery. 
doi:10.1001/jamasurg.2015.2202 
Goodarzi, M. O. (2014). Type 2 Diabetes Reference Module in Biomedical Sciences: Elsevier. 
Goyal, A., Chowdhury, R., Terry, P. D., Superak, H. M., Kutner, M. H., Nell-Dybdahl, C. L., & 
Phillips, L. S. (2014). Melatonin supplementation to treat the metabolic syndrome: a 
randomized controlled trial. Diabetology & metabolic syndrome, 6(1), 1-21. 
doi:10.1186/1758-5996-6-124 
Gregg, E., Sorlie, P., Paulose-Ram, R., Gu, Q., Eberhardt, M., Wolz, M., . . . Geiss, L. (2004). 
2000 national health and nutrition examination survey. Prevalence of lower-extremity 
disease in the US adult population 40 years of age with and without diabetes: 1999-2000 
national health and nutrition examination survey. Diabetes Care, 27(7), 1591-1597.  
Greico, C., Colberg, S., Somma, C., Thompson, A., & Vinik, A. (2013). Melatonin 
Supplementation Improves Glycemic Control While Lowering Oxidative Stress in Type 2 
Diabetes. International Journal of Diabetes Research, 2(3), 45-49. 
doi:10.5923/j.diabetes.20130203.02 
Grossman, E., Laudon, M., Yalcin, R., Zengil, H., Peleg, E., Sharabi, Y., . . . Zisapel, N. (2006). 
Melatonin Reduces Night Blood Pressure in Patients with Nocturnal Hypertension. Am J 





Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. 
(2013). Global estimates of diabetes prevalence for 2013 and projections for 2035. 
Diabetes Res Clin Pract, 103(2), 137-149. doi:10.1016/j.diabres.2013.11.002 
Gulichsen, E., Fleischer, J., Ejskjaer, N., Eldrup, E., & Tarnow, L. (2012). Screening for 
Diabetic Cardiac Autonomic Neuropathy Using a New Handheld Device. Journal Of 
Diabetes Science And Technology, 6(4), 965-972.  
Guo, J., Whittemore, R., Jeon, S., Grey, M., Zhou, Z.-G., He, G.-P., & Luo, Z.-Q. (2015). 
Diabetes self-management, depressive symptoms, metabolic control and satisfaction with 
quality of life over time in Chinese youth with type 1 diabetes. J Clin Nurs, 24(9/10), 
1258-1268 1211p. doi:10.1111/jocn.12698 
Hack, L. M., Lockley, S. W., Arendt, J., & Skene, D. J. (2003). The effects of low-dose 0.5-mg 
melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms, 18(5), 
420-429.  
Hage, F. G., Bansal, S., Chyun, D. A., Young, L. H., Inzucchi, S. E., & Iskandrian, A. E. (2013). 
The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in 
asymptomatic patients with type 2 diabetes. International Journal of Cardiology, 167(6), 
2952-2957.  
Hakkinen, A., Kukka, A., Onatsu, T., Jarvenpaa, S., Heinonen, A., Kyrolainen, H., . . . Kallinen, 
M. (2009). Health-related quality of life and physical activity in persons at high risk for 






Haloua, M. H., Sierevelt, I., & Theuvenet, W. J. (2011). Scientific article: Semmes-Weinstein 
Monofilaments: Influence of Temperature, Humidity, and Age. Journal of Hand Surgery, 
36, 1191-1196. doi:10.1016/j.jhsa.2011.04.009 
Happich, M., John, J., Stamenitis, S., Clouth, J., & Polnau, D. (2008). The quality of life and 
economic burden of neuropathy in diabetic patients in Germany in 2002--results from the 
Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract, 81(2), 
223-230. doi:10.1016/j.diabres.2008.03.019 
Hardeland, R., Cardinali, D. P., Brown, G. M., & Pandi-Perumal, S. R. (2015). Melatonin and 
brain inflammaging. Prog Neurobiol, 127-128, 46-63. 
doi:10.1016/j.pneurobio.2015.02.001 
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, 
S. R. (2011). Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol, 
93(3), 350-384. doi:10.1016/j.pneurobio.2010.12.004 
Hare, M. J., Shaw, J. E., & Zimmet, P. Z. (2012). Current controversies in the use of 
haemoglobin A1c. J Intern Med, 271(3), 227-236. doi:10.1111/j.1365-2796.2012.02513.x 
Härtter, S., Wang, X., Weigmann, H., Friedberg, T., Arand, M., Oesch, F., & Hiemke, C. (2001). 
Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation 
of Melatonin. Journal of Clinical Psychopharmacology, 21(2), 167-174.  
Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. 
Annals of medicine, 33(5), 350-357.  
Heathers, J. A. (2014). Everything Hertz: methodological issues in short-term frequency-domain 





Herman, W. H., & Kennedy, L. (2005). Underdiagnosis of peripheral neuropathy in type 2 
diabetes. Diabetes Care, 28(6), 1480-1481.  
Herrera-Rangel, A., Aranda-Moreno, C., Mantilla-Ochoa, T., Zainos-Saucedo, L., & Jáuregui-
Renaud, K. (2014). The influence of peripheral neuropathy, gender, and obesity on the 
postural stability of patients with type 2 diabetes mellitus. Journal of diabetes research, 
2014.  
Hogg, F., Peach, G., Price, P., Thompson, M., & Hinchliffe, R. (2012). Measures of health-
related quality of life in diabetes-related foot disease: a systematic review. Diabetologia, 
55(3), 552-565.  
Hussain, S. A., Khadim, H. M., Khalaf, B. H., Ismail, S. H., Hussein, K. I., & Sahib, A. S. 
(2006). Effects of melatonin and zinc on glycemic control in type 2 diabetic patients 
poorly controlled with metformin. Saudi Med J, 27(10), 1483-1488.  
International Diabetes Federation. (2014). IDF Diabetes Atlas 6th Edition.  Retrieved from 
http://www.idf.org/diabetesatlas/update-2014 
Jayaprakash, P., Bhansali, A., Bhansali, S., Dutta, P., Anantharaman, R., Shanmugasundar, G., & 
Ravikiran, M. (2011). Validation of bedside methods in evaluation of diabetic peripheral 
neuropathy. Indian Journal of Medical Research, 133(6), 645-649.  
Jeffcoate, W., Price, P. E., Phillips, C., Game, F., Mudge, E. J., Davies, S., . . . Johnson, A. 
(2009). Randomised controlled trial of the use of three dressing preparations in the 
management of chronic ulceration of the foot in diabetes. Health technology assessment, 





Ji, L., Zou, D., Liu, L., Qian, L., Kadziola, Z., Babineaux, S., . . . Wood, R. (2015). Increasing 
body mass index identifies Chinese patients with type 2 diabetes mellitus at risk of poor 
outcomes. J Diabetes Complications, 29(4), 488-496.  
Jung, K. H., Hong, S. W., Zheng, H. M., Lee, H. S., Lee, H., Lee, D. H., . . . Hong, S. S. (2010). 
Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear 
erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res, 48(3), 239-
250. doi:10.1111/j.1600-079X.2010.00748.x 
Kafa, N., Citaker, S., Tuna, Z., Guney, H., Kaya, D., Guzel, N. A., . . . Yetkin, I. (2015). Is 
plantar foot sensation associated with standing balance in type 2 diabetes mellitus 
patients. International Journal of Diabetes in Developing Countries, 35(3), 405-410.  
Karlsen, B., Oftedal, B., & Bru, E. (2012). The relationship between clinical indicators, coping 
styles, perceived support and diabetes-related distress among adults with type 2 diabetes. 
J Adv Nurs, 68(2), 391-401. doi:10.1111/j.1365-2648.2011.05751.x 
Kastenbauer, T., Sauseng, S., Brath, H., Abrahamian, H., & Irsigler, K. (2004). The value of the 
Rydel-Seiffer tuning fork as a predictor of diabetic polyneuropathy compared with a 
neurothesiometer. Diabetic Medicine, 21(6), 563-567. doi:10.1111/j.1464-
5491.2004.01205.x 
Katon, J. G., Reiber, G. E., & Nelson, K. M. (2013). Peripheral Neuropathy Defined by 
Monofilament Insensitivity and Diabetes Status: NHANES 1999–2004. Diabetes Care, 
36(6), 1604-1606. doi:10.2337/dc12-1102 
Kedziora-Kornatowska, K., Szewczyk-Golec, K., Kozakiewicz, M., Pawluk, H., Czuczejko, J., 





measured in the blood of elderly type 2 diabetic patients. J Pineal Res, 46(3), 333-337. 
doi:10.1111/j.1600-079X.2009.00666.x 
Kleiger, R. E., Miller, J. P., Bigger, J. T., & Moss, A. J. (1987). Decreased heart rate variability 
and its association with increased mortality after acute myocardial infarction. Am. J. 
Cardiol., 59, 256-262. doi:10.1016/0002-9149(87)90795-8 
Kolotkin, R. L., Crosby, R. D., & Williams, G. R. (2002). Health‐Related Quality of Life Varies 
among Obese Subgroups. Obesity Research, 10(8), 748-756.  
Kreier, F., Kalsbeek, A., Sauerwein, H. P., Fliers, E., Romijn, J. A., & Buijs, R. M. (2007). 
"Diabetes of the elderly" and type 2 diabetes in younger patients: possible role of the 
biological clock. Exp Gerontol, 42(1-2), 22-27. doi:10.1016/j.exger.2006.07.004 
La Rovere, M. T., Pinna, G. D., Maestri, R., & Sleight, P. (2012). Clinical value of baroreflex 
sensitivity. Neth Heart J. doi:10.1007/s12471-012-0349-8 
Laitinen, T., Lindstrom, J., Eriksson, J., Ilanne-Parikka, P., Aunola, S., Keinanen-Kiukaanniemi, 
S., . . . Uusitupa, M. (2011). Cardiovascular autonomic dysfunction is associated with 
central obesity in persons with impaired glucose tolerance. Diabet Med, 28(6), 699-704. 
doi:10.1111/j.1464-5491.2011.03278.x [doi] 
Lamparter, J., Raum, P., Pfeiffer, N., Peto, T., Höhn, R., Elflein, H., . . . Mirshahi, A. (2014). 
Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic 
subjects: The Gutenberg Health Study. J Diabetes Complications, 28(4), 482-487. 
doi:10.1016/j.jdiacomp.2014.02.008 
Lavery, L., & Gazewood, J. D. (2000). Assessing the feet of patients with diabetes. J Fam Pract, 





Lavery, L. A., Lavery, D. E., Lavery, D. C., Lafontaine, J., Bharara, M., & Najafi, B. (2012). 
Accuracy and durability of Semmes-Weinstein monofilaments: what is the useful service 
life? Diabetes Res Clin Pract, 97(3), 399-404. doi:10.1016/j.diabres.2012.04.006 
Lavery, L. A., Murdoch, D. P., Williams, J., & Lavery, D. C. (2008). Does anodyne light therapy 
improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized 
trial to evaluate monochromatic infrared photoenergy. Diabetes Care, 31(2), 316-321.  
Lee, J. A., Halpern, E. M., Lovblom, L. E., Yeung, E., Bril, V., & Perkins, B. A. (2014). 
Reliability and validity of a point-of-care sural nerve conduction device for identification 
of diabetic neuropathy. Plos One, 9(1), e86515-e86515. 
doi:10.1371/journal.pone.0086515 
Lee, S., Kim, H., Choi, S., Park, Y., Kim, Y., & Cho, B. (2003). Clinical usefulness of the two-
site Semmes-Weinstein monofilament test for detecting diabetic peripheral neuropathy. J 
Korean Med Sci, 18(1), 103.  
Lemoine, P., Wade, A. G., Katz, A., Nir, T., & Zisapel, N. (2012). Efficacy and safety of 
prolonged-release melatonin for insomnia in middle-aged and elderly patients with 
hypertension: a combined analysis of controlled clinical trials. Integr Blood Press 
Control, 5, 9-17. doi:10.2147/ibpc.s27240 
Lenters-Westra, E., & Slingerland, R. J. (2010). Six of eight hemoglobin A1c point-of-care 
instruments do not meet the general accepted analytical performance criteria. Clin Chem, 
56(1), 44-52. doi:10.1373/clinchem.2009.130641 
Lieb, D. C., Parson, H. K., Mamikunian, G., & Vinik, A. I. (2012). Cardiac autonomic imbalance 
in newly diagnosed and established diabetes is associated with markers of adipose tissue 





Lipsky, B. A., Berendt, A. R., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., . . . 
Tan, J. S. (2006). Diagnosis and treatment of diabetic foot infections. Plast Reconstr 
Surg, 117(7 Suppl), 212s-238s. doi:10.1097/01.prs.0000222737.09322.77 
Luscombe, F. A. (2000). Health‐Related Quality of Life Measurement in Type 2 Diabetes. Value 
in Health, 3(s1), 15-28.  
Mallien, J., Isenmann, S., Mrazek, A., Haensch, C.-A., Partonen, T., Hiroshi, K., & Romigi, A. 
(2014). Sleep disturbances and autonomic dysfunction in patients with postural 
orthostatic tachycardia syndrome. Frontiers in Neurology, 5, 1-6. 
doi:10.3389/fneur.2014.00118 
Mannarino, M., Tonelli, M., & Allan, G. M. (2013). Tools for practice: screening and diagnosis 
of type 2 diabetes with HbA1c. Can Fam Physician, 59(1), 42.  
Marcovecchio, M. L., Lucantoni, M., & Chiarelli, F. (2011). Role of chronic and acute 
hyperglycemia in the development of diabetes complications. Diabetes Technol Ther, 
13(3), 389-394. doi:10.1089/dia.2010.0146 
Marrero, D., Pan, Q., Barrett-Connor, E., Groot, M., Zhang, P., Percy, C., . . . Rubin, R. (2014). 
Impact of diagnosis of diabetes on health-related quality of life among high risk 
individuals: the Diabetes Prevention Program outcomes study. Quality of Life Research, 
23(1), 75-88. doi:10.1007/s11136-013-0436-3 
Maser, R. E., & Lenhard, M. J. (2005). Cardiovascular autonomic neuropathy due to diabetes 
mellitus: clinical manifestations, consequences, and treatment. J. Clin. Endocrinol. 





Maxwell, S. K., Barnett, C., Kokokyi, S., Leung, J. C., Yu, J. J., Bril, V., & Katzberg, H. D. 
(2013). Association of social support with quality of life in patients with polyneuropathy. 
Journal of the Peripheral Nervous System, 18(1), 37-43.  
Maxwell, S. K., Kokokyi, S., Breiner, A., Ebadi, H., Bril, V., & Katzberg, H. D. (2014). 
Characteristics of muscle cramps in patients with polyneuropathy. Neuromuscular 
Disorders, 24(8), 671-676. doi:10.1016/j.nmd.2014.04.008 
McKinlay, J., Piccolo, R., & Marceau, L. (2013). An additional cause of health care disparities: 
the variable clinical decisions of primary care doctors. J Eval Clin Pract, 19(4), 664-673. 
doi:10.1111/jep.12015 
Meijer, J. W., Smit, A. J., Lefrandt, J. D., van der Hoeven, J. H., Hoogenberg, K., & Links, T. P. 
(2005). Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! 
Diabetes Care, 28(9), 2201-2205.  
Meyer, C., Mühlsteff, J., Drexel, T., Eickholt, C., Kelm, M., Zahiragic, L., & Ziegler, D. (2015). 
POTS following traumatic stress: Interacting central and intracardiac neural control? J 
Diabetes Complications, 29(3), 459-461. doi:10.1016/j.jdiacomp.2015.02.003 
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008). Depression and type 2 diabetes 
over the lifespan a meta-analysis. Diabetes Care, 31(12), 2383-2390.  
Miscio, G., Guastamacchia, G., Brunani, A., Priano, L., Baudo, S., & Mauro, A. (2005). Obesity 
and peripheral neuropathy risk: a dangerous liaison. Journal of the Peripheral Nervous 
System, 10(4), 354-358. doi:10.1111/j.1085-9489.2005.00047.x 
Monnier, L., Hanefeld, M., Schnell, O., Colette, C., & Owens, D. (2013). Insulin and 






Murphy, P. J., Myers, B. L., & Badia, P. (1996). Nonsteroidal anti-inflammatory drugs alter 
body temperature and suppress melatonin in humans. Physiology & behavior, 59(1), 133-
139. doi:10.1016/0031-9384(95)02036-5 
Mustafa, E., Alemam, A., & Hamid, E. (2012). Subclinical peripheral neuropathy in 
prediabetics; Correlation with glycosylated hemoglobin and C-reactive protein.  
Nichols, G. A., Alexander, C. M., Girman, C. J., Kamal-Bahl, S. J., & Brown, J. B. (2006). 
Treatment escalation and rise in HbA1c following successful initial metformin therapy. 
Diabetes Care, 29(3), 504-509.  
Nishiyama, K., Yasue, H., Moriyama, Y., Tsunoda, R., Ogawa, H., Yoshimura, M., & 
Kugiyama, K. (2001). Acute effects of melatonin administration on cardiovascular 
autonomic regulation in healthy men. American Heart Journal, 141(5), 13A-17A.  
Nunes, D. M., Mota, R. M., Machado, M. O., Pereira, E. D., Bruin, V. M., & Bruin, P. F. (2008). 
Effect of melatonin administration on subjective sleep quality in chronic obstructive 
pulmonary disease. Braz J Med Biol Res, 41(10), 926-931.  
Okatani, Y., Wakatsuki, A., Reiter, R. J., & Miyahara, Y. (2002). Hepatic mitochondrial 
dysfunction in senescence-accelerated mice: correction by long-term, orally administered 
physiological levels of melatonin. J Pineal Res, 33(3), 127-133. doi:2o109 [pii] 
Page, K. A., Arora, J., Qiu, M., Relwani, R., Constable, R. T., & Sherwin, R. S. (2009). Small 
decrements in systemic glucose provoke increases in hypothalamic blood flow prior to 
the release of counterregulatory hormones. Diabetes, 58(2), 448-452. doi:10.2337/db08-
1224 
Pambianco, G., Costacou, T., Strotmeyer, E., & Orchard, T. J. (2011). The assessment of clinical 





from the Pittsburgh Epidemiology of Diabetes Complications Cohort. Diabetes Res Clin 
Pract, 92, 280-287. doi:10.1016/j.diabres.2011.02.005 
Papanas, N., Vinik, A. I., & Ziegler, D. (2011). Neuropathy in prediabetes: does the clock start 
ticking early? Nat Rev Endocrinol, 7(11), 682-690. doi:10.1038/nrendo.2011.113 
Papanas, N., & Ziegler, D. (2012). Prediabetic neuropathy: does it exist? Curr Diab Rep, 12(4), 
376-383. doi:10.1007/s11892-012-0278-3 
Paredes, S. D., Forman, K. A., Vara, E., Escames, G., & Tresguerres, J. A. (2014). Protective 
actions of melatonin and growth hormone on the aged cardiovascular system. Horm Mol 
Biol Clin Investig, 18(2), 79-88.  
Paskaloglu, K., Sener, G., & Ayangolu-Dulger, G. (2004). Melatonin treatment protects against 
diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. 
Eur J Pharmacol, 499(3), 345-354. doi:10.1016/j.ejphar.2004.08.002 
Perkins, B. A., Grewal, J., Ng, E., Ngo, M., & Bril, V. (2006). Validation of a novel point-of-
care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. 
Diabetes Care, 29(9), 2023-2027. doi:10.2337/dc08-0500 
Perkins, B. A., Olaleye, D., Zinman, B., & Bril, V. (2001). Simple screening tests for peripheral 
neuropathy in the diabetes clinic. Diabetes Care, 24(2), 250-256.  
Perkins, B. A., Orszag, A., Grewal, J., Ng, E., Ngo, M., & Bril, V. (2008). Multi-site testing with 
a point-of-care nerve conduction device can be used in an algorithm to diagnose diabetic 
sensorimotor polyneuropathy. Diabetes Care, 31(3), 522-524.  
Phillips, L. S., Ratner, R. E., Buse, J. B., & Kahn, S. E. (2014). We can change the natural 





Poanta, L., Cerghizan, A., & Pop, D. (2010). Blood pressure pattern and heart rate variability in 
normotensive patients with type 2 diabetes mellitus. Rom J Intern Med, 48(4), 321-327.  
Pop-Busui, R. (2010). Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes 
Care, 33, 434-441. doi:10.2337/dc09-1294 
Pourhamidi, K., Dahlin, L. B., Englund, E., & Rolandsson, O. (2014). Evaluation of clinical 
tools and their diagnostic use in distal symmetric polyneuropathy. Prim Care Diabetes, 
8(1), 77-84. doi:10.1016/j.pcd.2013.04.004 
 Prevention of Type 2 Diabetes: From Science to Therapy. (2012). D. LeRoith (Ed.)   
doi:10.1007/978-1-4614-3314-9 
Purewal, T. S., & Watkins, P. J. (1995). Postural hypotension in diabetic autonomic neuropathy: 
a review. Diabet Med, 12(3), 192-200.  
Radziuk, J., & Pye, S. (2006). Diurnal rhythm in endogenous glucose production is a major 
contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit 
cycle behaviour? Diabetologia, 49(7), 1619-1628. doi:10.1007/s00125-006-0273-9 
Rajabally, Y. A., & Cavanna, A. E. (2015). Health-related quality of life in chronic inflammatory 
neuropathies: A systematic review. J Neurol Sci, 348(1–2), 18-23. 
doi:10.1016/j.jns.2014.11.005 
Rapid Screening for Diabetic Neuropathy. (2013). Can J Diabetes, 37, S197-S212.  
Reiter, R. J. (1995). The role of the neurohormone melatonin as a buffer against macromolecular 
oxidative damage. Neurochem Int, 27(6), 453-460.  
Reiter, R. J., Guerrero, J. M., Escames, G., Pappolla, M. A., & AcuÑA-Castroviejo, D. (1997). 
Prophylactic Actions of Melatonin in Oxidative Neurotoxicity. Annals of the New York 





Reiter, R. J., Tan, D. X., Manchester, L. C., Pilar Terron, M., Flores, L. J., & Koppisepi, S. 
(2007). Medical implications of melatonin: receptor-mediated and receptor-independent 
actions. Adv Med Sci, 52, 11-28.  
Reutrakul, S., & Van Cauter, E. (2014). Interactions between sleep, circadian function, and 
glucose metabolism: implications for risk and severity of diabetes. Annals of the New 
York Academy of Sciences, 1311(1), 151-173. doi:10.1111/nyas.12355 
Robinson, C. C., Balbinot, L. F., Silva, M. F., Achaval, M., & Zaro, M. A. (2013). Plantar 
pressure distribution patterns of individuals with prediabetes in comparison with healthy 
individuals and individuals with diabetes. J Diabetes Sci Technol, 7(5), 1113-1121.  
Rodrigues, T. C., Ehrlich, J., Hunter, C. M., Kinney, G. L., Rewers, M., & Snell-Bergeon, J. K. 
(2010). Reduced heart rate variability predicts progression of coronary artery 
calcification in adults with type 1 diabetes and controls without diabetes. Diabetes 
Technol Ther, 12(12), 963-969.  
Rolim, L. C., de Souza, J. S. T., & Atala Dib, S. (2013). Tests for early diagnosis of 
cardiovascular autonomic neuropathy: critical analysis and relevance. Front Endocrinol 
(Lausanne), 4, 1-4. doi:10.3389/fendo.2013.00173 
Rota, E. (2005). Electrophysiological findings of peripheral neuropathy in newly diagnosed type 
II diabetes mellitus. J. Peripher. Nerv. Syst., 10, 348-353. doi:10.1111/j.1085-
9489.2005.00046.x 
Rota, E. (2007). Clinical and electrophysiological correlations in type 2 diabetes mellitus at 
diagnosis. Diabetes Res. Clin. Pract., 76, 152-154. doi:10.1016/j.diabres.2006.07.027 
Ruterbusch, J. A. (2014). Prediabetes: The Epidemic of the New Milennium. Nutritional 





Sadosky, A. A. M. B. N. A. S. M. (2008). A Review of the Epidemiology of Painful Diabetic 
Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied Neuropathic 
Pain Conditions. Pain Practice, 8(1), 45-56. doi:10.1111/j.1533-2500.2007.00164.x 
Sanchez-Mora, C., M, S. R.-O., Fernandez-Riejos, P., Mateo, J., Polo-Padillo, J., Goberna, R., & 
Sanchez-Margalet, V. (2011). Evaluation of two HbA1c point-of-care analyzers. Clin 
Chem Lab Med, 49(4), 653-657. doi:10.1515/CCLM.2011.101 
Scheer, F. A., Kalsbeek, A., & Buijs, R. M. (2003). Cardiovascular control by the 
suprachiasmatic nucleus: neural and neuroendocrine mechanisms in human and rat. Biol 
Chem, 384(5), 697-709. doi:10.1515/bc.2003.078 
Schwartz, A. V., Vittinghoff, E., Sellmeyer, D. E., Feingold, K. R., De Rekeneire, N., 
Strotmeyer, E. S., . . . Park, S. W. (2008). Diabetes-related complications, glycemic 
control, and falls in older adults. Diabetes Care, 31(3), 391-396.  
Selvin, E., Steffes, M. W., Gregg, E., Brancati, F. L., & Coresh, J. (2011). Performance of A1C 
for the classification and prediction of diabetes. Diabetes Care, 34(1), 84-89.  
Shah, B. M., Mezzio, D. J., Ho, J., & Ip, E. J. (2015). Association of ABC (HbA1c, blood 
pressure, LDL-cholesterol) goal attainment with depression and health-related quality of 
life among adults with type 2 diabetes. J Diabetes Complications, 29, 794-800. 
doi:10.1016/j.jdiacomp.2015.04.009 
Shah, K. M., & Mueller, M. J. (2012). Effect of selected exercises on in-shoe plantar pressures in 
people with diabetes and peripheral neuropathy. Foot (Edinb), 22(3), 130-134. 
doi:10.1016/j.foot.2012.05.001 
Sharma, S., Vas, P. R., & Rayman, G. (2015). Assessment of Diabetic Neuropathy Using a 





LDIFLARE Method and Clinical Neuropathy Scoring. Journal Of Diabetes Science And 
Technology, 9(1), 123-131.  
Shin, J. B., Seong, Y. J., Lee, H. J., Kim, S. H., & Park, J. R. (2000). Foot screening technique in 
a diabetic population. J Korean Med Sci, 15(1), 78-82. doi:10.3346/jkms.2000.15.1.78 
Sinclair, A., Dunning, T., & Rodriguez-Mañas, L. (2015). Diabetes in older people: new insights 
and remaining challenges. The Lancet Diabetes & Endocrinology, 3(4), 275-285. 
doi:10.1016/S2213-8587(14)70176-7 
Singh, N., Armstrong, D. G., & Lipsky, B. A. (2005). Preventing foot ulcers in patients with 
diabetes. JAMA, 293(2), 217-228. doi:10.1001/jama.293.2.217 
Siu, A. L. (2015). Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. 
Preventive Services Task Force Recommendation StatementScreening for Abnormal 
Blood Glucose and Type 2 Diabetes Mellitus. Annals of Internal Medicine, 163(11), 861-
868. doi:10.7326/M15-2345 
Smith, A. G., Gerardi, R., Lessard, M., Reyna, S. P., & Singleton, J. R. (2013). Sudoscan as a 
Diagnostic Tool for Peripheral Neuropathy. ESC, 10, 0.  
Smith, A. G., & Singleton, J. R. (2013). Obesity and hyperlipidemia are risk factors for early 
diabetic neuropathy. J Diabetes Complications, 27(5), 436-442. 
doi:10.1016/j.jdiacomp.2013.04.003 
Smith, G. A., Lessard, M., Reyna, S., Doudova, M., & Singleton, R. J. (2014). The diagnostic 
utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications. 
doi:10.1016/j.jdiacomp.2014.02.013 
Smith, G. A., & Singleton, R. J. (2006). Idiopathic neuropathy, prediabetes and the metabolic 





Smith, S., Lamping, D., & Maclaine, G. (2012). Measuring health-related quality of life in 
diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract, 96(3), 261-
270.  
Spadoni, G., Bedini, A., Rivara, S., & Mor, M. (2011). Melatonin Receptor Agonists: New 
Options for Insomnia and Depression Treatment. CNS Neuroscience & Therapeutics, 
17(6), 733-741. doi:10.1111/j.1755-5949.2010.00197.x 
Spallone, V. (2011). Cardiovascular autonomic neuropathy in diabetes: clinical impact, 
assessment, diagnosis, and management. Diabetes Metab. Res. Rev., 27, 639-653. 
doi:10.1002/dmrr.1239 
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop-Busui, R., . . . on behalf of 
The Toronto Consensus Panel on Diabetic, N. (2011). Cardiovascular autonomic 
neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. 
Diabetes/metabolism research and reviews, 27(7), 639-653. doi:10.1002/dmrr.1239 
Stuckey, M. I. (2013). Associations Between Heart Rate Variability and Metabolic Syndrome 
Risk Factors. The University of Western Ontario.    
Subbalakshmi, N., Adhikari, P., Poornima, V., & KN, S. R. (2015). Correlates of SDNN heart 
rate variability in healthy subjects and subjects with type 2 diabetes mellitus. 
International Journal of Biomedical and Advance Research, 6(3), 208-211.  
Subbalakshmi, N., Adhikari, P., Rao, K. S., & Jeganathan, P. (2012). Deterioration of cardiac 
autonomic function over a period of one year in relation to cardiovascular and somatic 






Sumpio, B. E., Forsythe, R. O., Ziegler, K. R., van Baal, J. G., Lepantalo, M. J. A., & Hinchliffe, 
R. J. (2013). Clinical implications of the angiosome model in peripheral vascular disease. 
J Vasc Surg, 58(3), 814-826. doi:10.1016/j.jvs.2013.06.056 
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012). Series: 
Prediabetes: a high-risk state for diabetes development. The Lancet, 379, 2279-2290. 
doi:10.1016/S0140-6736(12)60283-9 
Taksande, B., Ansari, S., Jaikishan, A., & Karwasara, V. (2011). The diagnostic sensitivity, 
specificity and reproducibility of the clinical physical examination signs in patients of 
diabetes mellitus for making diagnosis of peripheral neuropathy. Journal of 
Endocrinology and Metabolism, 1(1), 21-26.  
Tarvainen, M. P., Laitinen, T. P., Lipponen, J. A., Cornforth, D. J., & Jelinek, H. F. (2014). 
Cardiac autonomic dysfunction in type 2 diabetes - effect of hyperglycemia and disease 
duration. Front Endocrinol (Lausanne), 5, 130. doi:10.3389/fendo.2014.00130 
Tesfaye, S. (2010). Diabetic neuropathies: update on definitions, diagnostic criteria, estimation 
of severity, and treatments. Diabetes Care, 33, 2285-2293. doi:10.2337/dc10-1303 
Tesfaye, S. (2015). Neuropathy in diabetes. Medicine, 43(1), 26-32. 
doi:10.1016/j.mpmed.2014.10.013 
Tesfaye, S., Boulton, A. J., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., . . . Vinik, A. 
(2010). Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of 
severity, and treatments. Diabetes Care, 33(10), 2285-2293.  
Tesfaye, S., Boulton, A. J., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., . . . Toronto 





diagnostic criteria, estimation of severity, and treatments. Diabetes Care, 33(10), 2285-
2293. doi:10.2337/dc10-1303 
Tracey, E. H., Greene, A. J., & Doty, R. L. (2012). Optimizing reliability and sensitivity of 
Semmes-Weinstein monofilaments for establishing point tactile thresholds. Physiol 
Behav, 105(4), 982-986. doi:10.1016/j.physbeh.2011.11.002 
Tutuncu, N. B., Batur, M. K., Yildirir, A., Tutuncu, T., Deger, A., Koray, Z., . . . Erbas, T. 
(2005). Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic 
neuropathy. Journal of pineal research, 39(1), 43-49. doi:10.1111/j.1600-
079X.2005.00213.x 
Ul‐Haq, Z., Mackay, D. F., Fenwick, E., & Pell, J. P. (2013). Meta‐analysis of the association 
between body mass index and health‐related quality of life among adults, assessed by the 
SF‐36. Obesity, 21(3), E322-E327.  
Vazan, R., & Ravingerova, T. (2015). Protective effect of melatonin against myocardial injury 
induced by epinephrine. Journal of physiology and biochemistry, 71(1), 43-49.  
Veresiu, A. I., Bondor, C. I., Florea, B., Vinik, E. J., Vinik, A. I., & Gâvan, N. A. (2015). 
Detection of undisclosed neuropathy and assessment of its impact on quality of life: a 
survey in 25,000 Romanian patients with diabetes. J Diabetes Complications, 29, 644-
649. doi:10.1016/j.jdiacomp.2015.04.001 
Vickrey, B. G., Hays, R. D., & Beckstrand, M. (2000). Development of a health-related quality 






Vileikyte, L., Leventhal, H., Gonzales, J. S., Peyrot, M., Rubin, R. R., Ulbrecht, J. S., . . . 
Boulton, A. J. M. (2005). Diabetic peripheral neuropathy and depressive symptoms: the 
association revisited. Diabetes Care, 28(10), 2378-2383 2376p.  
Vileikyte, L., Peyrot, M., Bundy, C., Rubin, R. R., Leventhal, H., Mora, P., . . . Boulton, A. J. 
(2003). The development and validation of a neuropathy- and foot ulcer-specific quality 
of life instrument. Diabetes Care, 26(9), 2549-2555.  
Vileikyte, L., Peyrot, M., Gonzalez, J. S., Rubin, R., Ulbrecht, J., Leventhal, H., . . . Boulton, A. 
(2007). Longitudinal Validation of the Neuropathy and Foot Ulcer-Specific-Quality of 
Life Instrument (NeuroQoL). Diabetes, 56, A80-A80.  
Vinik, A., Maser, R., Mitchell, B., & Freeman, R. (2003). Diabetic autonomic neuropathy. 
Diabetes Care, 26, 1553 - 1579.  
Vinik, A., Mitchell, B., Leichter, S., Wagner, A., O’Brian, J., & Georges, L. (1995). 
Epidemiology of the complications of diabetes. Diabetes: clinical science in practice, 
221-287.  
Vinik, A., Ullal, J., Parson, H. K., & Casellini, C. M. (2006). Diabetic neuropathies: clinical 
manifestations and current treatment options. Nat Clin Pract Endocrinol Metab, 2(5), 
269-281. doi:10.1038/ncpendmet0142 
Vinik, A. I. (1999). Diabetic neuropathy: pathogenesis and therapy. Am J Med, 107(2), 17-26.  
Vinik, A. I. (2012). The conductor of the autonomic orchestra. Front Endocrinol (Lausanne), 3, 
71. doi:10.3389/fendo.2012.00071 [doi] 
Vinik, A. I., & Erbas, T. (2001). Recognizing and treating diabetic autonomic neuropathy. Cleve 





Vinik, A. I., & Erbas, T. (2006). Cardiovascular autonomic neuropathy: diagnosis and 
management. Curr Diab Rep, 6(6), 424-430.  
Vinik, A. I., Maser, R. E., & Ziegler, D. (2011). Autonomic imbalance: prophet of doom or 
scope for hope? Diabet Med, 28(6), 643-651. doi:10.1111/j.1464-5491.2010.03184.x 
[doi] 
Vinik, A. I., Nevoret, M.-L., Casellini, C., & Parson, H. (2013). Diabetic Neuropathy. 
Endocrinol Metab Clin North Am, 42(4), 747-787. doi:10.1016/j.ecl.2013.06.001 
Vinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, 
M. S. (2014). A randomized withdrawal, placebo-controlled study evaluating the efficacy 
and tolerability of tapentadol extended release in patients with chronic painful diabetic 
peripheral neuropathy. Diabetes Care, 37(8), 2302-2309. doi:10.2337/dc13-2291 
Vinik, A. I., Suwanwalaikorn, S., Stansberry, K. B., Holland, M. T., McNitt, P. M., & Colen, L. 
E. (1995). Quantitative measurement of cutaneous perception in diabetic neuropathy. 
Muscle Nerve, 18(6), 574-584. doi:10.1002/mus.880180603 
Vinik, A. I., Vinik, E. J., Colberg, S. R., & Morrison, S. (2015). Falls Risk in Older Adults with 
Type 2 Diabetes. Clinics in Geriatric Medicine, 31, 89-99. 
doi:10.1016/j.cger.2014.09.002 
Vinik, A. I., & Ziegler, D. (2007). Diabetic cardiovascular autonomic neuropathy. Circulation, 
115, 387-397. doi:10.1161/CIRCULATIONAHA.106.634949 
Vinik, E., Hayes, C., Oglesby, A., & Vinik, A. (2004). Identification of factors in the nerve fiber 
specific Norfolk Quality of Life (QOL-DN) inventory that reflect QOL and health status. 





Vinik, E., Silva, M., & Vinik, A. (2010). Relationship between quality of life and health-related 
measures including symptoms, biochemical markers and tumor burden. PANCREAS, 
39(2), 282. doi:doi: 10.1097/01.mpa.0000363950.68046.55 
Vinik, E. J., Hayes, R. P., Oglesby, A., Bastyr, E., Barlow, P., Ford-Molvik, S. L., & Vinik, A. I. 
(2005). The Development and Validation of the Norfolk QOL-DN, a New Measure of 
Patients' Perception of the Effects of Diabetes and Diabetic Neuropathy. Diabetes 
Technol Ther, 7(3), 497-508. doi:10.1089/dia.2005.7.497 
Vinik, E. J., Paulson, J. F., Ford-Molvik, S. L., & Vinik, A. I. (2008). German-translated Norfolk 
quality of life (QOL-DN) identifies the same factors as the English version of the tool 
and discriminates different levels of neuropathy severity. Journal Of Diabetes Science 
And Technology, 2(6), 1075-1086.  
Vinik, E. J., Stansberry, K. B., Ruck, S. M., & Vinik, A. I. (2003). DIABETES—Quality of 
Life/Preference Based Outcomes: PDB26: EVALUATION OF QUALITY OF LIFE IN 
PATIENTS WITH NEUROPATHY USING THE NORFOLK QUALITY OF LIFE 
(QOL) TOOL. Value in Health, 6, 336-337. doi:10.1016/S1098-3015(10)64191-5 
Vinik, E. J., Vinik, A. I., Paulson, J. F., Merkies, I. S., Packman, J., Grogan, D. R., & Coelho, T. 
(2014). Norfolk QOL‐DN: validation of a patient reported outcome measure in 
transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous 
System, 19(2), 104-114.  
Vriend, J., & Reiter, R. J. (2015). Melatonin feedback on clock genes: a theory involving the 
proteasome. J Pineal Res, 58(1), 1-11. doi:10.1111/jpi.12189 
Wade, A. G., Ford, I., Crawford, G., McMahon, A. D., Nir, T., Laudon, M., & Zisapel, N. 





quality of sleep and next-day alertness outcomes. Curr Med Res Opin, 23(10), 2597-
2605. doi:10.1185/030079907x233098 
Wong, C. K. H., Wong, W. C. W., Wan, E. Y. F., Wong, W. H. T., Chan, F. W. K., & Lam, C. 
L. K. (2015). Increased number of structured diabetes education attendance was not 
associated with the improvement in patient-reported health-related quality of life: results 
from Patient Empowerment Programme (PEP). Health & Quality of Life Outcomes, 
13(1), 1-8. doi:10.1186/s12955-015-0324-3 
World Health Organization. (2012). Use of glycated haemoglobin (HbA1C) in the diagnosis of 
diabetes mellitus:  Abbreviated report of a WHO consultation. Geneva:  World health 
Organization.  Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK304265/ 
Wykretowicz, A. (2005). Endothelial function and baroreflex sensitivity according to the oral 
glucose tolerance test in patients with coronary artery disease and normal fasting glucose 
levels. Clin Sci (Lond). 109, 397-403. doi:10.1042/CS20050095 
Xavier, A. T. d. F., Foss, M. C., Marques Junior, W., Santos, C. B. d., Onofre, P. T. B. N., & 
Pace, A. E. (2011). Cultural adaptation and validation of the Neuropathy-and Foot Ulcer-
Specific Quality of Life instrument (NeuroQol) for Brazilian Portuguese-Phase 1. Revista 
latino-americana de enfermagem, 19(6), 1352-1361.  
Yajnik, C. S., Kantikar, V. V., Pande, A. J., & Deslypere, J. P. (2012). Quick and Simple 
Evaluation of Sudomotor Function for Screening of Diabetic Neuropathy. ISRN 
Endocrinology, 1-7. doi:10.5402/2012/103714 
Ylitalo, K. R., Sowers, M., & Heeringa, S. (2011). Peripheral vascular disease and peripheral 





and Nutrition Examination Survey 2001-2004. Diabetes Care, 34(7), 1642-1647. 
doi:10.2337/dc10-2150 
Yu, L., Buysse, D. J., Germain, A., Moul, D. E., Stover, A., Dodds, N. E., . . . Pilkonis, P. A. 
(2011). Development of short forms from the PROMIS sleep disturbance and Sleep-
Related Impairment item banks. Behav Sleep Med, 10(1), 6-24. 
doi:10.1080/15402002.2012.636266 
Zgonis, T., Stapleton, J. J., Girard-Powell, V. A., & Hagino, R. T. (2008). Surgical management 
of diabetic foot infections and amputations. Aorn j, 87(5), 935-946; quiz 947-950.  
Zhou, J., & Zhou, S. (2014). Inflammation: therapeutic targets for diabetic neuropathy. 
Molecular neurobiology, 49(1), 536-546.  
Ziegler, D., Gries, F. A., Spuler, M., & Lessmann, F. (1992). The epidemiology of diabetic 
neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J 












A.  SCREENING QUESTIONNAIRE 
Screening Questionnaire 
Name:  ____________________________________ Date:  _____________________ 
Please answer the following questions as completely and honestly as possible. 
Current Age: __________________ Gender:  ___________________ 
Circle One 
Yes No Have you ever been told you have high blood sugar, prediabetes or diabetes? 
Yes No Do you have a first degree relative that has diabetes? 
Yes No  Have you been told that you have type I diabetes? 
Yes No Have you been told that you have type 2 diabetes? 
  If yes, how long have you had diabetes? _________ years/diagnosis date 
Yes No Have you been told you have hepatitis B or C? 
Yes No Have you been told you have HIV? 
Yes No Do you currently have a sore, ulcer, cut or other damage to either foot? 
Yes No Have you ever had any part of either lower extremity amputated? 
Yes No Do you have any numbness or pain in your feet? 
Yes No Do you have any type of foot deformity? 
Yes No Have you been diagnosed with peripheral vascular disease or nerve problems in   
 your lower extremities? 
Yes No Have you been diagnosed with kidney or liver problems, or are you on dialysis? 
Yes No Are you currently on any medications? (Please list at the bottom) 
Yes No Do you have any type of visual impairment? 
Yes No Do you smoke?  
If yes to any of the above, please explain:   
______________________________________________________________________ 
______________________________________________________________________ 
To be filled out by research staff:  Height:  _______________ Weight:  ____________ 
BMI: _____________Waist circumference:  _____________ Seated BP: ___________ 





B.  QOL-DN 
Quality of Life Questionnaire (QOL-DN) 
Diabetic Neuropathy Version 
 
Name:_______________________________ Date: __________ 
Subject #: _______________________________Visit: _________ 
Date of Birth:  ___________________________Gender: Male Female 
 
 
Do you have diabetes?  Yes   No 
 
  Do you have neuropathy (nerve damage)?  Yes   No 
 
Do you have any known medical condition that causes pain or weakness?  Yes   No 
        -- If yes, what condition:    
 
How long have you had any symptoms of neuropathy? _______Years  Months 
 
Are the symptoms the same on the right as on the left? .....  Yes   
 No…which is worse?   Left   Right 
      …only one side?  Left   Right 
 
Are the symptoms usually worse at night? ..........................  Yes   No 
 
How many medications or other treatments have you used for any of these symptoms (both in the past and 
presently)?  
 
Please write the number on the line. __________________________________________ 
 
Have you ever been told that you have neuropathy? ..........  Yes   No 
Have you ever had ulcer(s) on your feet?............................  Yes   No 
Have you ever had gangrene? ............................................  Yes   No 
Have you had any toes (or fingers) amputated?..................  Yes   No 
 
In the past 4 weeks, have you had a problem with involuntary urinating when laughing or coughing? 
 Yes   No  
 
(MALES ONLY) In the past 4 weeks, have you had a problem with obtaining or maintaining   erections? 
 Yes   No  
 
(FEMALES ONLY) In the past 4 weeks, have you had a problem with vaginal dryness during intercourse? 
 Yes   No 
  






  Native American includes American Indian, Eskimo, and Aleut 
Pacific Area Embraces Polynesian (including Hawaiian and Samoan), Micronesian (including 





Part I: Symptoms 
 





Feet Legs Hands Arms None 
1. Numbness................................................................ .......................................... ............. ………..... 
2. Tingling, Pins and Needles……..........…................ .......................................... ............. ………..... 
3. Electric Shocks ........................................................ .......................................... ............. ………..... 
4. Other Unusual Sensations....................................... .......................................... ............. ………..... 
5. Superficial Pain....................................................... .......................................... ............. ………..... 
6. Deep Pain ................................................................. .......................................... ............. ………..... 












10. In the past 4 weeks, have you burned or injured yourself and been unable to feel it? D D D D D 
11. In the past 4 weeks, have any symptoms kept you from doing your usual activities 
during the day? 
D D D D D 
12. In the past 4 weeks, have you had difficulty doing fine movements with your 
fingers, like buttoning your clothes, turning pages in a book, picking up coins 
from a table? 
D D D D D 
  13. In the past 4 weeks, have you felt unsteady on your feet when you walk? D D D D D 
14. In the past 4 weeks, have you had any problem getting out of a chair without 
pushing with your hands? 
D D D D D 
15. In the past 4 weeks, have you had a problem walking down stairs? D D D D D 
16. In the past 4 weeks, have you been unable to feel your feet when walking? D D D D D 
17. In the past 4 weeks, have you been unable to tell hot from cold water with your hands? D D D D D 
18. In the past 4 weeks, have you been unable to tell hot from cold water with your feet? D D D D D 
19. In the past 4 weeks, have you had a problem with vomiting, particularly after meals 
(but not due to flu or other illness)? 
D D D D D 
20. In the past 4 weeks, have you had a problem with diarrhea and/or loss of bowel 
control? 
D D D D D 
21. In the past 4 weeks, have you had a problem with fainting or dizziness when you 
stand? 
D D D D D 
In the past 4 weeks, how much difficulty have you had performing the following activities: 
 
22. Bathing/Showering?……………………………………………………..…...  D D D D D 
23. Dressing? …………………………………………………………….…...  D D D D D 
24. Walking? …………………………………………………………...…….  D D D D D 
25. Getting on or off the toilet? …………………………………………..…..  D D D D D 


























































Answer these questions according to the following scale:   0 1 2 3 4 
8. In the past 4 weeks, has pain kept you awake or woken you at night?      









































Answer these questions according to the following scale: 0 1 2 3 4 
In the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical or emotional 
health? 
     
27. Cut down on the amount of time you spent on work or other activities?……… D D D D D 
28. Accomplished less than you would like?………………………………………. D D D D D 
29. Were limited in the kind of work or other activities you could perform?…….... D D D D D 
30. Had difficulty performing the work/other activities (it took extra effort)?…….. D D D D D 
 
 
31. In general, would you say your health now is: 
 
Excellent Very Good Good Fair Poor 
D D D D D 
 
32. Compared with 3 months ago, how would you rate your health in general now? 
 
Much Somewhat About Somewhat Much 
Better Better the Same Worse Worse 




































Answer these questions according to the following scale: 0 1 2 3 4 
33. In the past 4 weeks, to what extent has your physical health interfered with your normal 
social activities with family, friends, neighbors, or groups? 
D D D D D 
34. In the past 4 weeks, how much did pain interfere with your normal work (including 
work both outside the home and housework)? 
D D D D D 
35. In the past 4 weeks, how much did weakness or shakiness interfere with your normal 
work (including work both outside the home and housework)? 







Manual and Scoring Algorithm for QOL-DN  
1) Description:  
 
The QOL-DN is a self-administered questionnaire, designed to capture and quantify the impact 
of diabetic neuropathy on the quality of life of individual patients with diabetic neuropathy. 
Fourteen of the items are of a health-related, biographical nature and are not scored. These are on 
the front page, and they are not numbered nor scored. The remaining 35 scored questions are 
numbered items that comprise the entire scale, and they are arranged thematically so that the 
wording of the questions and the type of response is grouped together. However, the content and 
topic of each individual question concerns particular functions or symptoms that are related to 
the following themes:  
Total Quality of Life Score  
Physical Functioning/Large Fiber Neuropathy  
Activities of Daily Living (ADLs)  
Symptoms  
Small Fiber Neuropathy  
Autonomic Neuropathy  
 
These scales and the administration of the questionnaire are described in detail below. In general, 
items 1-7 (Part I) are a simple inventory of symptoms of neuropathy. The presence of the 
symptom is checked in whichever box applies, and an absence of a symptom is checked under 
“none.” Positive responses are scored as 1; and negative responses, as 0. Items 8-35 (Part II) 
pertain to Activities of Daily Life, and most of these are scaled on a 5-point Likert scale ranging 
from 0 (“Not a problem”) to 4 (“Severe problem”). However, Questions 31 and 32 are scored 
differently. In Question 31, “Good”, the middle item, is scored as O. “Very Good” is scored as –
1, Excellent” is scored as –2. “Fair is scored as 1, and “Poor” is scored as 2. In Question 32, 
“About the Same”, the middle item, is scored as 0. "Somewhat better" is scored as –1, "Much 
better" is scored as -2. "Somewhat worse" is scored as 1, and "Much worse" is scored as 2.  
A final important point of the overall instrument is that the patient/subject is instructed to rate 
most items over the last 4 weeks, so responses should be interpreted as cumulative over that 
time period - not merely an inventory of the patient’s status at the moment of filling out the 
questionnaire.  
 
2) Administering the questionnaire:  
 
Administering the questionnaire to the patient or experimental subject is very straightforward: 
the patient simply fills out the paper form. It is important that the patient is in a quiet area, free of 
undue distractions, and patients are encouraged to answer the questions themselves (i.e. spouses 
and significant others should not fill out the questionnaire or influence the patient’s responses). 
These are subjective patient responses. The responses are coded and scored when they are 
entered into the appropriate database, and the algorithm is supplied below. All questions should 
be answered. The gender-specific sexual functions questions located on the biographical page 
should obviously be answered according to gender. It is not recommended to compare responses 
on this questionnaire directly to the patient’s medical history or any other sources of similar 






3) Data Accumulation:  
 
De-identified data are accumulated in database format (e.g. MS Excel 2000) and entered by a 
HIPAA certified research assistant. The original hard copies of the responses are retained as 
source documents in the patient/subject’s medical record. The database is secured by password 
access to authorized users only. The structure is that of a single table containing all fields for a 
single questionnaire.  
4) Sub-scales and Scoring Algorithm:  
 
The scales listed above were determined based on an exploratory factor analysis, so the questions 
have loaded into their respective domains. All symptoms (1-7) are scored as either a 1 or a 0, 
indicating a presence or absence of the symptom. With the exception of Questions 31, and 32, 
the other items are scored according to the 5-point Likert Scale (0-4, “No Problem” to “Severe 
Problem”). In Question 31, “Good”, the middle item, is scored as O. “Very Good” is scored as –
1, Excellent” is scored as –2. “Fair is scored as 1, and “Poor” is scored as 2. In Question 32, 
“About the Same”, the middle item, is scored as 0. "Somewhat better" is scored as –1, "Much 
better" is scored as -2. "Somewhat worse" is scored as 1, and "Much worse" is scored as 2.  
The Total QOL and five domains should be summed as follows:  
Total QOL Σ(1-7, 8-35)  
Physical Functioning/Large Fiber Σ(8, 11, 13-15, 24, 27-35 )  
Activities of Daily Living (ADLs) Σ(12, 22, 23, 25, 26)  
Symptoms Σ(1-7, 9)  
Small Fiber Σ(10, 16, 17, 18)  
Autonomic Σ(19, 20, 21)  
 
These scales and subscales are calculated without weighting of any kind, and reported as the 
































































































PERIPHERAL NEUROPATHY QOL-97 SCORING FORM 
 
Response (raw score) 
Scale/Item Numbers  1 2 3 4 5 6 Subtotal Final Score 
0-100 point scale 
 
Physical Health Dimensions 
Physical Functioning-11 
3a   0 50 100 - - - ____ 
3b   0 50 100 - - - ____ 
3c   0 50 100 - - - ____ 
3d   0 50 100 - - - ____ 
3e   0 50 100 - - - ____ 
3f   0 50 100 - - - ____ 
3g   0 50 100 - - - ____ 
3h   0 50 100 - - - ____ 
3i   0 50 100 - - - ____ 
3j   0 50 100 - - - ____ 
14c   100 75 50 25 0 - ____  
     Total ____  11 = ____ 
 
Role Limitations Due to Physical Health-6 
4a   0 25 50 75 100 - ____ 
4b   0 25 50 75 100 - ____ 
4c   0 25 50 75 100 - ____ 
4d   0 25 50 75 100 - ____ 
18b 1   100 75 50 25 0 - ____ 
14e    100 75 50 25 0 - ____  
     Total ____  6 = ____ 
 
Disease-Targeted Pain 
7   100 80 60 40 20 0 ____ 
8   100 75 50 25 0 - ____ 
16   100 80 60 40 20 0 ____ 
17    100 80 60 40 20 0 ____ 
24a    100 75 50 25 0 - ____ 
24b    100 75 50 25 0 - ____ 
24g    100 75 50 25 0 - ____  




                                                 





SCORING ALGORITHM (cont.)  
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM 
 
Response (raw score) 
Scale/Item Numbers  1 2 3 4 5 6 Subtotal Final Score 
0-100 point scale 
 
Energy/Fatigue-5 
9a   100 75 50 25 0 - ____ 
9e   100 75 50 25 0 - ____ 
9g  0 25 50 75 100 - ____ 
9i  0 25 50 75 100 - ____ 
18d    100 75 50 25 0 - ____ 
     Total ____  5 = ____ 
 
Upper Extremities 
14a    100 75 50 25 0 - ____ 
14b    100 75 50 25 0 - ____ 
14d    100 75 50 25 0 - ____ 
14g    100 75 50 25 0 - ____ 
24c    100 75 50 25 0 - ____ 
24f    100 75 50 25 0 - ____ 
     Total ____  6 = ____ 
 
Balance 
15   100 75 50 25 0 - ____ 
18e    100 75 50 25 0 - ____ 
18f    100 75 50 25 0 - ____ 
18g    100 75 50 25 0 - ____ 
18h    100 75 50 25 0 - ____ 
22e    100 75 50 25 0 - ____ 
24d    100 75 50 25 0 - ____ 
24e    100 75 50 25 0 - ____ 
     Total ____  8 = ____ 
 
Mental Health Dimensions 
Self Esteem 
22a    0 25 50 75 100 - ____ 
31a    100 75 50 25 0 - ____ 
31b    0 25 50 75 100 - ____ 
31c    100 75 50 25 0 - ____ 
31d    0 25 50 75 100 - ____ 
31e    0 25 50 75 100 - ____ 







SCORING ALGORITHM (cont.)  
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM 
 
Response (raw score) 
Scale/Item Numbers  1 2 3 4 5 6 Subtotal  Final Score 
0-100 point scale 
 
Emotional Well Being-7 
9b   0 25 50 75 100 - ____ 
9c   0 25 50 75 100 - ____ 
9d   100 75 50 25 0 - ____ 
9f   0 25 50 75 100 - ____ 
9h   100 75 50 25 0 - ____ 
9j    0 25 50 75 100 - ____ 
9k    100 75 50 25 0 - ____ 
Total ____  7 = ____ 
 
Stigma 
23a    0 25 50 75 100 - ____ 
23b    0 25 50 75 100 - ____ 
23c    0 25 50 75 100 - ____ 
     Total ____  3 = ____ 
  
Cognitive Function 
13d    0 25 50 75 100 - ____ 
13e    0 25 50 75 100 - ____ 
13f    0 25 50 75 100 - ____ 
     Total ____  3 = ____ 
 
Role Limitations Due to Emotional Problems  
5a   0 25 50 75 100 - ____ 
5b   0 25 50 75 100 - ____ 
5c   0 25 50 75 100 - ____ 
     Total ____  3 = ____ 
General Health Dimensions 
General Health Perceptions-7  
1   100 75 50 25 0 - ____ 
11a   0 25 50 75 100 - ____ 
11b   100 75 50 25 0 - ____ 
11c   0 25 50 75 100 - ____ 
11d   100 75 50 25 0 - ____ 
11e   0 25 50 75 100 - ____ 
11f   0 25 50 75 100 - ____ 







SCORING ALGORITHM (cont.)  
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM 
 
Response (raw score) 
Scale/Item Numbers  1 2 3 4 5 6 Subtotal  Final Score 
0-100 point scale 
 
Sleep  
18a    100 75 50 25 0 - ____ 
29a    100 75 50 25 0 - ____ 
29b    0 25 50 75 100  - ____ 
29c    0 25 50 75 100 - ____ 
29d    0 25 50 75 100 - ____ 
     Total ____  5 = ____ 
 
Disease-Targeted Social Functioning 
6   100 75 50 25 0 - ____ 
10   0 25 50 75 100 - ____ 
14f    100 75 50 25 0 - ____ 
18c    100 75 50 25 0 - ____ 
19    100 75 50 25 0 - ____ 
22b    100 75 50 25 0 - ____ 
22c    0 25 50 75 100 - ____ 
22d    0 25 50 75 100 - ____ 
22f    0 25 50 75 100 - ____ 
     Total ____  9 = ____ 
 
Sexual Function2 
25    100 66.7 33.3 0 - - ____ 
26    100 75 50 25 0 - ____ 
     Total ____  2 = ____ 
 
Health Distress 
13a    0 25 50 75 100 - ____ 
13b    0 25 50 75 100 - ____ 
13c    0 25 50 75 100 - ____ 
     Total ____  3 = ____ 
 
                                                 






SCORING ALGORITHM (cont.)  
PERIPHERAL NEUROPATHY QOL-97 SCORING FORM 
 
Response (raw score) 
Scale/Item Numbers  1 2 3 4 5 6         Subtotal Final Score3 




21   100 75 50 25 0 - _____ = ____ 
 





 2   100 75 50 25 0 - _____   = ____ 
  
Overall Health Rating 
 30   (no recoding necessary) 
 
Satisfaction with Sexual Functioning4 
 27   100 75 50 25 0 - _____   = ____ 
 
Sexual Activity5 
 28   (recoding not relevant)   
                                                 
3 Note: The total number of items in each scale is listed as the divisor for each subtotal.  
However, where all items in a scale are not answered, the divisor will be lower. 
4 Recode question 27 to missing if the response to question 28 is “no”. 
5 Item 28 on sexual activity is not counted as a quality-of-life item, but it is used for the scoring 






Physical Health Summary Score:  
 
 (((Pain Scale - 65.48214286) / 21.91750078) * 0.19922 )       =  ___________________ 
 
(((Physical Functioning - 72.96401515) / 25.74274538) * 0.20156 )    =  ___________________ 
 
(((Balance - 79.18080357) / 19.11524675) * 0.19139 )      =  ___________________ 
 
(((Social Functioning - 80.53993056) / 19.63613561) * 0.12088 )     =  ___________________ 
 
(((Role limitations—Physical Health - 65.84375000) / 33.29916333) * 0.11810 )   =  ___________________ 
 
(((Energy/fatigue - 56.80000000) / 23.41394154) * 0.12125 )     =  ___________________ 
 
(((Sleep Scale -71.14375000) / 18.40712984) * 0.12537 )    =  ___________________ 
 
(((Upper Extremities -91.89583333) / 11.21486152) * 0.12555 )     =  ___________________ 
 
(((General Health Perceptions - 58.61904762) / 20.30108094) * 0.086309 )    =  ___________________ 
 
(((Emotional Well Being - 71.40714286) / 17.15597900) *-0.08927 )    =  ___________________ 
 
(((Cognitive Functioning - 76.75000000) / 20.07002509) *-0.03316 )    =  ___________________ 
 
(((Self-esteem -79.91666667) / 16.93850049) *-0.05138 )     =  ___________________ 
 
(((Health Distress - 68.25000000) / 25.46321911) * 0.02889 )     =  ___________________ 
 
(((Role limitations—Emotional - 66.66666667) / 38.61162968) * 0.02849 )    =  ___________________ 
 
(((Stigma - 93.54166667) / 14.76342984) *-0.00849 )      =  ___________________ 
 
(((Sexual Function - 68.67094937) / 34.22217052) * 0.043288 )     =  ___________________ 
 
Subtotal =  ___________________ 
 
 





Mental Health Summary Score: 
 
(((Pain Scale - 65.48214286) / 21.91750078) * -0.05253 )     =  ___________________ 
 
(((Physical Functioning  - 72.96401515) / 25.74274538) * -0.07308 )    =  ___________________ 
 
(((Balance - 79.18080357) / 19.11524675) * -0.07198 )     =  ___________________ 
 
(((Social Functioning  - 80.53993056) / 19.63613561) * 0.06578 )    =  ___________________ 
 
(((Energy/fatigue - 56.80000000) / 23.41394154) * 0.05238 )     =  ___________________ 
 
(((Role limitations—Physical Health - 65.84375000) / 33.29916333) * 0.06440 )   =  ___________________ 
  
(((Sleep Scale - 71.14375000) / 18.40712984) * -0.01279 )     =  ___________________ 
 
(((Upper Extremities - 91.89583333) / 11.21486152) * -0.03518 )    =  ___________________ 
 
(((General Health Perceptions - 58.61904762) / 20.30108094) * 0.094966 )   =  ___________________ 
 
(((Emotional Well Being - 71.40714286) / 17.15597900) * 0.29507 )    =  ___________________ 
 
(((Self-esteem - 79.91666667) / 16.93850049) * 0.21516 )     =  ___________________ 
 
(((Cognitive Functioning - 76.75000000) / 20.07002509) * 0.20817 )    =  ___________________ 
 
(((Role limitations—Emotional - 66.66666667) / 38.61162968) * 0.15108 )    =  ___________________ 
 
(((Health Distress - 68.25000000) / 25.46321911) * 0.15045 )     =  ___________________ 
 
(((Stigma - 93.54166667) / 14.76342984) * 0.13053 )      =  ___________________ 
 
(((Sexual Function - 68.67094937) / 34.22217052) * 0.076409 )    =  ___________________ 
 
Subtotal = ___________________ 
 









(((DTPAIN-65.48214286)/21.91750078) * 0.19922 ) + 
(((PHYFUN-72.96401515)/25.74274538) * 0.20156 ) + 
(((BALANC-79.18080357)/19.11524675) * 0.19139 ) + 
(((DTSFUN-80.53993056)/19.63613561) * 0.12088 ) + 
(((PHROLE-65.84375000)/33.29916333) * 0.11810 ) + 
(((ENERGY-56.80000000)/23.41394154) * 0.12125 ) + 
(((SLEEP5-71.14375000)/18.40712984) * 0.12537 ) + 
(((UPPERE-91.89583333)/11.21486152) * 0.12555 ) + 
(((PERCEP-58.61904762)/20.30108094) * 0.086309) + 
(((EMOTWB-71.40714286)/17.15597900) *-0.08927 ) + 
(((COGFUN-76.75000000)/20.07002509) *-0.03316 ) + 
(((SELFES-79.91666667)/16.93850049) *-0.05138 ) + 
(((HDISTR-68.25000000)/25.46321911) * 0.02889 ) + 
(((EMROLE-66.66666667)/38.61162968) * 0.02849 ) + 
(((STIGMA-93.54166667)/14.76342984) *-0.00849 ) + 
(((SEX2  -68.67094937)/34.22217052) * 0.043288 ); 
 
mental1= 
(((DTPAIN-65.48214286)/21.91750078) *-0.05253 ) + 
(((PHYFUN-72.96401515)/25.74274538) *-0.07308 ) + 
(((BALANC-79.18080357)/19.11524675) *-0.07198 ) + 
(((DTSFUN-80.53993056)/19.63613561) * 0.06578 ) + 
(((ENERGY-56.80000000)/23.41394154) * 0.05238 ) + 
(((PHROLE-65.84375000)/33.29916333) * 0.06440 ) + 
(((SLEEP5-71.14375000)/18.40712984) *-0.01279 ) + 
(((UPPERE-91.89583333)/11.21486152) *-0.03518 ) + 
(((PERCEP-58.61904762)/20.30108094) * 0.094966) + 
(((EMOTWB-71.40714286)/17.15597900) * 0.29507 ) + 
(((SELFES-79.91666667)/16.93850049) * 0.21516 ) + 
(((COGFUN-76.75000000)/20.07002509) * 0.20817 ) + 
(((EMROLE-66.66666667)/38.61162968) * 0.15108 ) + 
(((HDISTR-68.25000000)/25.46321911) * 0.15045 ) + 
(((STIGMA-93.54166667)/14.76342984) * 0.13053 ) + 
(((SEX2  -68.67094937)/34.22217052) * 0.076409 ); 
 







D.  NEUROQOL-28 
NEUROPATHY-SPECIFIC 








 These questions ask about the effect your FOOT PROBLEMS may 
have on your daily life and well-being. By foot problems we mean 
lost or reduced feeling in your extremities, pain, discomfort and/or 
ulcers (open sores) on your feet and, in some cases unsteadiness 
while walking or standing. 
 Please note that many questions have two parts. Answer every 
question by ticking one box for each part (tick two boxes per line). 
Please make sure you answer all questions. 
 Please concentrate on how you have felt IN THE PAST 4 WEEKS 
for all of the questions. 
 There are no right or wrong answers. If you are unsure about how to 
answer a question, you can ask the person who gave you the 
questionnaire. Please DO NOT ask a relative or friend to help you. 





In the past 4 weeks 















How much bother did 






1. Burning in your legs 
or feet 
        
2. Excessive heat or 
cold in your legs or 
feet 
        
3. Pins and needles in 
your legs or feet 
        
4. Shooting or stabbing 
pain in your legs or 
feet 
        
5. Throbbing in your 
legs or feet 
        
6. Sensations in your 
legs or feet that 
make them jump 
        
7. Irritation of the skin 
caused by something 
touching your feet, 
such as bedsheets or 
socks 
        
A. Have these painful symptoms 








Not at all 
     
In the past 4 weeks 















How much bother did 






8. Numbness in your 
feet 





9. Inability to feel the 
difference between 
hot and cold with 
your feet 
        
10. Inability to feel 
objects with your 
feet 
        
B. Have these last three symptoms 
reduced your quality of life? 
Very 
much 
Quite a lot Somewhat 
A 
little 
Not at all 
     
In the past 4 


















How much bother did 






11. Weakness in 
your hands 
        




        




        
C. Have these last three 
symptoms reduced your 
quality of life? 
Very 
much  
Quite a lot  Somewhat  A little  Not at all  





The following questions ask about how your FOOT PROBLEMS affect 
your daily activities, relationships and feelings. 
 Are you in PAID WORK? Yes No 
If YES please go to Question 14. 
If NO please go to Question 15. 
In the past 4 
weeks, HOW 










A little Not at all 
How important is this 







14. Ability to 
perform your 
paid work? 
        
15. Ability to 
perform tasks 
around the house 
or garden? 
        
16.  Ability to take 
part in leisure 
activities? 
        
D. Have these changes in daily 
activities as a result of your 
foot problems reduced your 




Quite a lot  Somewhat  A little  Not at all  
     
In the past 4 weeks: 
How important is this 















17. How much 






close to you? 





18.Have you felt 
more physically 
dependent than 
you would like 
to be on people 
close to you as a 
result of your 
foot problems? 
        




you would like 
to be on people 
close to you as a 
result of your 
foot problems? 
        
20. has your role in 
the family 
changed as a 
result of your 
foot problems? 
        
E. Have these changes in 
relationships with other 
people as a result of your  
foot problems reduced your 
quality of life? 
Very 
much  
Quite a lot  Somewhat  A little  Not at all  
     
 
How much bother did 
this cause you? 
How much do 



















21. People treat me 
differently 
from other 
people as a 
result of my 
foot problems. 





22. I feel older 
than my years 
as a result of 
my foot 
problems. 
        
23. My self - 
confidence is 
affected as a 
result of my 
foot problems. 
        
24. My foot 
problems make 
my life a 
struggle. 
        
25. I generally feel 
frustrated 
because of my 
foot problems. 
        





        
27. I feel depressed 
because of my 
foot problems 
        
F. Have these 
feelings about 
yourself as a 
result of your 
foot problems 
reduced your 
quality of life? 
Very 
much  
Quite a lot  
Some
what  
A little  Not at all  








Quite a lot 
Some
what 
A little Not at all 
28. Overall, I 






     
 Excellent Very good Good Fair Poor 
29. Overall, I 
would rate my 
quality of life 
as: 





Assessment of Neuropathy- Specific Quality of Life (NeuroQoL) 
 
 The 35 item Neuropathy- Specific Quality of Life instrument (NeuroQoL) is an 
hierarchically organized scale (Fries and Singh, 1996; Spilker and Revicki, 1996) that assesses 
patients subjective reports (Gill and Feinstein, 1994) of functioning and quality of life in six 
specific domains.  Following the hierarchical model, the base of each domain is assessed with 
items that measure specific somatic experiences, social and personal dysfunctions and emotional 
states, and end with an overall assessment of quality of life or satisfaction with experiences in 
that domain.   
Thirteen items assess specific somatic experiences in three domains: i.e., Pain (items 1-
7), Lost/reduced feeling (items 8-10); and Diffuse sensory-motor symptoms (items 11-13).  
Specific functional, social and emotional experiences are assessed in three domains with an 
additional 14 items: Restrictions in activities of daily living (items 14–16), and Disruptions in 
social relationships (items 17-20), and Emotional distress (items 21- 27).  The frequency of these 
experiences, somatic, social and affective, are reported on 5 point scales (never, to all of the 
time).  A participant's score for a domain is the mean of the items in that scale with higher scores 
representing more severe symptoms or greater disruption in functioning. 
For each of these 27, specific items, patients are asked to judge the degree to which the 
somatic experience, restriction of activities, social function and emotional states have been a 
bother and/or important to them (O’Boyle, McGee and Joyce,1994).  The bother /importance 
items were scored as 1=none; 2= some; 3= very. Weighted scores were calculated by multiplying 
the scale score by the corresponding bother/importance score. Multiplying the frequency of 
experience by its bother and importance provides a more detailed picture of the degree to which 
the specific experience impacts satisfaction or quality of life.   
 In accord with the hierarchical model (Fries and Singh, 1996; Spilker and Revicki, 1996) 
and the accepted definition of quality of life as an overall judgment of satisfaction (Spilker B (ed) 
(1996). Quality of life and pharmacoeconomics in clinical trials; Leventhal H & Colman S. 
Quality of life: a process view. Psychol Health 12:753-767), a single item assesses quality of life 
in each of the six domains (items A, B, C, D, E & F).  
The two final items in the scale complete the hierarchical approach by assessing overall 
satisfaction or quality of life, one item requesting that the patient make a judgment specific to his 
or her experience with foot problems, and a final item asking for an overall judgment of quality 
of life (Spilker B (ed) (1996). Quality of life and pharmacoeconomics in clinical trials). 
        Satisfaction with quality of life in each domain and overall satisfaction are assessed using 
five point scales (not at all to very much). (NOTE: as the 6-item (lettered) QoL scale 
significantly correlates with a 1-item overall DN impact on QoL scale (item 28) at .88, item 28 
could replace a 6-item scale if a shorter version of the NeuroQoL is needed. A short version of 
the NeuroQoL should, therefore, include items 1-13 (symptoms); 14-27 (psychosocial 






E.  NEUROLOGICAL FORM 
Effect of Melatonin on ANS Study 
PATIENT NAME:         
SUBJECT ID:          
DATE:         
   
  
PHYSICAL EXAMINATION    
            
SITE:                NORMAL ABNORMAL                                 COMMENT 
HEAD, NECK              
EYES               
EARS, NOSE, THROAT             
LYMPH NODES             
CHEST, LUNGS             
HEART               
ABDOMEN              
MUSCULOSKELETAL             
EXTREMITIES             
PERIPHERAL 
VASCULAR             
SKIN               
OTHER:          
            
ANEMIA          
CYANOSIS              
JAUNDICE              
CLUBBING              
JVP               
EDEMA              
            
 
SUPINE BP     PULSE         
SITTING BP     PULSE     
 
   
STANDING BP     PULSE     
 
   
            
     HEIGHT   Inches 
BMI      WEIGHT   Lbs. 
            
Exam performed by:______________________________    
   
Transcribed by:______________________________     






F. INCLUSION/EXCLUSION SCREENING FORM 
Melatonin and Autonomic Nervous System (ANS) Function 
 
INCLUSION/EXCLUSION SCREENING FORM 
 
Subject Name __________________Subject #______Visit Date______________ 
  
INCLUSION CRITERIA 
Must be “YES” for inclusion in the study. 
 
  YES    NO    Subjects may be males or non-pregnant, non-lactating females age                  
40-75 years of age    
 
  YES    NO    Subject must have been diagnosed with type 2 diabetes mellitus  
 
EXCLUSION CRITERIA 
Must be “NO” for Inclusion in the study.  
 
  YES    NO    History of congestive heart failure 
 
  YES    NO    Recent myocardial infarction or cardiovascular event within last year 
 
  YES    NO    History of major macrovascular events such as myocardial infarction or 
stroke within the last 6 months 
 
  YES    NO    History of unstable or irregular heartbeat 
 
  YES    NO    Presence of end-stage renal disease (undergoing renal dialysis) 
 
  YES    NO    Presence of moderate or severe hepatic insufficiency  
 
  YES    NO    Presence of severe orthostatic hypotension 
 
  YES    NO    Current tobacco use 
 
  YES    NO    Presence of Type 1 diabetes 
    
  YES    NO    Presence of hepatitis B or C 
 
  YES    NO    Presence of HIV 
 
  YES    NO    Presence of active malignancy (diagnosed or treated in last year) 
 
  YES    NO    Night time shift work 
 






  YES    NO    Amputation of any portion of a hand or a foot   
 
  YES    NO     Other serious medical conditions which would compromise the subject’s 
participation, in the opinion of the investigator 
 
  YES    NO    Participation in another clinical trial concurrently or within the last month 
 
 
FINAL DETERMINATION OF ELIGIBILITY (CHECK ONE) 
 
    Based on medical history, physical exam, and lab tests patient has met all study criteria and 
can be enrolled in the study.   
 
    Patient failed the screening process required for entry into the study.  Please indicate reason 









Transcribed By________________________   Date_________________ 
 
 






G.  PSQI 
PITTSBURGH SLEEP QUALITY INDEX (PSQI) 
 
INSTRUCTIONS: The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and nights in the past month. 
Please answer all questions. 
During the past month, when have you usually gone to bed at night? 
USUAL BED TIME    _ 
 
During the past month, how long (in minutes) has it usually take you to fall asleep each night? 
NUMBER OF MINUTES   
 
During the past month, when have you usually gotten up in the morning? 
USUAL GETTING UP TIME  _  _  
 
During the past month, how many hours of actual sleep did you get at night? {This may be different than the 
number of hours you spend in bed.) 
HOURS OF SLEEP PER NIGHT  _  
 
 
INSTRUCTIONS: For each of the remaining questions, check the one best response. 
Please answer all questions. 
 
 
During the past month, how often have you had trouble sleeping because you... 
 
 Not during the 
past month 
Less than 
once a week 
Once or twice 
a week 
Three or more 
times a week 
(a) ...cannot get to sleep within 30 minutes D D D D 
(b)   ...wake  up in the  middle of the  night or 
 early morning D D D D 
(c) ...have to get up to use the bathroom D D D D 
(d) ...cannot breathe comfortably D D D D 
(e) ...cough or snore loudly D D D D 
(f) ...feel too cold D D D D 
(g) ...feel too hot D D D D 
(h) ...had bad dreams D D D D 
(i) ...have pain D D D D 
(j) Other reason(s), please describe     
 
How often during the past month have 
you had trouble sleeping because of this?  
 
No problem Only a very Somewhat of A very 
at all  slight problem a problem big problem 
 










During the past month, how would you 
rate your  sleep quality overall?  
 
Very good Fairly good Fairly bad very bad 
 
D  D  D  D 
 
 
During the past month, how often have you taken medicine (prescribed or "over the counter") to help you 
sleep? 
 
Not during the Less than  Once or  Three or more 
 past month once a week twice a week times a week 
D  D  D  D 
 
 
No problem Only a very Somewhat of A very 
at all  slight problem a problem big problem 
 
D  D  D  D 
 
During the past month, how often have 
you had trouble staying awake while driving, eating meals, or engaging in social activity? 
 
No problem Only a very Somewhat of A very 
at all  slight problem a problem big problem 
 






9. During the past month, how much of a problem has it been for you to keep up enough enthusiasm to get 
things done? 
 
No problem Only a very Somewhat of A very 
at all  slight problem a problem big problem 
 
D  D  D  D 
 
No bed Partner/ Partner in same Partner or Partner in room  
    room, but not roommate in other room    
    same bed  same bed 
D  D  D  D 
 
  
10. During the past month, how much of a problem has it been for you to keep up enough enthusiasm to get 
things done? 
 
No problem Only a very Somewhat of A very 
at all  slight problem a problem big problem 
 







If you have a roommate or bed partner, ask him/her how often in the past month you have had... 
 
Not during the Less than Once or  Three or more 
past month  once a week twice a week times a week 
 
...loud snoring    D  D  D  D 
...long pauses between breaths  
while asleep    D  D  D  D 
...legs twitching or jerking while  
you sleep    D  D  D   D 
...episodes of disorientation or  
confusion during sleep 
      D  D  D  D 
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